Extensive	O	O
evidence	O	O
gathered	O	O
from	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
analysis	O	O
has	O	O
identified	O	O
and	O	O
confirmed	O	O
specific	O	O
positions	O	O
in	O	O
the	O	O
glucagon	O	O
sequence	O	O
that	O	O
are	O	O
important	O	O
either	O	O
for	O	O
binding	O	O
to	O	O
its	O	O
receptor	O	O
or	O	O
for	O	O
signal	O	O
transduction	O	O
.	O	O
These	O	O
diastereoisomers	O	O
were	O	O
formed	O	O
in	O	O
unequal	O	O
amounts	O	O
when	O	O
1	O	O
,	O	O
its	O	O
hexadeuterated	O	O
analogue	O	O
8	O	O
or	O	O
heptadeuterated	O	O
analogue	O	O
9	O	O
,	O	O
were	O	O
incubated	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
rat	O	O
liver	O	O
microsomal	O	O
fraction	O	O
.	O	O
The	O	O
in	O	O
vitro	O	O
screening	O	O
for	O	O
trypanocidal	O	O
activity	O	O
against	O	O
Trypanosoma	O	O
brucei	O	O
rhodesiense	O	O
of	O	O
an	O	O
in	O	O
-	O	O
house	O	O
library	O	O
of	O	O
62	O	O
compounds	O	O
[	O	O
i.e.	O	O
alkane	O	O
,	O	O
diphenyl	O	B-IUPAC
,	O	O
and	O	O
azaalkane	O	O
bisguanidines	O	O
and	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoimidazolines	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	O	I-IUPAC
,	O	O
which	O	O
were	O	O
chosen	O	O
for	O	O
their	O	O
structural	O	O
similarity	O	O
to	O	O
the	O	O
trypanocidal	O	O
agents	O	O
synthalin	O	O
(	O	O
1,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
decanediguanidine	I-IUPAC	I-IUPAC
)	O	O
and	O	O
4,4	B-IUPAC	B-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diguanidinodiphenylmethane	I-IUPAC	I-IUPAC
and	O	O
the	O	O
polyamine	B-IUPAC	O
N	I-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propane	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamine	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
,	O	O
is	O	O
reported	O	O
.	O	O
The	O	O
metabolites	O	O
were	O	O
isolated	O	O
in	O	O
crystalline	O	O
form	O	O
from	O	O
urine	O	O
for	O	O
structure	O	O
determination	O	O
.	O	O
A	O	O
series	O	O
of	O	O
2	B-IUPAC	B-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
alkyl	I-IUPAC	I-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
2	B-IUPAC	B-MODIFIER
-	I-IUPAC	I-MODIFIER
aryl	I-IUPAC	I-MODIFIER
-	O	I-MODIFIER
substituted	B-MODIFIER	I-MODIFIER
8	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
hydroxy	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
8	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
methoxy	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylquinazolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
has	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
PARP	O	O
inhibitory	O	O
activity	O	O
in	O	O
permeabilized	O	O
L1210	O	O
murine	O	O
leukemia	O	O
cells	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
our	O	O
previous	O	O
observation	O	O
that	O	O
N1	B-IUPAC	O
-	I-IUPAC	O
alkyl	I-IUPAC	O
substituted	B-MODIFIER	O
chlorpropamide	B-IUPAC	O
derivatives	B-MODIFIER	O
when	O	O
administered	O	O
to	O	O
rats	O	O
nonenzymatically	O	O
eliminated	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
isocyanate	I-IUPAC	I-IUPAC
,	O	O
a	O	O
known	O	O
inhibitor	O	O
of	O	O
aldehyde	O	O
dehydrogenase	O	O
(	O	O
AlDH	O	O
)	O	O
,	O	O
we	O	O
have	O	O
synthesized	O	O
other	O	O
latentiated	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
isocyanates	I-IUPAC	B-MODIFIER
as	O	O
in	O	O
vivo	O	O
inhibitors	O	O
of	O	O
AlDH	O	O
.	O	O
Several	O	O
subsequent	O	O
analogues	O	O
,	O	O
including	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorobenzoyl	I-IUPAC	I-IUPAC
(	O	O
18	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorothiophene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
(	O	O
51	O	O
)	O	O
,	O	O
(	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethylcyclopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
(	O	O
80	O	O
)	O	O
,	O	O
and	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
(	O	O
92	O	O
)	O	O
derivatives	B-MODIFIER	O
,	O	O
were	O	O
highly	O	O
effective	O	O
in	O	O
rats	O	O
,	O	O
surpassing	O	O
9	O	O
and	O	O
losartan	O	O
in	O	O
duration	O	O
of	O	O
action	O	O
and	O	O
/	O	O
or	O	O
potency	O	O
.	O	O
Pyrrole	B-IUPAC	O
bis	I-IUPAC	O
(	I-IUPAC	O
carbamates	I-IUPAC	O
)	I-IUPAC	O
20	O	O
and	O	O
21	O	O
,	O	O
which	O	O
exhibited	O	O
antileukemic	O	O
activity	O	O
,	O	O
also	O	O
showed	O	O
reactivity	O	O
toward	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
while	O	O
the	O	O
inactive	O	O
bis	B-IUPAC	O
(	I-IUPAC	O
carbamates	I-IUPAC	O
)	I-IUPAC	O
were	O	O
unreactive	O	O
in	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitrobenzyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
assay	O	O
.	O	O
The	O	O
affinity	O	O
of	O	O
6beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzoyloxynortropane	I-IUPAC	I-IUPAC
and	O	O
other	O	O
analogues	O	O
with	O	O
larger	O	O
acyl	O	O
moieties	O	O
was	O	O
little	O	O
affected	O	O
by	O	O
N	O	O
-	O	O
methylation	O	O
or	O	O
in	O	O
some	O	O
cases	O	O
was	O	O
increased	O	O
.	O	O
Furthermore	O	O
,	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
2	O	O
-	O	O
Fu	O	O
-	O	O
AMPA	O	O
,	O	O
7f	O	O
)	O	O
and	O	O
its	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
7g	O	O
)	O	O
were	O	O
synthesized	O	O
,	O	O
and	O	O
(	O	O
S	O	O
)	O	O
-	O	O
2	O	O
-	O	O
Fu	O	O
-	O	O
AMPA	O	O
(	O	O
8	O	O
)	O	O
and	O	O
(	O	O
R	O	O
)	O	O
-	O	O
2	O	O
-	O	O
Fu	O	O
-	O	O
AMPA	O	O
(	O	O
9	O	O
)	O	O
were	O	O
prepared	O	O
by	O	O
semipreparative	O	O
chiral	O	O
HPLC	O	O
resolution	O	O
of	O	O
7f	O	O
.	O	O
In	O	O
vitro	O	O
quantitative	O	O
autoradiography	O	O
determined	O	O
that	O	O
3	O	O
,	O	O
7	O	O
,	O	O
and	O	O
8	O	O
had	O	O
potent	O	O
binding	O	O
affinities	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0.07-0.19	O	O
nM	O	O
)	O	O
for	O	O
PBR	O	O
in	O	O
the	O	O
rat	O	O
brain	O	O
.	O	O
The	O	O
alkyl	B-PARTIUPAC	O
substituent	B-MODIFIER	O
on	O	O
this	O	O
side	O	O
chain	O	O
can	O	O
be	O	O
methyl	B-PARTIUPAC	O
,	O	O
ethyl	B-PARTIUPAC	O
,	O	O
or	O	O
cyclopropyl	B-PARTIUPAC	O
.	O	O
Nevertheless	O	O
,	O	O
these	O	O
21	O	O
-	O	O
functionalized	O	O
derivatives	O	O
of	O	O
(	B-IUPAC	B-IUPAC
9R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythromycylamine	I-IUPAC	I-IUPAC
provide	O	I-IUPAC
an	O	O
entry	O	O
into	O	O
novel	O	O
analogues	O	O
of	O	O
the	O	O
important	O	O
macrolide	O	O
antibiotic	O	O
erythromycin	O	O
.	O	O
The	O	O
pyrrolidinyl	B-IUPAC	O
(	O	O
or	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dialkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
ethylenediamine	I-IUPAC	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
,	O	O
and	O	O
phenylethyl	B-IUPAC	O
portions	B-MODIFIER	O
of	O	O
this	O	O
sigma	O	O
receptor	O	O
pharmacophore	O	O
were	O	O
restricted	O	O
by	O	O
its	O	O
incorporation	O	O
into	O	O
1,2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanediamine	I-IUPAC	I-IUPAC
-	O	I-IUPAC
,	O	O
pyrrolidine	B-IUPAC	O
-	O	O
,	O	O
piperidine	B-PARTIUPAC	O
-	O	O
,	O	O
homopiperidine	B-PARTIUPAC	O
-	O	O
,	O	O
and	O	O
tetrahydroisoquinoline	B-IUPAC	O
-	O	O
containing	B-MODIFIER	O
ligands	I-MODIFIER	O
.	O	O
Accessible	O	O
conformers	O	O
of	O	O
each	O	O
molecule	O	O
were	O	O
identified	O	O
by	O	O
using	O	O
the	O	O
method	O	O
of	O	O
molecular	O	O
mechanics	O	O
as	O	O
encoded	O	O
in	O	O
the	O	O
MMP2	O	O
(	O	O
85	O	O
)	O	O
program	O	O
.	O	O
Both	O	O
di	O	O
-	O	O
and	O	O
triacetylated	O	O
derivatives	O	O
of	O	O
6	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acetylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
olide	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylbutyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
acetylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
olide	I-IUPAC	I-IUPAC
(	O	O
9	O	O
)	O	O
,	O	O
were	O	O
inactive	O	O
.	O	O
The	O	O
dithionite	O	O
reduction	O	O
product	O	O
,	O	O
7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiohomofolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
was	O	O
able	O	O
to	O	O
function	O	O
as	O	O
a	O	O
substrate	O	O
of	O	O
L	O	O
.	O	O
Among	O	O
the	O	O
four	O	O
isomers	O	O
of	O	O
3	O	O
,	O	O
the	O	O
(	O	O
aR	O	O
,	O	O
S	O	O
)	O	O
-	O	O
enantiomer	O	O
(	O	O
3a	O	O
-	O	O
A	O	O
)	O	O
exhibited	O	O
the	O	O
most	O	O
potent	O	O
antagonistic	O	O
activities	O	O
with	O	O
an	O	O
IC50	O	O
value	O	O
of	O	O
0.80	O	O
nM	O	O
(	O	O
in	O	O
vitro	O	O
inhibition	O	O
of	O	O
[	O	O
125I	O	O
]	O	O
BH	O	O
-	O	O
SP	O	O
binding	O	O
in	O	O
human	O	O
IM	O	O
-	O	O
9	O	O
cells	O	O
)	O	O
and	O	O
ED50	O	O
values	O	O
of	O	O
9.3	O	O
micrograms	O	O
/	O	O
kg	O	O
(	O	O
iv	O	O
)	O	O
and	O	O
67.7	O	O
micrograms	O	O
/	O	O
kg	O	O
(	O	O
po	O	O
)	O	O
(	O	O
in	O	O
vivo	O	O
inhibition	O	O
of	O	O
capsaicin	O	O
-	O	O
induced	O	O
plasma	O	O
extravasation	O	O
in	O	O
guinea	O	O
pig	O	O
trachea	O	O
)	O	O
,	O	O
while	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
(	O	O
aS	O	O
,	O	O
R	O	O
)	O	O
-	O	O
enantiomer	O	O
(	O	O
3b	O	O
-	O	O
B	O	O
)	O	O
was	O	O
the	O	O
weakest	O	O
with	O	O
an	O	O
IC50	O	O
value	O	O
of	O	O
620	O	O
nM	O	O
.	O	O
Some	O	O
novel	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	O	O
substituted	B-MODIFIER	B-MODIFIER
-	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoquinoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
have	O	O
been	O	O
prepared	O	O
.	O	O
Related	O	O
pyran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
pyran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
and	O	O
thiopyran	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
showed	O	O
similar	O	O
IC50	O	O
values	O	O
against	O	O
DNA	O	O
-	O	O
PK	O	O
,	O	O
whereas	O	O
the	O	O
pyridin	B-IUPAC	O
-	I-IUPAC	O
4	I-IUPAC	O
-	I-IUPAC	O
one	I-IUPAC	O
system	B-MODIFIER	O
proved	O	O
,	O	O
in	O	O
general	O	O
,	O	O
ineffective	O	O
at	O	O
inhibiting	O	O
DNA	O	O
-	O	O
PK	O	O
.	O	O
A	O	O
series	O	O
of	O	O
straight	O	O
-	O	O
chain	O	O
N5	B-IUPAC	O
-	I-IUPAC	O
aminoalkylacyl	I-IUPAC	O
derivatives	B-MODIFIER	O
demonstrated	O	O
that	O	O
for	O	O
A2B	O	O
receptors	O	O
the	O	O
optimal	O	O
chain	O	O
length	O	O
occurs	O	O
with	O	O
three	O	O
methylene	O	O
groups	O	O
,	O	O
i.e.	O	O
,	O	O
the	O	O
N5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
gamma	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminobutyryl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
27	O	O
which	O	O
had	O	O
a	O	O
pA2	O	O
value	O	O
of	O	O
8.0	O	O
but	O	O
was	O	O
not	O	O
selective	O	O
for	O	O
A2B	O	O
receptors	O	O
.	O	O
Preliminary	O	O
biological	O	O
studies	O	O
showed	O	O
that	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
and	O	O
5,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
(	O	O
1b	O	O
and	O	O
1e	O	O
)	O	O
were	O	O
less	O	O
active	O	O
than	O	O
methotrexate	O	O
against	O	O
human	O	O
leukemic	O	O
HL	O	O
-	O	O
60	O	O
and	O	O
murine	O	O
L	O	O
-	O	O
1210	O	O
cells	O	O
in	O	O
tissue	O	O
culture	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
used	O	O
as	O	O
intermediates	O	O
for	O	O
the	O	O
synthesis	O	O
of	O	O
a	O	O
new	O	O
series	O	O
of	O	O
water	O	O
-	O	O
soluble	O	O
compounds	O	O
derived	O	O
from	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dialkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinoxalinecarbonitrile	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxides	I-IUPAC	I-IUPAC
10a	O	O
-	O	O
i	O	O
and	O	O
11a	O	O
-	O	O
i	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
several	O	O
analogues	O	O
of	O	O
(	B-IUPAC	B-IUPAC
8R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,6,7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroimidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
diazepin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ol	I-IUPAC	I-IUPAC
(	O	O
pentostatin	O	O
,	O	O
1a	O	O
)	O	O
is	O	O
described	O	O
.	O	O
Side	O	O
chain	O	O
mobility	O	O
is	O	O
analyzed	O	O
with	O	O
time	O	O
-	O	O
dependent	O	O
distance	O	O
restraints	O	O
.	O	O
The	O	O
newly	O	O
synthesized	O	O
radioactive	O	O
inhibitors	O	O
were	O	O
utilized	O	O
to	O	O
study	O	O
ex	O	O
vivo	O	O
biodistribution	O	O
in	O	O
mice	O	O
,	O	O
and	O	O
the	O	O
tumor	O	O
-	O	O
to	O	O
-	O	O
blood	O	O
ratio	O	O
of	O	O
tissue	O	O
uptake	O	O
of	O	O
[	O	O
(	O	O
131	O	O
)	O	O
I	O	O
]	O	O
IBG	O	O
and	O	O
[	O	O
(	O	O
131	O	O
)	O	O
I	O	O
]	O	O
IBGG	O	O
was	O	O
determined	O	O
to	O	O
be	O	O
0.24	O	O
and	O	O
0.76	O	O
after	O	O
0.5	O	O
h	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
hydroxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
estrogens	I-IUPAC	I-IUPAC
were	O	O
prepared	O	O
by	O	O
oxidative	O	O
hydroboration	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkenylestradiols	I-IUPAC	I-IUPAC
.	O	O
Of	O	O
the	O	O
investigated	O	O
compounds	O	O
,	O	O
the	O	O
most	O	O
active	O	O
was	O	O
2,5,9,11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetramethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinoline	I-IUPAC	I-IUPAC
,	O	O
a	O	O
compound	O	O
bearing	O	O
the	O	O
highest	O	O
number	O	O
of	O	O
symmetrically	O	O
distributed	O	O
methyl	B-IUPAC	O
groups	B-MODIFIER	O
.	O	O
A	O	O
series	O	O
of	O	O
sulfonyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidine	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
was	O	O
designed	O	O
and	O	O
synthesized	O	O
for	O	O
cytotoxic	O	O
evaluation	O	O
as	O	O
potential	O	O
anticancer	O	O
agents	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
lead	O	O
compound	O	O
LY	O	O
-	O	O
181984	O	O
.	O	O
Preferred	O	O
compounds	O	O
are	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azido	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iminothiazoline	I-IUPAC	I-IUPAC
for	O	O
alpha4beta2	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0.47	O	O
nM	O	O
)	O	O
and	O	O
with	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitroiminothiazoline	I-IUPAC	I-IUPAC
or	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
nitromethyleneimidazolidine	I-IUPAC	I-IUPAC
for	O	O
Drosophila	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
0.72-3.9	O	O
nM	O	O
)	O	O
.	O	O
The	O	O
42	O	O
platinum	O	O
(	O	O
II	O	O
)	O	O
complexes	O	O
having	O	O
a	O	O
seven	O	O
-	O	O
membered	O	O
ring	O	O
structure	O	O
in	O	O
this	O	O
series	O	O
have	O	O
been	O	O
prepared	O	O
and	O	O
characterized	O	O
by	O	O
1H	O	O
NMR	O	O
,	O	O
13C	O	O
NMR	O	O
,	O	O
IR	O	O
,	O	O
FAB	O	O
-	O	O
MS	O	O
,	O	O
and	O	O
elemental	O	O
analysis	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
studies	O	O
using	O	O
potassium	O	O
-	O	O
depolarized	O	O
rabbit	O	O
aorta	O	O
show	O	O
that	O	O
ortho	B-IUPAC	O
,	O	O
meta	B-MODIFIER	O
-	I-MODIFIER	O
disubstituted	I-MODIFIER	O
aryl	B-IUPAC	O
derivatives	B-MODIFIER	O
are	O	O
more	O	O
potent	O	O
than	O	O
either	O	O
ortho	O	O
-	O	O
or	O	O
meta	O	O
-	O	O
monosubstituted	O	O
compounds	O	O
.	O	O
Consequently	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
the	O	O
heteroatom	O	O
does	O	O
not	O	O
eradicate	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
heteroarotinoids	O	O
and	O	O
thus	O	O
they	O	O
may	O	O
have	O	O
potential	O	O
as	O	O
chemotherapeutic	O	O
agents	O	O
.	O	O
The	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
analogs	B-MODIFIER	B-MODIFIER
showed	O	O
selective	O	O
5	O	O
-	O	O
HT1A	O	O
receptor	O	O
activity	O	O
in	O	O
vitro	O	O
but	O	O
displayed	O	O
mixed	O	O
5	O	O
-	O	O
HT1A	O	O
and	O	O
D2	O	O
agonist	O	O
properties	O	O
in	O	O
vivo	O	O
.	O	O
The	O	O
requisite	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyquinazolinones	I-IUPAC	I-IUPAC
(	O	O
6	O	O
,	O	O
35-39	O	O
)	O	O
were	O	O
synthesized	O	O
by	O	O
demethylation	O	O
of	O	O
the	O	O
corresponding	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxyquinazolinones	I-IUPAC	I-IUPAC
with	O	O
BBr3	O	O
.	O	O
The	O	O
in	O	O
vitro	O	O
antitumor	O	O
activity	O	O
in	O	O
ovarian	O	O
cancer	O	O
cells	O	O
(	O	O
CH1	O	O
)	O	O
has	O	O
been	O	O
determined	O	O
by	O	O
means	O	O
of	O	O
the	O	O
MTT	O	O
assay	O	O
.	O	O
Modification	O	O
of	O	O
the	O	O
benzodiazepine	O	O
(	O	O
BZ	O	O
)	O	O
receptor	O	O
binding	O	O
template	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinazolin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
by	O	O
replacement	O	O
of	O	O
the	O	O
annelated	O	O
benzene	O	O
ring	O	O
with	O	O
various	O	O
alicyclic	O	O
and	O	O
heterocyclic	O	O
moieties	O	O
led	O	O
to	O	O
novel	O	O
structures	O	O
with	O	O
potent	O	O
BZ	O	O
receptor	O	O
binding	O	O
affinity	O	O
.	O	O
To	O	O
shed	O	O
light	O	O
on	O	O
the	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
underlying	O	O
this	O	O
quite	O	O
enigmatic	O	O
pharmacological	O	O
profile	O	O
of	O	O
4	O	O
-	O	O
AHCP	O	O
,	O	O
we	O	O
have	O	O
now	O	O
developed	O	O
a	O	O
synthesis	O	O
of	O	O
(	O	O
S	O	O
)	O	O
-	O	O
4	O	O
-	O	O
AHCP	O	O
(	O	O
6	O	O
)	O	O
and	O	O
(	O	O
R	O	O
)	O	O
-	O	O
4	O	O
-	O	O
AHCP	O	O
(	O	O
7	O	O
)	O	O
.	O	O
Triamines	O	O
11	O	O
and	O	O
13	O	O
[	O	O
Ki	O	O
(	O	O
sigma	O	O
-	O	O
2	O	O
)	O	O
/	O	O
K	O	O
(	O	O
i	O	O
)	O	O
(	O	O
sigma	O	O
-	O	O
1	O	O
)	O	O
=	O	O
0.19	O	O
and	O	O
0.10	O	O
,	O	O
respectively	O	O
]	O	O
containing	O	O
the	O	O
N	O	O
-	O	O
N	O	O
-	O	O
N	O	O
-	O	O
Ar	O	O
spacings	O	O
3-3-2	O	O
and	O	O
4-4-2	O	O
,	O	O
proved	O	O
to	O	O
be	O	O
the	O	O
most	O	O
sigma	O	O
-	O	O
2	O	O
subtype	O	O
selective	O	O
of	O	O
the	O	O
15	O	O
polyamines	O	O
examined	O	O
in	O	O
this	O	O
study	O	O
.	O	O
These	O	O
results	O	O
make	O	O
meta	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylhistamines	I-IUPAC	I-IUPAC
,	O	O
especially	O	O
2	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
3	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
trifluoromethyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
phenyl	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
histamine	I-IUPAC	I-IUPAC
(	O	O
39	O	O
and	O	O
35	O	O
,	O	O
respectively	O	O
)	O	O
valuable	O	O
experimental	O	O
tools	O	O
for	O	O
the	O	O
selective	O	O
stimulation	O	O
of	O	O
histamine	O	O
H1	O	O
receptors	O	O
and	O	O
the	O	O
study	O	O
of	O	O
H1	O	O
receptor	O	O
-	O	O
mediated	O	O
functions	O	O
.	O	O
Within	O	O
the	O	O
group	O	O
of	O	O
heterocyclic	O	O
analogs	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
proved	O	O
to	O	O
be	O	O
the	O	O
best	O	O
modification	O	O
,	O	O
displaying	O	O
a	O	O
delta	O	O
receptor	O	O
Ki	O	O
of	O	O
1.38	O	O
nM	O	O
,	O	O
while	O	O
the	O	O
polar	O	O
histidine	O	O
analog	O	O
suffered	O	O
the	O	O
greatest	O	O
loss	O	O
in	O	O
delta	O	O
binding	O	O
(	O	O
Ki	O	O
=	O	O
317	O	O
)	O	O
.	O	O
We	O	O
are	O	O
able	O	O
to	O	O
rationalize	O	O
the	O	O
observed	O	O
selectivities	O	O
by	O	O
comparing	O	O
the	O	O
docking	O	O
of	O	O
4	O	O
and	O	O
6	O	O
to	O	O
subtype	O	O
constructs	O	O
,	O	O
i.e.	O	O
,	O	O
a	O	O
crystal	O	O
structure	O	O
of	O	O
the	O	O
extracellular	O	O
binding	O	O
domain	O	O
of	O	O
GluR2	O	O
and	O	O
a	O	O
homology	O	O
model	O	O
of	O	O
GluR5	O	O
.	O	O
The	O	O
antiviral	O	O
activity	O	O
of	O	O
both	O	O
compounds	O	O
was	O	O
well	O	O
separated	O	O
from	O	O
cytotoxicity	O	O
in	O	O
KB	O	O
,	O	O
HFF	O	O
,	O	O
and	O	O
L1210	O	O
cells	O	O
.	O	O
Six	O	O
of	O	O
the	O	O
eight	O	O
diamidines	O	O
gave	O	O
in	O	O
vitro	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
values	O	O
of	O	O
63	O	O
nM	O	O
or	O	O
less	O	O
vs	O	O
T	O	O
.	O	O
Active	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydronaphthoquinone	I-IUPAC	I-IUPAC
acetates	I-IUPAC	I-IUPAC
(	O	O
IC50	O	O
less	O	O
than	O	O
20	O	O
microM	O	O
)	O	O
were	O	O
evaluated	O	O
in	O	O
an	O	O
ex	O	O
vivo	O	O
LTB4	O	O
inhibition	O	O
assay	O	O
.	O	O
carinii	O	O
DHFR	O	O
,	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
trimethoxyanilino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methy	I-IUPAC	I-IUPAC
l	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinazoline	I-IUPAC	I-IUPAC
(	O	O
10	O	O
)	O	O
had	O	O
an	O	O
IC50	O	O
of	O	O
0.012	O	O
microM	O	O
and	O	O
was	O	O
slightly	O	O
more	O	O
potent	O	O
than	O	O
TMQ	O	O
and	O	O
PTX	O	O
.	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
for	O	O
spermidine	O	O
uptake	O	O
were	O	O
also	O	O
determined	O	O
in	O	O
L1210	O	O
cells	O	O
.	O	O
;	O	O
Wilson	O	O
,	O	O
I	O	O
.	O	O
The	O	O
compound	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
3a	O	O
)	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.11	O	O
microM	O	O
;	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.2	O	O
microM	O	O
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
regioisostere	O	O
of	O	O
2	O	O
with	O	O
a	O	O
methoxy	O	O
group	O	O
substituted	O	O
for	O	O
the	O	O
methyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
,	O	O
was	O	O
approximately	O	O
equipotent	O	O
with	O	O
2	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.020	O	O
microM	O	O
;	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.0	O	O
microM	O	O
)	O	O
as	O	O
an	O	O
inhibitor	O	O
of	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
AMPA	O	O
binding	O	O
and	O	O
as	O	O
an	O	O
AMPA	O	O
agonist	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
the	O	O
corresponding	O	O
3	O	B-IUPAC
-	O	I-IUPAC
ethoxy	O	I-IUPAC
analogue	O	B-MODIFIER
3b	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.0	O	O
microM	O	O
;	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
4.8	O	O
microM	O	O
)	O	O
was	O	O
slightly	O	O
weaker	O	O
.	O	O
These	O	O
data	O	O
for	O	O
the	O	O
heteroarotinoid	O	O
1b	O	O
revealed	O	O
that	O	O
the	O	O
two	O	O
aryl	O	O
ring	O	O
systems	O	O
were	O	O
nearly	O	O
perpendicular	O	O
in	O	O
each	O	O
of	O	O
the	O	O
two	O	O
molecules	O	O
present	O	O
in	O	O
the	O	O
unit	O	O
cell	O	O
(	O	O
86.37	O	O
degrees	O	O
and	O	O
84.17	O	O
degrees	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
In	O	O
one	O	O
of	O	O
the	O	O
biological	O	O
tests	O	O
a	O	O
significant	O	O
difference	O	O
was	O	O
found	O	O
between	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
(	O	O
nomifensine	O	O
)	O	O
and	O	O
the	O	O
new	O	O
compounds	O	O
synthesized	O	O
.	O	O
The	O	O
7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
(	O	O
18a	O	O
)	O	O
and	O	O
7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dichloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
(	O	O
18b	O	O
)	O	O
analogs	B-MODIFIER	O
are	O	O
the	O	O
most	O	O
potent	O	O
THHBADs	O	O
prepared	O	O
and	O	O
have	O	O
apparent	O	O
antagonist	O	O
dissociation	O	O
constants	O	O
(	O	O
Kb	O	O
values	O	O
)	O	O
of	O	O
0.0041	O	O
and	O	O
0.0028	O	O
microM	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
NMDA	O	O
receptors	O	O
and	O	O
0.51	O	O
and	O	O
0.72	O	O
microM	O	O
,	O	O
respectively	O	O
,	O	O
for	O	O
AMPA	O	O
receptors	O	O
.	O	O
The	O	O
(	B-IUPAC	B-IUPAC
propargyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
acyclonucleoside	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
,	O	O
adenine	B-IUPAC	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxypurine	I-IUPAC	I-IUPAC
,	O	O
hypoxanthine	B-IUPAC	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopurine	I-IUPAC	I-IUPAC
,	O	O
and	O	O
azathioprine	B-IUPAC	O
have	O	O
been	O	O
prepared	O	O
.	O	O
As	O	O
part	O	O
of	O	O
a	O	O
search	O	O
for	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
inhibitors	O	O
combining	O	O
the	O	O
high	O	O
potency	O	O
of	O	O
piritrexim	O	O
(	O	O
PTX	O	O
)	O	O
with	O	O
the	O	O
high	O	O
antiparasitic	O	O
vs	O	O
mammalian	O	O
selectivity	O	O
of	O	O
trimethoprim	O	O
(	O	O
TMP	O	O
)	O	O
,	O	O
the	O	O
heretofore	O	O
undescribed	O	O
2,4	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
diamino	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2'	B-MODIFIER	I-IUPAC
,	I-MODIFIER	I-IUPAC
5'	I-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
disubstituted	I-MODIFIER	I-IUPAC
benzyl	B-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
pyrido	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
2,3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
d	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
pyrimidines	I-PARTIUPAC	I-IUPAC
6-14	O	O
with	O	O
O	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
omega	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	O
or	O	O
omega	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkynyl	I-IUPAC	I-IUPAC
groups	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
benzyl	B-IUPAC	B-IUPAC
moiety	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
and	O	O
tested	O	O
against	O	O
Pneumocystis	O	O
carinii	O	O
,	O	O
Toxoplasma	O	O
gondii	O	O
,	O	O
and	O	O
Mycobacterium	O	O
avium	O	O
DHFR	O	O
vs	O	O
rat	O	O
DHFR	O	O
.	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Dialkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indoles	I-IUPAC	I-IUPAC
appeared	O	O
as	O	O
a	O	O
promising	O	O
new	O	O
class	O	O
of	O	O
antineoplastic	O	O
agents	O	O
.	O	O
A	O	O
series	O	O
of	O	O
N	B-IUPAC	B-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
[	I-IUPAC	I-PARTIUPAC
4	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
(	I-IUPAC	I-PARTIUPAC
3	I-IUPAC	I-PARTIUPAC
-	I-IUPAC	I-PARTIUPAC
pyridinyl	I-IUPAC	I-PARTIUPAC
)	I-IUPAC	I-PARTIUPAC
butyl	I-IUPAC	I-PARTIUPAC
]	I-IUPAC	I-PARTIUPAC
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
propenyl	B-IUPAC	B-IUPAC
carboxamide	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
bearing	O	O
an	O	O
unsaturated	O	O
bicyclic	O	O
moiety	O	O
in	O	O
the	O	O
3	O	O
-	O	O
position	O	O
was	O	O
prepared	O	O
and	O	O
evaluated	O	O
for	O	O
PAF	O	O
(	O	O
platelet	O	O
activating	O	O
factor	O	O
)	O	O
antagonist	O	O
activity	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indanylamide	I-IUPAC	I-IUPAC
7a	O	O
displayed	O	O
a	O	O
lower	O	O
affinity	O	O
(	O	O
K	O	O
(	O	O
i	O	O
)	O	O
675	O	O
nM	O	O
)	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
studies	O	O
showed	O	O
that	O	O
the	O	O
C	O	O
-	O	O
5	O	O
substituent	O	O
(	O	O
I	O	O
,	O	O
Br	O	O
,	O	O
Cl	O	O
)	O	O
was	O	O
a	O	O
determinant	O	O
of	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
activity	O	O
where	O	O
the	O	O
potency	O	O
order	O	O
was	O	O
I	O	O
&	O	O
gt	O	O
;	O	O
or	O	O
=	O	O
Br	O	O
&	O	O
gt	O	O
;	O	O
Cl	O	O
.	O	O
Radiolabeled	O	O
[	O	O
125I	O	O
]	O	O
-	O	O
8	O	O
was	O	O
prepared	O	O
from	O	O
the	O	O
corresponding	O	O
tri	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyltin	I-IUPAC	I-IUPAC
precursor	O	O
via	O	O
an	O	O
oxidative	O	O
iododestannylation	O	O
reaction	O	O
with	O	O
sodium	O	O
[	O	O
125I	O	O
]	O	O
iodide	O	O
.	O	O
Either	O	O
the	O	O
bond	O	O
between	O	O
the	O	O
inhibitor	O	O
and	O	O
the	O	O
enzyme	O	O
did	O	O
not	O	O
withstand	O	O
the	O	O
hydrolytic	O	O
conditions	O	O
and	O	O
/	O	O
or	O	O
there	O	O
was	O	O
less	O	O
than	O	O
10%	O	O
decrease	O	O
in	O	O
the	O	O
amino	O	O
acids	O	O
with	O	O
nucleophilic	O	O
side	O	O
chains	O	O
upon	O	O
inactivation	O	O
.	O	O
Compounds	O	O
were	O	O
assayed	O	O
in	O	O
vitro	O	O
in	O	O
a	O	O
PAF	O	O
-	O	O
binding	O	O
assay	O	O
employing	O	O
washed	O	O
,	O	O
whole	O	O
dog	O	O
platelets	O	O
as	O	O
the	O	O
receptor	O	O
source	O	O
and	O	O
in	O	O
vivo	O	O
after	O	O
intravenous	O	O
or	O	O
oral	O	O
administration	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
prevent	O	O
PAF	O	O
-	O	O
induced	O	O
bronchoconstriction	O	O
in	O	O
guinea	O	O
pigs	O	O
.	O	O
The	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenanthridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
designed	O	O
to	O	O
improve	O	O
the	O	O
solubility	O	O
and	O	O
pharmacokinetic	O	O
profiles	O	O
for	O	O
this	O	O
series	O	O
of	O	O
PARP	O	O
-	O	O
1	O	O
inhibitors	O	O
.	O	O
Enzyme	O	O
-	O	O
mediated	O	O
addition	O	O
of	O	O
water	O	O
across	O	O
the	O	O
5,6	O	O
-	O	O
double	O	O
bond	O	O
could	O	O
generate	O	O
electrophilic	O	O
acyl	O	O
halide	O	O
or	O	O
alpha	B-IUPAC	O
-	I-IUPAC	O
halo	I-IUPAC	O
ketone	I-IUPAC	O
species	O	O
that	O	O
could	O	O
undergo	O	O
nucleophilic	O	O
attack	O	O
by	O	O
proximal	O	O
groups	O	O
on	O	O
the	O	O
enzyme	O	O
.	O	O
No	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
retention	O	O
times	O	O
and	O	O
antagonist	O	O
potency	O	O
or	O	O
duration	O	O
of	O	O
action	O	O
.	O	O
From	O	O
these	O	O
studies	O	O
,	O	O
an	O	O
initial	O	O
rate	O	O
constant	O	O
,	O	O
Ki	O	O
,	O	O
for	O	O
7d	O	O
and	O	O
7n	O	O
was	O	O
found	O	O
to	O	O
be	O	O
345	O	O
and	O	O
465	O	O
nM	O	O
,	O	O
respectively	O	O
.	O	O
Among	O	O
them	O	O
,	O	O
we	O	O
have	O	O
found	O	O
that	O	O
methyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxooleana	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,9	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
28	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oate	I-IUPAC	I-IUPAC
(	O	O
25	O	O
)	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxooleana	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,9	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
28	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
CDDO	O	O
)	O	O
(	O	O
26	O	O
)	O	O
,	O	O
and	O	O
methyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxooleana	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,9	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dien	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
28	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oate	I-IUPAC	I-IUPAC
(	O	O
29	O	O
)	O	O
have	O	O
extremely	O	O
high	O	O
potency	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.1	O	O
nM	O	O
level	O	O
)	O	O
.	O	O
When	O	O
tested	O	O
iv	O	O
,	O	O
activity	O	O
was	O	O
found	O	O
in	O	O
the	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dioxamic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
up	O	O
to	O	O
2500	O	O
times	O	O
that	O	O
shown	O	O
by	O	O
disodium	O	O
cromoglycate	O	O
[	O	O
50%	O	O
inhibition	O	O
at	O	O
0.001	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
N	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dioxamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
compound	O	O
61	O	O
)	O	O
]	O	O
.	O	O
The	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
halo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
AZT	O	O
are	O	O
more	O	O
lipophilic	O	O
(	O	O
P	O	O
=	O	O
3.3-18.8	O	O
range	O	O
)	O	O
than	O	O
the	O	O
parent	O	O
compound	O	O
AZT	O	O
(	O	O
P	O	O
=	O	O
1.29	O	O
)	O	O
.	O	O
This	O	O
trend	O	O
was	O	O
consistent	O	O
with	O	O
the	O	O
published	O	O
literature	O	O
on	O	O
the	O	O
corresponding	O	O
DHFR	O	O
inhibitors	O	O
with	O	O
a	O	O
glutamate	O	O
side	O	O
chain	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Aminopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
was	O	O
converted	O	O
into	O	O
the	O	O
desired	O	O
intermediate	O	O
,	O	O
ethyl	B-IUPAC	B-IUPAC
pyrazolo	I-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
.	O	O
All	O	O
peptide	O	O
bonds	O	O
are	O	O
found	O	O
to	O	O
be	O	O
trans	O	O
.	O	O
Isopycnic	O	O
centrifugation	O	O
of	O	O
32P	O	O
-	O	O
labeled	O	O
DNA	O	O
indicated	O	O
that	O	O
if	O	O
0.5	O	O
or	O	O
2	O	O
microM	O	O
TFPe	O	O
-	O	O
dUrd	O	O
was	O	O
present	O	O
for	O	O
0-6	O	O
h	O	O
postinfection	O	O
,	O	O
viral	O	O
DNA	O	O
synthesis	O	O
was	O	O
reduced	O	O
by	O	O
ca.	O	O
50	O	O
and	O	O
85%	O	O
,	O	O
respectively	O	O
;	O	O
concomitantly	O	O
,	O	O
a	O	O
new	O	O
DNA	O	O
band	O	O
appeared	O	O
at	O	O
lower	O	O
density	O	O
than	O	O
normal	O	O
cellular	O	O
or	O	O
viral	O	O
DNA	O	O
.	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxythymidine	I-IUPAC	I-IUPAC
5'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triphosphate	I-IUPAC	I-IUPAC
was	O	O
synthesized	O	O
and	O	O
proved	O	O
to	O	O
be	O	O
a	O	O
competitive	O	O
inhibitor	O	O
,	O	O
with	O	O
respect	O	O
to	O	O
dTTP	O	O
,	O	O
of	O	O
a	O	O
number	O	O
of	O	O
DNA	O	O
polymerases	O	O
,	O	O
including	O	O
the	O	O
reverse	O	O
transcriptases	O	O
of	O	O
human	O	O
immunodeficiency	O	O
virus	O	O
type	O	O
1	O	O
(	O	O
HIV	O	O
-	O	O
1	O	O
)	O	O
and	O	O
avian	O	O
myeloblastosis	O	O
virus	O	O
(	O	O
AMV	O	O
)	O	O
.	O	O
All	O	O
these	O	O
peptides	O	O
share	O	O
a	O	O
common	O	O
rigid	O	O
tripeptide	O	O
cycle	O	O
with	O	O
a	O	O
single	O	O
energetically	O	O
preferred	O	O
backbone	O	O
conformation	O	O
and	O	O
three	O	O
different	O	O
conformers	O	O
of	O	O
the	O	O
D	O	O
-	O	O
Cys	O	O
,	O	O
D	O	O
-	O	O
Pen	O	O
disulfide	O	O
bridge	O	O
,	O	O
two	O	O
of	O	O
which	O	O
are	O	O
observed	O	O
in	O	O
the	O	O
solid	O	O
state	O	O
and	O	O
in	O	O
aqueous	O	O
solution	O	O
,	O	O
as	O	O
previously	O	O
determined	O	O
from	O	O
X	O	O
-	O	O
ray	O	O
crystallography	O	O
and	O	O
1H	O	O
NMR	O	O
spectroscopy	O	O
data	O	O
(	O	O
Lomize	O	O
,	O	O
A	O	O
;	O	O
et	O	O
al.	O	O
J	O	O
.	O	O
The	O	O
only	O	O
relevant	O	O
difference	O	O
between	O	O
the	O	O
active	O	O
and	O	O
the	O	O
inactive	O	O
compounds	O	O
detected	O	O
thus	O	O
far	O	O
is	O	O
the	O	O
rotational	O	O
barrier	O	O
of	O	O
the	O	O
phenyl	O	O
in	O	O
the	O	O
5	O	O
-	O	O
position	O	O
.	O	O
Formylation	O	O
of	O	O
amines	O	O
10-27	O	O
gave	O	O
17	B-IUPAC	B-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylformamides	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
28-41	O	O
;	O	O
however	O	O
,	O	O
acylation	O	O
afforded	O	O
17	B-IUPAC	B-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
/	I-IUPAC	O
aryl	I-IUPAC	O
)	I-IUPAC	O
alkyl	I-IUPAC	O
/	I-IUPAC	O
arylamides	I-IUPAC	O
]	I-IUPAC	O
42-53	O	O
.	O	O
The	O	O
anticancer	O	O
activity	O	O
of	O	O
pyrrolidinones	O	O
16a	O	O
-	O	O
e	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylidenefuranones	I-IUPAC	I-IUPAC
18a	O	O
-	O	O
c	O	O
was	O	O
much	O	O
weaker	O	O
than	O	O
that	O	O
of	O	O
furanones	O	O
13a	O	O
-	O	O
e	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
able	O	O
to	O	O
displace	O	O
the	O	O
highly	O	O
selective	O	O
sigma	O	O
receptor	O	O
probe	O	O
[	B-IUPAC	O
3H	I-IUPAC	O
]	I-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
+	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
pentazocine	I-IUPAC	O
from	O	O
guinea	O	O
pig	O	O
brain	O	O
homogenates	O	O
with	O	O
Ki	O	O
values	O	O
ranging	O	O
from	O	O
125	O	O
to	O	O
9170	O	O
nM	O	O
.	O	O
Several	O	O
8	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
O6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzylguanines	I-IUPAC	I-IUPAC
,	O	O
2	B-MODIFIER	B-PARTIUPAC
-	I-MODIFIER	I-PARTIUPAC
and	O	O
/	O	O
or	O	O
8	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
purines	I-IUPAC	I-IUPAC
,	O	O
substituted	B-MODIFIER	B-MODIFIER
6	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
,	O	O
and	O	O
a	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
s	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazine	I-IUPAC	I-IUPAC
were	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inactivate	O	O
the	O	O
human	O	O
DNA	O	O
repair	O	O
protein	O	O
,	O	O
O6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkylguanine	I-IUPAC	I-IUPAC
-	O	O
DNA	O	O
alkyltransferase	O	O
(	O	O
AGT	O	O
,	O	O
alkyltransferase	O	O
)	O	O
.	O	O
However	O	O
,	O	O
contrary	O	O
to	O	O
expectations	O	O
based	O	O
on	O	O
the	O	O
aforementioned	O	O
F2Pmp	O	O
work	O	O
,	O	O
incorporation	O	O
of	O	O
this	O	O
putative	O	O
pTyr	O	O
mimetic	O	O
into	O	O
the	O	O
pseudo	O	B-IUPAC
-	O	I-IUPAC
dipeptide	O	I-IUPAC
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxymethyloxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
resulted	O	O
in	O	O
a	O	O
substantial	O	O
loss	O	O
of	O	O
binding	O	O
affinity	O	O
.	O	O
Neuroprotective	O	O
properties	O	O
assessed	O	O
after	O	O
postischemic	O	O
dosing	O	O
in	O	O
a	O	O
Mongolian	O	O
gerbil	O	O
severe	O	O
temporary	O	O
forebrain	O	O
ischemia	O	O
paradigm	O	O
,	O	O
using	O	O
hippocampal	O	O
CA1	O	O
damage	O	O
endpoints	O	O
,	O	O
and	O	O
the	O	O
efficacy	O	O
of	O	O
these	O	O
agonists	O	O
in	O	O
an	O	O
A	O	O
(	O	O
1	O	O
)	O	O
functional	O	O
assay	O	O
show	O	O
similarities	O	O
to	O	O
some	O	O
reference	O	O
adenosine	O	O
agonists	O	O
.	O	O
The	O	O
disodium	O	O
salts	O	O
of	O	O
the	O	O
phosphate	O	O
prodrugs	O	O
exhibited	O	O
high	O	O
water	O	O
solubility	O	O
(	B-IUPAC	B-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxystyryl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphatylpropyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propargylxan	I-IUPAC	I-IUPAC
thine	I-IUPAC	I-IUPAC
disodium	I-IUPAC	I-IUPAC
salt	I-IUPAC	I-IUPAC
,	O	O
9b	O	O
:	O	O
17	O	O
mM	O	O
,	O	O
9	O	O
mg	O	O
/	O	O
mL	O	O
)	O	O
.	O	O
Treatment	O	O
of	O	O
4b	O	O
with	O	O
benzaldehyde	B-IUPAC	O
gave	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
styryltetrahydropyrimido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
quinoline	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
.	O	O
A	O	O
prodrug	O	O
of	O	O
N1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethylchlorpropamide	I-IUPAC	I-IUPAC
,	O	O
viz	O	O
.	O	O
A	O	O
series	O	O
of	O	O
new	O	O
dipeptidyl	O	O
alpha	O	O
-	O	O
keto	O	O
amides	O	O
of	O	O
the	O	O
general	O	O
structure	O	O
R1	O	O
-	O	O
L	O	O
-	O	O
Leu	O	O
-	O	O
D	O	O
,	O	O
L	O	O
-	O	O
AA	O	O
-	O	O
CONH	O	O
-	O	O
R2	O	O
were	O	O
synthesized	O	O
and	O	O
evaluated	O	O
as	O	O
inhibitors	O	O
for	O	O
the	O	O
cysteine	O	O
proteases	O	O
calpain	O	O
I	O	O
,	O	O
calpain	O	O
II	O	O
,	O	O
and	O	O
cathepsin	O	O
B	O	O
.	O	O
Steric	O	O
and	O	O
electrostatic	O	O
requirements	O	O
at	O	O
position	O	O
6	O	O
of	O	O
[	O	O
Nle	O	O
(	O	O
10	O	O
)	O	O
]	O	O
NKA	O	O
(	O	O
4-10	O	O
)	O	O
,	O	O
a	O	O
full	O	O
agonist	O	O
of	O	O
NK	O	O
-	O	O
2	O	O
receptors	O	O
,	O	O
for	O	O
molecular	O	O
recognition	O	O
by	O	O
the	O	O
receptor	O	O
were	O	O
studied	O	O
.	O	O
HBr	O	O
and	O	O
its	O	O
analogs	O	O
is	O	O
different	O	O
from	O	O
that	O	O
of	O	O
compound	O	O
10	O	O
as	O	O
indicated	O	O
by	O	O
the	O	O
mutual	O	O
exclusivity	O	O
with	O	O
other	O	O
inhibitors	O	O
and	O	O
the	O	O
relative	O	O
inhibition	O	O
of	O	O
the	O	O
activity	O	O
with	O	O
various	O	O
electron	O	O
acceptors	O	O
.	O	O
)	O	O
demonstrated	O	O
that	O	O
substratelike	O	O
turnover	O	O
was	O	O
proceeding	O	O
at	O	O
considerably	O	O
slower	O	O
rates	O	O
than	O	O
for	O	O
the	O	O
corresponding	O	O
true	O	O
substrates	O	O
and	O	O
with	O	O
rate	O	O
-	O	O
limiting	O	O
deacylation	O	O
of	O	O
the	O	O
acyl	O	B-IUPAC
-	O	I-IUPAC
enzyme	O	I-IUPAC
.	O	O
The	O	O
synthesis	O	O
of	O	O
5,11	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methenyltetrahydrohomofolate	I-IUPAC	I-IUPAC
was	O	O
accomplished	O	O
by	O	O
treatment	O	O
of	O	O
tetrahydrohomofolate	O	O
(	O	O
H4homofolate	O	O
)	O	O
with	O	O
triethyl	O	O
orthoformate	O	O
in	O	O
glacial	O	O
acetic	O	O
acid	O	O
.	O	O
3'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
C	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyluridine	I-IUPAC	I-IUPAC
did	O	O
not	O	O
suppress	O	O
HIV	O	O
-	O	O
1	O	O
replication	O	O
in	O	O
MT	O	O
-	O	O
4	O	O
cells	O	O
at	O	O
500	O	O
microM	O	O
while	O	O
its	O	O
5'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phosphite	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
exhibited	O	O
modest	O	O
anti	O	O
-	O	O
HIV	O	O
-	O	O
1	O	O
activity	O	O
.	O	O
Key	O	O
steps	O	O
in	O	O
the	O	O
sequence	O	O
are	O	O
the	O	O
peptide	O	O
coupling	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
with	O	O
oligo	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
gamma	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
esters	I-IUPAC	I-IUPAC
,	O	O
removal	O	O
of	O	O
blocking	O	O
groups	O	O
by	O	O
catalytic	O	O
hydrogenolysis	O	O
,	O	O
and	O	O
introduction	O	O
of	O	O
the	O	O
(	B-IUPAC	B-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pteridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
grouping	B-MODIFIER	B-MODIFIER
by	O	O
alkylation	O	O
with	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pteridinediamine	I-IUPAC	I-IUPAC
hydrobromide	I-IUPAC	I-IUPAC
.	O	O
The	O	O
(	O	O
4R	O	O
,	O	O
5R	O	O
)	O	O
-	O	O
stereoisomer	O	O
1a	O	O
-	O	O
h	O	O
exhibited	O	O
the	O	O
higher	O	O
antitumor	O	O
activity	O	O
than	O	O
the	O	O
corresponding	O	O
(	O	O
4S	O	O
,	O	O
5S	O	O
)	O	O
-	O	O
stereoisomer	O	O
2a	O	O
-	O	O
h	O	O
in	O	O
the	O	O
(	B-IUPAC	B-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclobutanedicarboxylato	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
platinum	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
II	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
complexes	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
in	O	O
vitro	O	O
pharmacological	O	O
properties	O	O
and	O	O
conformational	O	O
features	O	O
of	O	O
analogs	O	O
of	O	O
the	O	O
delta	O	O
opioid	O	O
receptor	O	O
selective	O	O
tetrapeptide	O	O
Tyr	O	O
-	O	O
c	O	O
[	O	O
D	O	O
-	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
D	O	O
-	O	O
Pen	O	O
]	O	O
OH	O	O
(	O	O
JOM	O	O
-	O	O
13	O	O
)	O	O
in	O	O
which	O	O
the	O	O
Phe3	O	O
residue	O	O
was	O	O
replaced	O	O
by	O	O
each	O	O
of	O	O
the	O	O
four	O	O
stereoisomers	O	O
of	O	O
beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylphenylalanine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
MePhe	O	O
)	O	O
were	O	O
investigated	O	O
.	O	O
In	O	O
vivo	O	O
noninvasive	O	O
optical	O	O
imaging	O	O
and	O	O
biodistribution	O	O
data	O	O
showed	O	O
that	O	O
the	O	O
compounds	O	O
were	O	O
retained	O	O
in	O	O
A549	O	O
tumor	O	O
tissue	O	O
.	O	O
Compound	O	O
1	O	O
and	O	O
its	O	O
polyglutamylated	O	O
homologues	O	O
inhibited	O	O
glycinamide	O	O
ribonucleotide	O	O
transformylase	O	O
(	O	O
GAR	O	O
-	O	O
TFase	O	O
)	O	O
and	O	O
aminoimidazole	O	O
ribonucleotide	O	O
transformylase	O	O
(	O	O
AICAR	O	O
-	O	O
TFase	O	O
)	O	O
,	O	O
the	O	O
folate	O	O
-	O	O
dependent	O	O
enzymes	O	O
in	O	O
de	O	O
novo	O	O
purine	O	O
biosynthesis	O	O
;	O	O
and	O	O
1	O	O
was	O	O
an	O	O
effective	O	O
substrate	O	O
for	O	O
mammalian	O	O
folyl	O	O
-	O	O
polyglutamate	O	O
synthetase	O	O
.	O	O
In	O	O
an	O	O
attempt	O	O
to	O	O
determine	O	O
some	O	O
of	O	O
the	O	O
structural	O	O
features	O	O
in	O	O
position	O	O
1	O	O
that	O	O
account	O	O
for	O	O
antivasopressor	O	O
activity	O	O
,	O	O
eight	O	O
new	O	O
1	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
beta	O	I-IUPAC
,	O	I-IUPAC
beta	O	I-IUPAC
-	O	I-IUPAC
dialkyl	O	I-IUPAC
-	O	O
substituted	O	O
)	O	O
analogues	O	B-MODIFIER
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopropanoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
and	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopropanoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyltyrosine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
arginine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
have	O	O
been	O	O
designed	O	O
and	O	O
synthesized	O	O
.	O	O
A	O	O
series	O	O
of	O	O
new	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
pyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkylamides	I-IUPAC	I-IUPAC
44-84	O	O
has	O	O
been	O	O
prepared	O	O
in	O	O
the	O	O
search	O	O
of	O	O
novel	O	O
antiallergic	O	O
compounds	O	O
.	O	O
Two	O	O
simple	O	O
9,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenanthrenes	I-IUPAC	I-IUPAC
,	O	O
2,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenanthrene	I-IUPAC	I-IUPAC
(	O	O
2h	O	O
,	O	O
desvinyljuncusol	O	O
)	O	O
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenanthrene	I-IUPAC	I-IUPAC
(	O	O
3h	O	O
)	O	O
,	O	O
were	O	O
found	O	O
to	O	O
possess	O	O
in	O	O
vitro	O	O
antimicrobial	O	O
activity	O	O
comparable	O	O
with	O	O
that	O	O
of	O	O
the	O	O
natural	O	O
product	O	O
.	O	O
Substitution	O	O
with	O	O
ethoxymethyl	B-IUPAC	O
and	O	O
(	B-IUPAC	O
benzyloxy	I-IUPAC	O
)	I-IUPAC	O
methyl	I-IUPAC	O
groups	B-MODIFIER	O
further	O	O
potentiated	O	O
the	O	O
activity	O	O
[	O	O
EC50	O	O
:	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
27	O	O
)	O	O
,	O	O
0.33	O	O
microM	O	O
;	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
benzyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
thymine	I-IUPAC	I-IUPAC
(	O	O
31	O	O
)	O	O
,	O	O
0.088	O	O
microM	O	O
]	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
evaluated	O	O
as	O	O
inhibitors	O	O
of	O	O
DHFR	O	O
from	O	O
human	O	O
,	O	O
Pneumocystis	O	O
carinii	O	O
,	O	O
T	O	O
.	O	O
Out	O	O
of	O	O
the	O	O
33	O	O
novel	O	O
analogues	O	O
tested	O	O
for	O	O
the	O	O
duration	O	O
of	O	O
action	O	O
in	O	O
this	O	O
series	O	O
,	O	O
two	O	O
analogues	O	O
(	O	O
[	B-IUPAC	O
N	I-IUPAC	O
(	I-IUPAC	O
epsilon	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
cyclohexyl	I-IUPAC	O
-	I-IUPAC	O
Lys	I-IUPAC	O
(	I-IUPAC	O
8	I-IUPAC	O
)	I-IUPAC	O
]	I-IUPAC	O
degarelix	I-IUPAC	O
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.50	O	O
nM	O	O
)	O	O
(	O	O
23	O	O
)	O	O
and	O	O
(	O	O
[	B-IUPAC	O
N	I-IUPAC	O
(	I-IUPAC	O
beta	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
IbetaAla	I-IUPAC	O
)	I-IUPAC	O
Dap	I-IUPAC	O
(	I-IUPAC	O
8	I-IUPAC	O
)	I-IUPAC	O
]	I-IUPAC	O
degarelix	I-IUPAC	O
,	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
1.98	O	O
nM	O	O
)	O	O
(	O	O
26	O	O
)	O	O
had	O	O
antagonist	O	O
potencies	O	O
and	O	O
duration	O	O
of	O	O
action	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
azaline	O	O
B	O	O
{	O	O
inhibited	O	O
LH	O	O
(	O	O
&	O	O
gt	O	O
;	O	O
80%	O	O
)	O	O
release	O	O
for	O	O
&	O	O
gt	O	O
;	O	O
72	O	O
h	O	O
after	O	O
sc	O	O
injection	O	O
to	O	O
castrated	O	O
male	O	O
rats	O	O
at	O	O
a	O	O
standard	O	O
dose	O	O
of	O	O
50	O	O
mug	O	O
/	O	O
rat	O	O
in	O	O
5%	O	O
mannitol	O	O
}	O	O
.	O	O
The	O	O
results	O	O
establish	O	O
that	O	O
alpha	B-IUPAC	O
-	I-IUPAC	O
naphthoflavone	I-IUPAC	O
is	O	O
the	O	O
most	O	O
effective	O	O
in	O	O
vitro	O	O
inhibitor	O	O
.	O	O
These	O	O
four	O	O
compounds	O	O
together	O	O
with	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
desamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
were	O	O
tested	O	O
for	O	O
their	O	O
activity	O	O
against	O	O
L1210	O	O
thymidylate	O	O
synthase	O	O
(	O	O
TS	O	O
)	O	O
.	O	O
The	O	O
nature	O	O
of	O	O
the	O	O
substituents	O	O
on	O	O
the	O	O
mesoionic	O	O
ring	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
have	O	O
marked	O	O
effects	O	O
on	O	O
potency	O	O
unlike	O	O
the	O	O
marked	O	O
effect	O	O
of	O	O
the	O	O
nature	O	O
of	O	O
1,3	O	O
-	O	O
substituents	O	O
on	O	O
activity	O	O
of	O	O
nonmesoionic	O	O
xanthines	O	O
.	O	O
In	O	O
order	O	O
to	O	O
develop	O	O
tracers	O	O
with	O	O
higher	O	O
specific	O	O
activity	O	O
to	O	O
supplant	O	O
the	O	O
currently	O	O
used	O	O
[	O	B-IUPAC
3H	O	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
8	O	I-IUPAC
-	O	I-IUPAC
OH	O	I-IUPAC
-	O	I-IUPAC
DPAT	O	I-IUPAC
[	O	I-IUPAC
8	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tetralin	I-IUPAC	I-IUPAC
]	O	O
for	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
evaluation	O	O
of	O	O
5	O	O
-	O	O
HT1A	O	O
receptors	O	O
,	O	O
a	O	O
new	O	O
radioiodinated	O	O
ligand	O	O
was	O	O
prepared	O	O
.	O	O
The	O	O
compound	O	O
3h	O	O
,	O	O
which	O	O
has	O	O
a	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylaminopropyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
on	O	O
the	O	O
quinolone	O	O
nitrogen	O	O
and	O	O
a	O	O
methoxycarbonyl	B-IUPAC	O
substituent	B-MODIFIER	O
at	O	O
position	O	O
9	O	O
,	O	O
had	O	O
marked	O	O
antitumor	O	O
activity	O	O
.	O	O
All	O	O
analogues	O	O
were	O	O
found	O	O
to	O	O
be	O	O
antagonists	O	O
unable	O	O
to	O	O
activate	O	O
the	O	O
adenylate	O	O
cyclase	O	O
system	O	O
even	O	O
at	O	O
concentrations	O	O
as	O	O
high	O	O
as	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
except	O	O
for	O	O
analogues	O	O
6	O	O
and	O	O
8	O	O
,	O	O
which	O	O
were	O	O
found	O	O
to	O	O
be	O	O
weak	O	O
partial	O	O
agonists	O	O
/	O	O
partial	O	O
antagonists	O	O
with	O	O
maximum	O	O
stimulation	O	O
between	O	O
6-12%	O	O
.	O	O
The	O	O
modification	O	O
of	O	O
the	O	O
substituents	O	O
on	O	O
the	O	O
indoline	O	O
ring	O	O
of	O	O
4b	O	O
has	O	O
led	O	O
to	O	O
the	O	O
separation	O	O
of	O	O
these	O	O
activities	O	O
.	O	O
The	O	O
most	O	O
active	O	O
compounds	O	O
are	O	O
the	O	O
alkyl	O	O
derivatives	O	O
of	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
mesitylamino	I-IUPAC	I-IUPAC
/	O	I-IUPAC
2	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mesitylimino	I-IUPAC	I-IUPAC
tautomeric	B-MODIFIER	O
forms	I-MODIFIER	O
.	O	O
With	O	O
use	O	O
of	O	O
the	O	O
correlation	O	O
as	O	O
a	O	O
guide	O	O
,	O	O
one	O	O
additional	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
containing	O	O
a	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
sulfonyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
to	O	O
improve	O	O
aqueous	O	O
solubility	O	O
was	O	O
prepared	O	O
.	O	O
The	O	O
four	O	O
optically	O	O
pure	O	O
compounds	O	O
were	O	O
tested	O	O
in	O	O
vitro	O	O
on	O	O
guinea	O	O
pig	O	O
and	O	O
their	O	O
muscarinic	O	O
potency	O	O
was	O	O
evaluated	O	O
at	O	O
M3	O	O
(	O	O
ileum	O	O
and	O	O
bladder	O	O
)	O	O
and	O	O
M2	O	O
(	O	O
heart	O	O
)	O	O
muscarinic	O	O
receptor	O	O
subtypes	O	O
.	O	O
Two	O	O
members	O	O
of	O	O
this	O	O
series	O	O
,	O	O
[	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentadienamide	I-IUPAC	I-IUPAC
(	O	O
31	O	O
)	O	O
and	O	O
[	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
decadienamide	I-IUPAC	I-IUPAC
(	O	O
58	O	O
)	O	O
,	O	O
were	O	O
selected	O	O
for	O	O
further	O	O
pharmacological	O	O
evaluation	O	O
.	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
(	O	O
45	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
6	O	O
nM	O	O
)	O	O
potentiates	O	O
the	O	O
cytotoxicity	O	O
of	O	O
both	O	O
temozolomide	O	O
and	O	O
topotecan	O	O
against	O	O
A2780	O	O
cells	O	O
in	O	O
vitro	O	O
(	O	O
by	O	O
2.8	O	O
-	O	O
and	O	O
2.9	O	O
-	O	O
fold	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
tested	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
displace	O	O
[	O	O
3H	O	O
]	O	O
BTCP	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
cocaine	O	O
and	O	O
to	O	O
inhibit	O	O
[	O	O
3H	O	O
]	O	O
DA	O	O
uptake	O	O
in	O	O
rat	O	O
striatal	O	O
homogenates	O	O
.	O	O
In	O	O
the	O	O
primary	O	O
anthelmintic	O	O
screen	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isothiocyanatophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxadiazole	I-IUPAC	I-IUPAC
(	O	O
39	O	O
)	O	O
showed	O	O
100%	O	O
nematocidal	O	O
activity	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isothiocyanatophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxadiazole	I-IUPAC	I-IUPAC
(	O	O
63	O	O
)	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isothiocyanatophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxadiazole	I-IUPAC	I-IUPAC
(	O	O
64	O	O
)	O	O
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furanyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isothiocyanatophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxadiazole	I-IUPAC	I-IUPAC
(	O	O
66	O	O
)	O	O
showed	O	O
100%	O	O
taeniacidal	O	O
activity	O	O
when	O	O
administered	O	O
orally	O	O
to	O	O
mice	O	O
.	O	O
The	O	O
compounds	O	O
,	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrobenzofuran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropane	I-IUPAC	I-IUPAC
(	O	O
6a	O	O
)	O	O
and	O	O
its	O	O
7	O	O
-	O	O
brominated	O	O
analogue	O	O
6b	O	O
,	O	O
possessed	O	O
activity	O	O
comparable	O	O
to	O	O
their	O	O
conformationally	O	O
flexible	O	O
counterparts	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminopropane	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
and	O	O
its	O	O
4	O	B-IUPAC
-	O	I-IUPAC
bromo	O	I-IUPAC
derivative	O	B-MODIFIER
DOB	O	O
(	O	O
5	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
In	O	O
direct	O	O
contrast	O	O
,	O	O
nearly	O	O
all	O	O
of	O	O
the	O	O
thioamide	B-IUPAC	O
derivates	B-MODIFIER	O
6a	O	O
-	O	O
1	O	O
,	O	O
including	O	O
the	O	O
aglycone	O	O
of	O	O
thiosangivamycin	O	O
(	O	O
6m	O	O
)	O	O
,	O	O
were	O	O
good	O	O
inhibitors	O	O
of	O	O
HCMV	O	O
and	O	O
HSV	O	O
-	O	O
1	O	O
.	O	O
[	O	O
Carbonyl	O	O
-	O	O
11C	O	O
]	O	O
4a	O	O
cleared	O	O
the	O	O
brain	O	O
with	O	O
a	O	O
biological	O	O
half	O	O
-	O	O
life	O	O
averaging	O	O
41	O	O
min	O	O
.	O	O
With	O	O
FdUrd	O	O
-	O	O
resistant	O	O
L5178Y	O	O
cells	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxycytidine	I-IUPAC	I-IUPAC
(	O	O
5e	O	O
)	O	O
caused	O	O
almost	O	O
3	O	O
-	O	O
fold	O	O
stronger	O	O
growth	O	O
inhibition	O	O
than	O	O
FdUrd	O	O
;	O	O
5e	O	O
was	O	O
only	O	O
some	O	O
3	O	O
-	O	O
fold	O	O
weaker	O	O
growth	O	O
inhibitor	O	O
of	O	O
the	O	O
resistant	O	O
cells	O	O
than	O	O
of	O	O
the	O	O
parental	O	O
cells	O	O
.	O	O
The	O	O
best	O	O
substrates	O	O
of	O	O
the	O	O
studied	O	O
series	O	O
for	O	O
NOS	O	O
I	O	O
and	O	O
NOS	O	O
III	O	O
were	O	O
N	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
para	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
hydroxyphenyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
meta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
N'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyguanidine	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
In	O	O
general	O	O
,	O	O
moderate	O	O
affinities	O	O
for	O	O
the	O	O
polyamine	O	O
transporter	O	O
were	O	O
observed	O	O
for	O	O
the	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
arylmethyl	I-IUPAC	I-IUPAC
4,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triamine	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
with	O	O
their	O	O
L1210	O	O
K	O	O
(	O	O
i	O	O
)	O	O
values	O	O
all	O	O
near	O	O
3	O	O
microM	O	O
.	O	O
In	O	O
the	O	O
case	O	O
of	O	O
5	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	O
cytosine	B-IUPAC	O
analogues	B-MODIFIER	O
,	O	O
the	O	O
antiviral	O	O
potency	O	O
was	O	O
found	O	O
to	O	O
be	O	O
in	O	O
the	O	O
following	O	O
decreasing	O	O
order	O	O
:	O	O
cytosine	O	O
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodocytosine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluorocytosine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylcytosine	I-IUPAC	I-IUPAC
(	O	O
alpha	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylcytosine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromocytosine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
&	O	O
gt	O	O
;	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chlorocytosine	I-IUPAC	I-IUPAC
(	O	O
beta	O	O
-	O	O
isomer	O	O
)	O	O
.	O	O
Synthesis	O	O
of	O	O
the	O	O
desired	O	O
ethyl	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyindol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetates	I-IUPAC	I-IUPAC
1-4	O	O
was	O	O
achieved	O	O
by	O	O
indolization	O	O
under	O	O
Fischer	O	O
conditions	O	O
;	O	O
Japp	O	O
-	O	O
Klingemann	O	O
method	O	O
followed	O	O
by	O	O
2	O	O
-	O	O
decarboxylation	O	O
afforded	O	O
the	O	O
ethyl	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
alkanoates	I-IUPAC	I-IUPAC
17-25	O	O
.	O	O
The	O	O
(	O	O
N	O	O
)	O	O
isomer	O	O
was	O	O
hardly	O	O
hydrolyzed	O	O
by	O	O
NTPDase	O	O
2	O	O
,	O	O
while	O	O
the	O	O
(	O	O
S	O	O
)	O	O
isomer	O	O
was	O	O
hydrolyzed	O	O
at	O	O
one	O	O
-	O	O
third	O	O
of	O	O
the	O	O
rate	O	O
of	O	O
ATP	O	O
hydrolysis	O	O
.	O	O
The	O	O
high	O	O
-	O	O
potency	O	O
phenolic	O	O
antagonist	O	O
21	O	O
and	O	O
its	O	O
low	O	O
-	O	O
potency	O	O
O	O	O
-	O	O
methylated	O	O
analogue	O	O
18	O	O
are	O	O
both	O	O
potent	O	O
anticonvulsants	O	O
in	O	O
a	O	O
mouse	O	O
maximal	O	O
electroshock	O	O
-	O	O
induced	O	O
seizure	O	O
(	O	O
MES	O	O
)	O	O
study	O	O
(	O	O
ED	O	O
(	O	O
50	O	O
)	O	O
(	O	O
iv	O	O
)	O	O
=	O	O
0.23	O	O
and	O	O
0.56	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
The	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
(	O	O
SAR	O	O
)	O	O
associated	O	O
with	O	O
position	O	O
1	O	O
and	O	O
3	O	O
substituents	O	O
in	O	O
beta	O	O
-	O	O
carbolines	O	O
has	O	O
been	O	O
discussed	O	O
.	O	O
The	O	O
solubility	O	O
of	O	O
platinum	O	O
complexes	O	O
was	O	O
related	O	O
to	O	O
the	O	O
nature	O	O
of	O	O
leaving	O	O
ligands	O	O
and	O	O
2	O	O
-	O	O
substituents	O	O
in	O	O
the	O	O
4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
aminomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxolane	I-IUPAC	I-IUPAC
carrier	O	O
ligands	O	O
.	O	O
Moderate	O	O
activity	O	O
was	O	O
observed	O	O
against	O	O
P388	O	O
leukemia	O	O
in	O	O
vivo	O	O
.	O	O
Comparison	O	O
of	O	O
the	O	O
binding	O	O
data	O	O
of	O	O
different	O	O
N	O	O
-	O	O
substituted	O	O
homologues	O	O
of	O	O
1	O	O
with	O	O
those	O	O
of	O	O
the	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylpiperazines	I-IUPAC	I-IUPAC
suggests	O	O
that	O	O
the	O	O
two	O	O
nitrogen	O	O
atoms	O	O
of	O	O
1	O	O
are	O	O
working	O	O
in	O	O
opposition	O	O
to	O	O
one	O	O
another	O	O
in	O	O
terms	O	O
of	O	O
their	O	O
sensitivity	O	O
to	O	O
steric	O	O
bulk	O	O
.	O	O
Selected	O	O
compounds	O	O
were	O	O
also	O	O
tested	O	O
for	O	O
their	O	O
affinity	O	O
to	O	O
the	O	O
D1	O	O
(	O	O
rat	O	O
striatum	O	O
)	O	O
,	O	O
D2	O	O
(	O	O
rat	O	O
striatum	O	O
)	O	O
,	O	O
D2A	O	O
(	O	O
human	O	O
cloned	O	O
)	O	O
,	O	O
and	O	O
5	O	O
-	O	O
HT2A	O	O
(	O	O
rat	O	O
cortex	O	O
)	O	O
receptors	O	O
.	O	O
This	O	O
amide	O	O
was	O	O
406	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
astemizole	O	O
in	O	O
the	O	O
ovalbumin	O	O
-	O	O
induced	O	O
histamine	O	O
release	O	O
assay	O	O
,	O	O
using	O	O
guinea	O	O
pig	O	O
peritoneal	O	O
mast	O	O
cells	O	O
,	O	O
with	O	O
an	O	O
IC50	O	O
=	O	O
0.016	O	O
microM	O	O
.	O	O
Substitution	O	O
at	O	O
the	O	O
1	O	O
-	O	O
position	O	O
was	O	O
necessary	O	O
for	O	O
high	O	O
affinity	O	O
at	O	O
adenosine	O	O
receptors	O	O
.	O	O
These	O	O
guanidines	O	O
are	O	O
radiotracer	O	O
analogues	O	O
of	O	O
guanethidine	O	O
,	O	O
an	O	O
antihypertensive	O	O
agent	O	O
thought	O	O
to	O	O
mediate	O	O
neuron	O	O
blockade	O	O
by	O	O
uptake	O	O
into	O	O
adrenergic	O	O
nerves	O	O
.	O	O
The	O	O
data	O	O
revealed	O	O
that	O	O
when	O	O
neutral	O	O
molecules	O	O
(	O	O
cargo	O	O
fragments	O	O
)	O	O
were	O	O
fixed	O	O
to	O	O
the	O	O
polyamine	O	O
vector	O	O
,	O	O
the	O	O
conjugates	O	O
competed	O	O
well	O	O
with	O	O
spermidine	O	O
for	O	O
transport	O	O
and	O	O
were	O	O
accumulated	O	O
intracellularly	O	O
to	O	O
millimolar	O	O
levels	O	O
.	O	O
Degarelix	O	O
(	O	O
FE200486	O	O
,	O	O
Ac	O	O
-	O	O
d	O	O
-	O	O
2Nal	O	O
(	O	O
1	O	O
)	O	O
-	O	O
d	O	O
-	O	O
4Cpa	O	O
(	O	O
2	O	O
)	O	O
-	O	O
d	O	O
-	O	O
3Pal	O	O
(	O	O
3	O	O
)	O	O
-	O	O
Ser	O	O
(	O	O
4	O	O
)	O	O
-	O	O
4Aph	O	O
(	O	O
l	O	O
-	O	O
Hor	O	O
)	O	O
(	O	O
5	O	O
)	O	O
-	O	O
d	O	O
-	O	O
4Aph	O	O
(	O	O
Cbm	O	O
)	O	O
(	O	O
6	O	O
)	O	O
-	O	O
Leu	O	O
(	O	O
7	O	O
)	O	O
-	O	O
ILys	O	O
(	O	O
8	O	O
)	O	O
-	O	O
Pro	O	O
(	O	O
9	O	O
)	O	O
-	O	O
d	O	O
-	O	O
Ala	O	O
(	O	O
10	O	O
)	O	O
-	O	O
NH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
is	O	O
a	O	O
potent	O	O
and	O	O
very	O	O
long	O	O
acting	O	O
antagonist	O	O
of	O	O
gonadotropin	O	O
-	O	O
releasing	O	O
hormone	O	O
(	O	O
GnRH	O	O
)	O	O
after	O	O
subcutaneous	O	O
administration	O	O
in	O	O
mammals	O	O
including	O	O
humans	O	O
.	O	O
For	O	O
comparison	O	O
reasons	O	O
,	O	O
the	O	O
cytotoxicity	O	O
of	O	O
the	O	O
complexes	O	O
alpha	O	O
-	O	O
[	O	O
Ru	O	O
(	O	O
azpy	O	O
)	O	O
(	O	O
2	O	O
)	O	O
Cl	O	O
(	O	O
2	O	O
)	O	O
]	O	O
,	O	O
alpha	O	O
-	O	O
[	O	O
Ru	O	O
(	O	O
azpy	O	O
)	O	O
(	O	O
2	O	O
)	O	O
(	O	O
NO	O	O
(	O	O
3	O	O
)	O	O
)	O	O
(	O	O
2	O	O
)	O	O
]	O	O
,	O	O
beta	O	O
-	O	O
[	O	O
Ru	O	O
(	O	O
azpy	O	O
)	O	O
(	O	O
2	O	O
)	O	O
Cl	O	O
(	O	O
2	O	O
)	O	O
]	O	O
(	O	O
beta	O	O
indicating	O	O
the	O	O
coordinating	O	O
pairs	O	O
Cl	O	O
,	O	O
N	O	O
(	O	O
py	O	O
)	O	O
,	O	O
and	O	O
N	O	O
(	O	O
azo	O	O
)	O	O
as	O	O
cis	O	O
,	O	O
cis	O	O
,	O	O
cis	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
and	O	O
beta	O	O
-	O	O
[	O	O
Ru	O	O
(	O	O
azpy	O	O
)	O	O
(	O	O
2	O	O
)	O	O
(	O	O
NO	O	O
(	O	O
3	O	O
)	O	O
)	O	O
(	O	O
2	O	O
)	O	O
]	O	O
have	O	O
been	O	O
determined	O	O
in	O	O
this	O	O
cell	O	O
line	O	O
.	O	O
All	O	O
target	O	O
compounds	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
inhibitory	O	O
effects	O	O
on	O	O
apomorphine	O	O
-	O	O
induced	O	O
stereotyped	O	O
behavior	O	O
in	O	O
rats	O	O
,	O	O
and	O	O
a	O	O
good	O	O
correlation	O	O
between	O	O
structure	O	O
and	O	O
activity	O	O
was	O	O
found	O	O
throughout	O	O
the	O	O
series	O	O
.	O	O
The	O	O
Kd	O	O
for	O	O
[	O	O
64Cu	O	O
]	O	O
CPTA	O	O
-	O	O
D	O	O
-	O	O
Phe1	O	O
-	O	O
octreotide	O	O
was	O	O
78.5	O	O
pM	O	O
.	O	O
A	O	O
number	O	O
of	O	O
3,4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
pyrazolo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
ribonucleosides	B-MODIFIER	B-MODIFIER
were	O	O
synthesized	O	O
and	O	O
tested	O	O
for	O	O
their	O	O
biological	O	O
activity	O	O
.	O	O
We	O	O
initially	O	O
investigated	O	O
the	O	O
stability	O	O
of	O	O
1	O	O
in	O	O
guinea	O	O
pig	O	O
plasma	O	O
and	O	O
liver	O	O
homogenate	O	O
to	O	O
elucidate	O	O
the	O	O
most	O	O
labile	O	O
part	O	O
in	O	O
the	O	O
structure	O	O
.	O	O
The	O	O
cytotoxic	O	O
activities	O	O
of	O	O
the	O	O
derived	O	O
compounds	O	O
against	O	O
the	O	O
human	O	O
tumor	O	O
cell	O	O
lines	O	O
were	O	O
equal	O	O
to	O	O
or	O	O
greater	O	O
than	O	O
that	O	O
of	O	O
the	O	O
lead	O	O
compound	O	O
.	O	O
Synthetic	O	O
procedures	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
various	O	O
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
unsubstituted	I-MODIFIER	I-MODIFIER
xanthines	B-IUPAC	B-IUPAC
,	O	O
including	O	O
paraxanthine	O	O
analogs	O	O
(	O	O
1,7	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
xanthines	B-IUPAC	B-IUPAC
)	O	O
and	O	O
1,8	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
xanthines	B-IUPAC	B-IUPAC
,	O	O
were	O	O
developed	O	O
.	O	O
Also	O	O
examined	O	O
were	O	O
analogues	O	O
in	O	O
which	O	O
tyrosine	O	O
was	O	O
replaced	O	O
with	O	O
either	O	O
trans	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
proline	I-IUPAC	I-IUPAC
(	O	O
t	O	O
-	O	O
Hpp	O	O
)	O	O
or	O	O
cis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
proline	I-IUPAC	I-IUPAC
(	O	O
c	O	O
-	O	O
Hpp	O	O
)	O	O
,	O	O
residues	O	O
in	O	O
which	O	O
rotations	O	O
about	O	O
C	O	O
alpha	O	O
-	O	O
C	O	O
beta	O	O
,	O	O
but	O	O
not	O	O
C	O	O
beta	O	O
-	O	O
C	O	O
gamma	O	O
,	O	O
are	O	O
restricted	O	O
.	O	O
The	O	O
affinity	O	O
and	O	O
selectivity	O	O
of	O	O
these	O	O
compounds	O	O
for	O	O
D	O	O
-	O	O
1	O	O
and	O	O
D	O	O
-	O	O
2	O	O
subtypes	O	O
was	O	O
determined	O	O
in	O	O
radioligand	O	O
competition	O	O
assays	O	O
for	O	O
the	O	O
DA	O	O
receptors	O	O
of	O	O
rat	O	O
striatum	O	O
membranes	O	O
using	O	O
[	O	O
3H	O	O
]	O	O
SCH	O	O
23390	O	O
(	O	O
D	O	O
-	O	O
1	O	O
selective	O	O
)	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
spiperone	O	O
(	O	O
D	O	O
-	O	O
2	O	O
selective	O	O
)	O	O
as	O	O
radioligands	O	O
.	O	O
All	O	O
compounds	O	O
were	O	O
tested	O	O
for	O	O
A1	O	O
adenosine	O	O
receptor	O	O
affinity	O	O
by	O	O
using	O	O
a	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
phenylisopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenosine	I-IUPAC	I-IUPAC
binding	O	O
assay	O	O
.	O	O
However	O	O
,	O	O
the	O	O
potency	O	O
of	O	O
all	O	O
of	O	O
these	O	O
latter	O	O
derivatives	O	O
was	O	O
at	O	O
least	O	O
1	O	O
order	O	O
of	O	O
magnitude	O	O
less	O	O
than	O	O
[	O	O
dPen1	O	O
,	O	O
cyclo	O	O
(	O	O
Glu4	O	O
,	O	O
Lys8	O	O
)	O	O
]	O	O
oxytocin	O	O
.	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Butylhomoibotenic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4c	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
homoibotenic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4e	O	O
)	O	O
were	O	O
equipotent	O	O
as	O	O
inhibitors	O	O
of	O	O
[	O	O
3H	O	O
]	O	O
AMPA	O	O
binding	O	O
(	O	O
IC50	O	O
=	O	O
2	O	O
microM	O	O
)	O	O
and	O	O
showed	O	O
similar	O	O
excitatory	O	O
activity	O	O
in	O	O
the	O	O
rat	O	O
cortical	O	O
slice	O	O
preparation	O	O
.	O	O
Pirenzepine	O	O
displayed	O	O
the	O	O
highest	O	O
affinity	O	O
for	O	O
hippocampal	O	O
,	O	O
striatal	O	O
,	O	O
and	O	O
amygdaloid	O	O
muscarinic	O	O
receptors	O	O
(	O	O
IC50	O	O
values	O	O
less	O	O
than	O	O
0.4	O	O
microM	O	O
)	O	O
,	O	O
with	O	O
a	O	O
slightly	O	O
lower	O	O
affinity	O	O
for	O	O
cortical	O	O
receptors	O	O
(	O	O
IC50	O	O
values	O	O
between	O	O
0.4	O	O
and	O	O
0.8	O	O
microM	O	O
)	O	O
.	O	O
A	O	O
broad	O	O
structure	O	O
-	O	O
activity	O	O
program	O	O
was	O	O
undertaken	O	O
in	O	O
search	O	O
of	O	O
effective	O	O
surrogates	O	O
for	O	O
the	O	O
key	O	O
benzothiazole	O	O
side	O	O
chain	O	O
of	O	O
the	O	O
potent	O	O
aldose	O	O
reductase	O	O
inhibitor	O	O
,	O	O
zopolrestat	O	O
(	O	O
1	O	O
)	O	O
.	O	O
It	O	O
was	O	O
hypothesized	O	O
that	O	O
the	O	O
reduced	O	O
flexibility	O	O
of	O	O
indoles	O	O
4-8	O	O
would	O	O
both	O	O
facilitate	O	O
the	O	O
mapping	O	O
of	O	O
the	O	O
BzR	O	O
binding	O	O
cleft	O	O
and	O	O
increase	O	O
the	O	O
chances	O	O
of	O	O
conferring	O	O
selectivity	O	O
for	O	O
the	O	O
considered	O	O
receptor	O	O
subtypes	O	O
.	O	O
DFO	O	O
-	O	O
HOPO	O	O
and	O	O
3,4,3	O	O
-	O	O
LIHOPO	O	O
and	O	O
its	O	O
Zn	O	O
(	O	O
II	O	O
)	O	O
and	O	O
Fe	O	O
(	O	O
III	O	O
)	O	O
complexes	O	O
promoted	O	O
significantly	O	O
more	O	O
Pu	O	O
excretion	O	O
than	O	O
CaNa3	O	O
-	O	O
DTPA	O	O
(	O	O
61%	O	O
of	O	O
injected	O	O
Pu	O	O
)	O	O
.	O	O
We	O	O
have	O	O
previously	O	O
shown	O	O
that	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
[	O	O
(	O	O
S	O	O
)	O	O
-	O	O
APPA	O	O
,	O	O
2	O	O
]	O	O
is	O	O
a	O	O
weak	O	O
agonist	O	O
at	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
)	O	O
receptors	O	O
,	O	O
specifically	O	O
activated	O	O
by	O	O
(	O	O
S	O	O
)	O	O
-	O	O
AMPA	O	O
(	O	O
1	O	O
)	O	O
,	O	O
whereas	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
[	O	O
(	O	O
S	O	O
)	O	O
-	O	O
2	O	O
-	O	O
Py	O	O
-	O	O
AMPA	O	O
,	O	O
5	O	O
]	O	O
and	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
are	O	O
potent	O	O
AMPA	O	O
agonists	O	O
.	O	O
The	O	O
novel	O	O
acidic	O	O
amino	O	O
acids	O	O
6a	O	O
-	O	O
c	O	O
,	O	O
7	O	O
,	O	O
and	O	O
8	O	O
have	O	O
been	O	O
synthesized	O	O
via	O	O
1,3	O	O
-	O	O
dipolar	O	O
cycloadditions	O	O
,	O	O
using	O	O
nitrile	O	O
oxides	O	O
and	O	O
alkynes	O	O
.	O	O
Two	O	O
major	O	O
diastereomers	O	O
of	O	O
[	O	O
99mTc	O	O
]	O	O
TRODAT	O	O
-	O	O
1	O	O
(	O	O
2	O	O
)	O	O
,	O	O
designated	O	O
as	O	O
peak	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
and	O	O
peak	O	O
B	O	O
(	O	O
2B	O	O
)	O	O
,	O	O
were	O	O
separated	O	O
by	O	O
HPLC	O	O
.	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
of	O	O
AMPA	O	O
,	O	O
compounds	O	O
8a	O	O
,	O	O
b	O	O
,	O	O
showed	O	O
high	O	O
affinity	O	O
for	O	O
[	O	O
3H	O	O
]	O	O
AMPA	O	O
receptor	O	O
binding	O	O
sites	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.15	O	O
+	O	O
/	O	O
-	O	O
0.03	O	O
microM	O	O
and	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
0.13	O	O
+	O	O
/	O	O
-	O	O
0.02	O	O
microM	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O
The	O	O
agonists	O	O
are	O	O
characterized	O	O
in	O	O
terms	O	O
of	O	O
their	O	O
in	O	O
vitro	O	O
profiles	O	O
,	O	O
both	O	O
binding	O	O
and	O	O
functional	O	O
,	O	O
and	O	O
in	O	O
vivo	O	O
activity	O	O
in	O	O
relevant	O	O
animal	O	O
models	O	O
.	O	O
Preliminary	O	O
stroke	O	O
results	O	O
from	O	O
1	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
and	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenanthridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
prompted	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
to	O	O
be	O	O
established	O	O
for	O	O
several	O	O
2	B-MODIFIER	B-PARTIUPAC
-	I-MODIFIER	I-PARTIUPAC
and	O	O
3	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenanthridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
.	O	O
The	O	O
[	B-IUPAC	B-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazine	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
3	O	O
,	O	O
more	O	O
commonly	O	O
known	O	O
in	O	O
the	O	O
field	O	O
of	O	O
adenosine	O	O
research	O	O
as	O	O
ZM	O	O
-	O	O
241385	O	O
,	O	O
has	O	O
previously	O	O
been	O	O
demonstrated	O	O
to	O	O
be	O	O
a	O	O
potent	O	O
and	O	O
selective	O	O
adenosine	O	O
A2a	O	O
receptor	O	O
antagonist	O	O
,	O	O
although	O	O
with	O	O
limited	O	O
oral	O	O
bioavailability	O	O
.	O	O
7	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
are	O	O
potent	O	O
inhibitors	O	O
of	O	O
protein	O	O
tyrosine	O	O
kinases	O	O
,	O	O
with	O	O
some	O	O
selectivity	O	O
for	O	O
c	O	O
-	O	O
Src	O	O
.	O	O
The	O	O
determination	O	O
of	O	O
the	O	O
structure	O	O
and	O	O
function	O	O
of	O	O
the	O	O
sigma	O	O
receptor	O	O
subtypes	O	O
and	O	O
their	O	O
physiological	O	O
role	O	O
(	O	O
s	O	O
)	O	O
has	O	O
been	O	O
impeded	O	O
by	O	O
the	O	O
unavailability	O	O
of	O	O
selective	O	O
ligands	O	O
.	O	O
The	O	O
carbonyl	B-IUPAC	O
group	B-MODIFIER	O
at	O	O
position	O	O
4	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chromanone	I-IUPAC	I-IUPAC
was	O	O
essential	O	O
for	O	O
potent	O	O
ACAT	O	O
inhibitory	O	O
activity	O	O
.	O	O
A	O	O
series	O	O
of	O	O
erythro	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
azole	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
have	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
adenosine	O	O
deaminase	O	O
(	O	O
ADA	O	O
)	O	O
inhibitory	O	O
activity	O	O
,	O	O
in	O	O
order	O	O
to	O	O
introduce	O	O
simplifications	O	O
in	O	O
the	O	O
ADA	O	O
inhibitor	O	O
erythro	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
(	O	O
EHNA	O	O
,	O	O
1a	O	O
)	O	O
.	O	O
Nitration	O	O
of	O	O
4	O	O
,	O	O
followed	O	O
by	O	O
oxidation	O	O
with	O	O
selenium	O	O
dioxide	O	O
,	O	O
produced	O	O
aldehyde	O	O
18	O	O
,	O	O
which	O	O
was	O	O
then	O	O
converted	O	O
to	O	O
the	O	O
cyclic	O	O
ethylene	O	O
acetal	O	O
19	O	O
.	O	O
The	O	O
absolute	O	O
configurations	O	O
of	O	O
the	O	O
latter	O	O
were	O	O
established	O	O
by	O	O
conversion	O	O
of	O	O
1L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
2,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tri	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxybenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
to	O	O
the	O	O
known	O	O
1L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4,5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
penta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
myo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
inositol	I-IUPAC	I-IUPAC
.	O	O
carinii	O	O
DHFR	O	O
was	O	O
20	O	O
-	O	O
fold	O	O
greater	O	O
than	O	O
that	O	O
of	O	O
PTX	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
13	O	O
nM	O	O
)	O	O
,	O	O
and	O	O
its	O	O
selectivity	O	O
index	O	O
(	O	O
SI	O	O
)	O	O
relative	O	O
to	O	O
rat	O	O
DHFR	O	O
was	O	O
85	O	O
,	O	O
whereas	O	O
PTX	O	O
was	O	O
nonselective	O	O
.	O	O
Hydrogenolytic	O	O
removal	O	O
of	O	O
the	O	O
carbobenzyloxy	O	O
groups	O	O
,	O	O
followed	O	O
by	O	O
iodoacetylation	O	O
of	O	O
the	O	O
omega	O	O
-	O	O
amino	O	O
groups	O	O
with	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
iodoacetoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
succinimide	I-IUPAC	I-IUPAC
,	O	O
gave	O	O
N6	O	O
-	O	O
R	O	O
-	O	O
ATP	O	O
,	O	O
where	O	O
R	O	O
=	O	O
(	O	O
CH2	O	O
)	O	O
nNHCOCH2I	O	O
(	O	O
n	O	O
=	O	O
2	O	O
-	O	O
-	O	O
8	O	O
)	O	O
or	O	O
(	O	O
CH2	O	O
)	O	O
nCON	O	O
)	O	O
CH3	O	O
)	O	O
(	O	O
CH2	O	O
)	O	O
mN	O	O
(	O	O
CH3	O	O
)	O	O
CO	O	O
(	O	O
CH2	O	O
)	O	O
nNHCOCH2I	O	O
(	O	O
n	O	O
=	O	O
m	O	O
=	O	O
3	O	O
;	O	O
n	O	O
=	O	O
3	O	O
,	O	O
m	O	O
=	O	O
4	O	O
;	O	O
n	O	O
=	O	O
4	O	O
,	O	O
m	O	O
=	O	O
3	O	O
;	O	O
n	O	O
=	O	O
m	O	O
=	O	O
4	O	O
)	O	O
.	O	O
The	O	O
rates	O	O
of	O	O
hydrolysis	O	O
of	O	O
Northern	O	O
(	O	O
N	O	O
)	O	O
and	O	O
Southern	O	O
(	O	O
S	O	O
)	O	O
methanocarba	O	O
analogues	O	O
of	O	O
AMP	O	O
by	O	O
rat	O	O
5'	O	O
-	O	O
ectonucleotidase	O	O
were	O	O
negligible	O	O
.	O	O
An	O	O
n	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
gives	O	O
high	O	O
dopaminergic	O	O
efficacy	O	O
at	O	O
both	O	O
receptor	O	O
sites	O	O
(	O	O
pre	O	O
-	O	O
and	O	O
postsynaptic	O	O
)	O	O
in	O	O
all	O	O
series	O	O
.	O	O
Binding	O	O
to	O	O
alpha	O	O
1	O	O
-	O	O
ARs	O	O
was	O	O
relatively	O	O
sensitive	O	O
to	O	O
size	O	O
and	O	O
electronic	O	O
features	O	O
of	O	O
the	O	O
arylpiperazine	B-IUPAC	O
portion	O	O
of	O	O
the	O	O
antagonists	O	O
and	O	O
permissive	O	O
to	O	O
these	O	O
features	O	O
on	O	O
the	O	O
heteroaryl	O	O
carboxamide	O	O
side	O	O
.	O	O
The	O	O
third	O	O
step	O	O
is	O	O
the	O	O
P	O	O
-	O	O
N	O	O
ring	O	O
opening	O	O
of	O	O
the	O	O
oxazaphosphorines	O	O
3a	O	O
,	O	O
b	O	O
leading	O	O
to	O	O
the	O	O
phosphoric	O	O
acid	O	O
monoesters	O	O
,	O	O
H	O	O
(	O	O
2	O	O
)	O	O
N	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
3	O	O
)	O	O
OP	O	O
(	O	O
O	O	O
)	O	O
(	O	O
OH	O	O
)	O	O
(	O	O
2	O	O
)	O	O
(	O	O
4a	O	O
)	O	O
and	O	O
Cl	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
2	O	O
)	O	O
HN	O	O
(	O	O
CH	O	O
(	O	O
2	O	O
)	O	O
)	O	O
(	O	O
3	O	O
)	O	O
OP	O	O
(	O	O
O	O	O
)	O	O
(	O	O
OH	O	O
)	O	O
(	O	O
2	O	O
)	O	O
(	O	O
4b	O	O
-	O	O
1	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
The	O	O
sigma	O	O
receptor	O	O
binding	O	O
affinities	O	O
of	O	O
these	O	O
compounds	O	O
were	O	O
determined	O	O
using	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
+	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentazocine	I-IUPAC	I-IUPAC
in	O	O
guinea	O	O
pig	O	O
brain	O	O
homogenates	O	O
.	O	O
(	O	O
1	O	O
)	O	O
Other	O	O
closely	O	O
related	O	O
analogues	O	O
,	O	O
such	O	O
as	O	O
those	O	O
where	O	O
the	O	O
[	O	O
DAsp	O	O
(	O	O
1	O	O
)	O	O
(	O	O
betaAla	O	O
)	O	O
,	O	O
DOrn	O	O
(	O	O
3	O	O
)	O	O
]	O	O
cycle	O	O
of	O	O
21	O	O
was	O	O
changed	O	O
to	O	O
[	O	O
DOrn	O	O
(	O	O
1	O	O
)	O	O
(	O	O
betaAla	O	O
)	O	O
,	O	O
DAsp	O	O
(	O	O
3	O	O
)	O	O
]	O	O
of	O	O
cyclo	O	O
(	O	O
1,1	O	O
'	O	O
-	O	O
3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DOrn	O	O
(	O	O
1	O	O
)	O	O
(	O	O
betaAla	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DAsp	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DAla	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
22	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
2.2	O	O
nM	O	O
)	O	O
or	O	O
where	O	O
the	O	O
size	O	O
of	O	O
the	O	O
cycle	O	O
was	O	O
conserved	O	O
and	O	O
[	O	O
DAsp	O	O
(	O	O
1	O	O
)	O	O
(	O	O
betaAla	O	O
)	O	O
,	O	O
DOrn	O	O
(	O	O
3	O	O
)	O	O
]	O	O
was	O	O
replaced	O	O
by	O	O
[	O	O
DGlu	O	O
(	O	O
1	O	O
)	O	O
(	O	O
Gly	O	O
)	O	O
,	O	O
DOrn	O	O
(	O	O
3	O	O
)	O	O
]	O	O
as	O	O
in	O	O
cyclo	O	O
(	O	O
1	O	O
,	O	O
1'	O	O
-	O	O
3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DGlu	O	O
(	O	O
1	O	O
)	O	O
(	O	O
Gly	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DOrn	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DA	O	O
la	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
23	O	O
,	O	O
K	O	O
(	O	O
i	O	O
)	O	O
=	O	O
4.2	O	O
nM	O	O
)	O	O
,	O	O
were	O	O
approximately	O	O
100	O	O
and	O	O
25	O	O
times	O	O
less	O	O
potent	O	O
in	O	O
vivo	O	O
,	O	O
respectively	O	O
.	O	O
One	O	O
of	O	O
these	O	O
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8,9,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
,	O	O
showed	O	O
good	O	O
activity	O	O
in	O	O
rats	O	O
as	O	O
a	O	O
potential	O	O
anxiolytic	O	O
agent	O	O
without	O	O
sedative	O	O
liability	O	O
.	O	O
Deamination	O	O
of	O	O
12	O	O
with	O	O
nitrous	O	O
acid	O	O
produced	O	O
3	O	O
,	O	O
thereby	O	O
confirming	O	O
that	O	O
alkylation	O	O
of	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bis	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trimethylsilyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
oxy	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
had	O	O
occurred	O	O
at	O	O
N1	O	O
.	O	O
The	O	O
latter	O	O
reaction	O	O
with	O	O
6	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	O	I-IUPAC
substituted	B-MODIFIER	B-MODIFIER
amino	B-IUPAC	B-IUPAC
)	O	I-IUPAC
-	B-PARTIUPAC	I-IUPAC
4,5	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
diaminopyridines	I-PARTIUPAC	I-IUPAC
gave	O	O
imidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
ring	B-MODIFIER	O
analogues	I-MODIFIER	O
of	O	O
1	O	O
.	O	O
In	O	O
these	O	O
compounds	O	O
,	O	O
the	O	O
planes	O	O
of	O	O
the	O	O
phenyl	O	B-IUPAC
and	O	O
piperidyl	O	B-IUPAC
moieties	O	B-MODIFIER
of	O	O
the	O	O
parent	O	O
ligand	O	O
1	O	O
are	O	O
held	O	O
at	O	O
right	O	O
angles	O	O
by	O	O
vinyl	O	O
,	O	O
ethylene	O	O
,	O	O
and	O	O
propylene	O	O
bridges	O	O
to	O	O
form	O	O
N	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	O
derivatives	B-MODIFIER	O
of	O	O
spiro	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
indene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
,	O	I-IUPAC
2,3	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrospiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
indene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
,	O	O
and	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydrospiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
naphthalene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
,	O	O
respectively	O	O
.	O	O
Inclusion	O	O
of	O	O
ClogP	O	O
did	O	O
not	O	O
improve	O	O
the	O	O
models	O	O
significantly	O	O
and	O	O
exhibited	O	O
comparable	O	O
correlation	O	O
coefficients	O	O
with	O	O
CoMFA	O	O
steric	O	O
and	O	O
electrostatic	O	O
models	O	O
.	O	O
The	O	O
ineffectiveness	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylpyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
is	O	O
imputable	O	O
to	O	O
the	O	O
alkyl	O	O
chain	O	O
which	O	O
could	O	O
hinder	O	O
the	O	O
coordination	O	O
with	O	O
molybdenum	O	O
according	O	O
to	O	O
the	O	O
known	O	O
mechanism	O	O
for	O	O
the	O	O
binding	O	O
of	O	O
the	O	O
inhibitor	O	O
allopurinol	O	O
;	O	O
the	O	O
effectiveness	O	O
of	O	O
imidazole	O	O
derivatives	O	O
,	O	O
by	O	O
contrast	O	O
with	O	O
the	O	O
ineffectiveness	O	O
of	O	O
4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
thioalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxypyrimidines	I-IUPAC	I-IUPAC
,	O	O
indicates	O	O
the	O	O
relative	O	O
importance	O	O
of	O	O
the	O	O
five	O	O
-	O	O
membered	O	O
ring	O	O
in	O	O
the	O	O
interaction	O	O
with	O	O
the	O	O
enzyme	O	O
.	O	O
Bromination	O	O
-	O	O
dehydrobromination	O	O
of	O	O
the	O	O
5'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
bromohomovinyl	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
11	O	O
and	O	O
deprotection	O	O
gave	O	O
(	B-IUPAC	B-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hex	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
.	O	O
The	O	O
compounds	O	O
were	O	O
also	O	O
evaluated	O	O
against	O	O
TS	O	O
from	O	O
(	O	O
recombinant	O	O
)	O	O
human	O	O
and	O	O
L	O	O
.	O	O
The	O	O
three	O	O
most	O	O
potent	O	O
inhibitors	O	O
of	O	O
P	O	O
.	O	O
Cyclic	O	O
dianhydride	O	O
of	O	O
diethylenetriaminepentaacetic	O	O
acid	O	O
(	O	O
DTPA	O	O
)	O	O
was	O	O
coupled	O	O
to	O	O
a	O	O
portion	O	O
of	O	O
the	O	O
protected	O	O
peptide	O	O
-	O	O
resin	O	O
following	O	O
disulfide	O	O
bond	O	O
formation	O	O
.	O	O
Fluorescence	O	O
measurements	O	O
show	O	O
that	O	O
there	O	O
are	O	O
two	O	O
species	O	O
of	O	O
tomaymycin	O	O
bound	O	O
to	O	O
d	O	O
(	O	O
ATGCAT	O	O
)	O	O
2	O	O
,	O	O
which	O	O
are	O	O
tentatively	O	O
identified	O	O
as	O	O
the	O	O
11R	O	O
,	O	O
11aS	O	O
and	O	O
11S	O	O
,	O	O
11aS	O	O
diastereomers	O	O
.	O	O
The	O	O
best	O	O
inhibitor	O	O
of	O	O
P	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
SAR	O	O
of	O	O
a	O	O
series	O	O
of	O	O
known	O	O
gamma	O	B-IUPAC
-	O	I-IUPAC
aminobutyric	O	I-IUPAC
acid	O	I-IUPAC
(	O	O
GABA	O	O
)	O	O
uptake	O	O
inhibitors	O	O
,	O	O
including	O	O
4	O	O
(	O	O
SKF	O	O
89976	O	O
)	O	O
,	O	O
new	O	O
tricyclic	O	O
analogues	O	O
have	O	O
been	O	O
prepared	O	O
.	O	O
6,7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclopenta	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
33	O	O
)	O	O
exhibited	O	O
a	O	O
K	O	O
(	O	O
i	O	O
)	O	O
value	O	O
of	O	O
630	O	O
nM	O	O
and	O	O
excelled	O	O
in	O	O
its	O	O
low	O	O
susceptibility	O	O
to	O	O
CEase	O	O
-	O	O
catalyzed	O	O
degradation	O	O
.	O	O
Selected	O	O
ion	O	O
-	O	O
monitoring	O	O
GC	O	O
-	O	O
MS	O	O
analysis	O	O
,	O	O
based	O	O
on	O	O
use	O	O
of	O	O
the	O	O
synthesized	O	O
mixture	O	O
of	O	O
diastereoisomers	O	O
of	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propanol	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
as	O	O
a	O	O
standard	O	O
,	O	O
established	O	O
formation	O	O
of	O	O
both	O	O
diastereoisomers	O	O
of	O	O
2	O	O
as	O	O
metabolites	O	O
of	O	O
1	O	O
.	O	O
1,3	B-MODIFIER	O
-	I-MODIFIER	O
Disubstituted	I-MODIFIER	O
xanthines	B-IUPAC	O
generally	O	O
had	O	O
higher	O	O
affinity	O	O
than	O	O
1,7	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
disubstituted	I-MODIFIER	I-MODIFIER
xanthines	B-IUPAC	B-IUPAC
.	O	O
gondii	O	O
)	O	O
was	O	O
ca.	O	O
30	O	O
-	O	O
fold	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
TMQ	O	O
or	O	O
PTX	O	O
.	O	O
This	O	O
study	O	O
should	O	O
be	O	O
applicable	O	O
to	O	O
other	O	O
biologically	O	O
active	O	O
peptides	O	O
.	O	O
Only	O	O
1%	O	O
of	O	O
298	O	O
enzyme	O	O
-	O	O
inhibitor	O	O
combinations	O	O
exhibited	O	O
ATP	O	O
-	O	O
site	O	O
-	O	O
directed	O	O
inactivation	O	O
,	O	O
signifying	O	O
that	O	O
few	O	O
suitably	O	O
positioned	O	O
and	O	O
sufficiently	O	O
reactive	O	O
nucleophilic	O	O
groups	O	O
were	O	O
present	O	O
near	O	O
the	O	O
enzymic	O	O
ATP	O	O
sites	O	O
.	O	O
In	O	O
general	O	O
,	O	O
an	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
or	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
enhanced	O	O
inhibitory	O	O
activity	O	O
in	O	O
comparison	O	O
with	O	O
an	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
.	O	O
The	O	O
17	O	O
-	O	O
O	O	O
-	O	O
THP	O	O
derivative	O	O
of	O	O
3	O	O
was	O	O
treated	O	O
with	O	O
LiAlH4	O	O
to	O	O
give	O	O
17beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyranyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
secoestra	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3,5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triene	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
.	O	O
In	O	O
this	O	O
model	O	O
,	O	O
ICI	O	O
204,219	O	O
was	O	O
active	O	O
at	O	O
0.4	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
Half	O	O
-	O	O
maximal	O	O
hydroosmotic	O	O
responses	O	O
(	O	O
ED	O	O
-	O	O
50	O	O
values	O	O
)	O	O
were	O	O
obtained	O	O
with	O	O
2.5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
9	O	O
)	O	O
M	O	O
for	O	O
the	O	O
iodinated	O	O
analogue	O	O
,	O	O
with	O	O
0.9	O	O
X	O	O
10	O	O
(	O	O
-	O	O
10	O	O
)	O	O
M	O	O
for	O	O
the	O	O
photoaffinity	O	O
analogue	O	O
,	O	O
and	O	O
with	O	O
1.2	O	O
X	O	O
10	O	O
(	O	O
-	O	O
8	O	O
)	O	O
M	O	O
for	O	O
the	O	O
biotinyl	O	O
analogue	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
studies	O	O
indicate	O	O
that	O	O
the	O	O
role	O	O
of	O	O
the	O	O
NPS	O	O
and	O	O
CmPS	O	O
moieties	O	O
could	O	O
be	O	O
related	O	O
to	O	O
the	O	O
adoption	O	O
of	O	O
a	O	O
preferential	O	O
active	O	O
conformation	O	O
.	O	O
Molecular	O	O
modeling	O	O
dynamics	O	O
studies	O	O
using	O	O
compounds	O	O
10	O	O
and	O	O
13	O	O
indicated	O	O
a	O	O
slight	O	O
binding	O	O
preference	O	O
for	O	O
the	O	O
latter	O	O
,	O	O
in	O	O
qualitative	O	O
agreement	O	O
with	O	O
the	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
data	O	O
.	O	O
In	O	O
summary	O	O
,	O	O
there	O	O
are	O	O
clear	O	O
limits	O	O
to	O	O
the	O	O
size	O	O
of	O	O
N	O	O
(	O	O
1	O	O
)	O	O
-	O	O
substituents	O	O
,	O	O
which	O	O
can	O	O
be	O	O
accommodated	O	O
by	O	O
the	O	O
polyamine	O	O
transporter	O	O
.	O	O
Further	O	O
structural	O	O
manipulation	O	O
was	O	O
guided	O	O
by	O	O
molecular	O	O
modeling	O	O
through	O	O
comparison	O	O
of	O	O
fieldpoint	O	O
-	O	O
based	O	O
structures	O	O
of	O	O
candidate	O	O
compounds	O	O
with	O	O
a	O	O
selected	O	O
low	O	O
-	O	O
energy	O	O
conformation	O	O
of	O	O
the	O	O
representative	O	O
CCK	O	O
(	O	O
2	O	O
)	O	O
receptor	O	O
antagonist	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dicarboxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
adamantylmethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
carbonyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
indole	I-IUPAC	I-IUPAC
(	O	O
JB93182	O	O
(	O	O
3	O	O
)	O	O
)	O	O
.	O	O
The	O	O
4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphtho	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bc	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiophene	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxaspiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4.5	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
dec	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthol	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bc	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
thiophene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
toluenesulfonate	I-IUPAC	I-IUPAC
(	O	O
17	O	O
)	O	O
also	O	O
has	O	O
high	O	O
kappa	O	O
opioid	O	O
receptor	O	O
affinity	O	O
and	O	O
selectivity	O	O
(	O	O
kappa	O	O
Ki	O	O
=	O	O
4.65	O	O
nM	O	O
,	O	O
mu	O	O
/	O	O
kappa	O	O
=	O	O
109	O	O
)	O	O
.	O	O
Reaction	O	O
of	O	O
2	O	O
with	O	O
sodium	O	O
azide	O	O
,	O	O
ceric	O	O
ammonium	O	O
nitrate	O	O
,	O	O
and	O	O
acetonitrile	O	B-IUPAC
-	O	I-IUPAC
methanol	O	I-IUPAC
or	O	O
water	O	O
afforded	O	O
the	O	O
5	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
1	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
hydroxy	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
azidoethyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
(	O	O
10	O	O
)	O	O
and	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azidoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxyuridines	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
.	O	O
The	O	O
results	O	O
indicate	O	O
that	O	O
compounds	O	O
6	O	O
and	O	O
11	O	O
have	O	O
animal	O	O
behavioral	O	O
pharmacology	O	O
similar	O	O
to	O	O
the	O	O
methylenedioxy	O	O
compounds	O	O
1	O	O
and	O	O
2	O	O
,	O	O
but	O	O
that	O	O
they	O	O
do	O	O
not	O	O
induce	O	O
the	O	O
serotonin	O	O
neurotoxicity	O	O
that	O	O
has	O	O
been	O	O
observed	O	O
for	O	O
the	O	O
latter	O	O
two	O	O
drugs	O	O
.	O	O
Synthesis	O	O
of	O	O
new	O	O
analogues	O	O
of	O	O
1	O	O
,	O	O
modified	O	O
only	O	O
in	O	O
the	O	O
heterocyclic	O	O
moiety	O	O
(	O	O
five	O	O
-	O	O
,	O	O
six	O	O
-	O	O
,	O	O
or	O	O
seven	O	O
-	O	O
membered	O	O
rings	O	O
with	O	O
NH	O	O
,	O	O
S	O	O
,	O	O
O	O	O
,	O	O
and	O	O
CH2	O	O
substituents	O	O
)	O	O
,	O	O
gave	O	O
compounds	O	O
varying	O	O
from	O	O
4	O	O
-	O	O
fold	O	O
higher	O	O
potency	O	O
(	B-IUPAC	O
2	I-IUPAC	O
-	I-IUPAC	O
iminothiazole	I-IUPAC	O
analogue	O	O
10	O	O
)	O	O
to	O	O
&	O	O
gt	O	O
;	O	O
6000	O	O
-	O	O
fold	O	O
less	O	O
active	O	O
than	O	O
(	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nicotine	I-IUPAC	I-IUPAC
.	O	O
It	O	O
was	O	O
consequently	O	O
revealed	O	O
that	O	O
the	O	O
benzyl	O	O
ester	O	O
part	O	O
was	O	O
easily	O	O
hydrolyzed	O	O
to	O	O
produce	O	O
the	O	O
inactive	O	O
acid	O	O
analog	O	O
.	O	O
A	O	O
series	O	O
of	O	O
functionalized	O	O
congeners	O	O
of	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dialkylxanthines	I-IUPAC	I-IUPAC
has	O	O
been	O	O
prepared	O	O
as	O	O
adenosine	O	O
receptor	O	O
antagonists	O	O
.	O	O
A	O	O
series	O	O
of	O	O
eight	O	O
previously	O	O
undescribed	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminothieno	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
of	O	O
the	O	O
potent	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
inhibitors	O	O
trimetrexate	O	O
(	O	O
TMQ	O	O
)	O	O
and	O	O
piritrexim	O	O
(	O	O
PTX	O	O
)	O	O
were	O	O
synthesized	O	O
as	O	O
potential	O	O
drugs	O	O
against	O	O
Pneumocystis	O	O
carinii	O	O
and	O	O
Toxoplasma	O	O
gondii	O	O
,	O	O
which	O	O
are	O	O
major	O	O
causes	O	O
of	O	O
severe	O	O
opportunistic	O	O
infections	O	O
in	O	O
AIDS	O	O
patients	O	O
.	O	O
The	O	O
pharmacological	O	O
/	O	O
pharmaceutical	O	O
properties	O	O
of	O	O
four	O	O
compounds	O	O
(	O	O
4	O	O
,	O	O
RHPS4	O	O
)	O	O
,	O	O
(	O	O
5	O	O
,	O	O
IH383	O	O
)	O	O
,	O	O
(	O	O
6	O	O
,	O	O
RHPS16	O	O
)	O	O
,	O	O
and	O	O
(	O	O
17	O	O
,	O	O
RHPS19	O	O
)	O	O
were	O	O
measured	O	O
to	O	O
assess	O	O
their	O	O
clinical	O	O
potential	O	O
as	O	O
DNA	O	O
G	O	O
-	O	O
quadruplex	O	O
-	O	O
stabilizing	O	O
/	O	O
telomerase	O	O
inhibitory	O	O
agents	O	O
.	O	O
Reaction	O	O
of	O	O
5,6,7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrofolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
THF	O	O
,	O	O
7	O	O
)	O	O
with	O	O
phosgene	O	O
,	O	O
thiophosgene	O	O
,	O	O
and	O	O
cyanogen	O	O
bromide	O	O
gave	O	O
the	O	O
bridged	O	O
derivatives	O	O
,	O	O
5,10	O	O
-	O	O
(	O	O
CO	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
8	O	O
)	O	O
,	O	O
5,10	O	O
-	O	O
(	O	O
CS	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
9	O	O
)	O	O
,	O	O
and	O	O
5,10	O	O
-	O	O
(	O	O
C	O	O
=	O	O
NH	O	O
)	O	O
-	O	O
THF	O	O
(	O	O
11	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O
Further	O	O
,	O	O
both	O	O
17c	O	O
and	O	O
26	O	O
displayed	O	O
high	O	O
intrinsic	O	O
activity	O	O
in	O	O
stimulating	O	O
the	O	O
release	O	O
of	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
dopamine	O	O
from	O	O
striatal	O	O
synaptosomes	O	O
;	O	O
however	O	O
,	O	O
only	O	O
17c	O	O
was	O	O
effective	O	O
at	O	O
stimulating	O	O
the	O	O
release	O	O
of	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
acetylcholine	O	O
from	O	O
cortical	O	O
synaptosomes	O	O
,	O	O
suggesting	O	O
differential	O	O
selectivity	O	O
.	O	O
Pomeranz	O	O
-	O	O
Fritsch	O	O
condensation	O	O
followed	O	O
by	O	O
borohydride	O	O
reduction	O	O
and	O	O
acid	O	O
-	O	O
catalyzed	O	O
cyclization	O	O
led	O	O
smoothly	O	O
to	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinoline	I-IUPAC	I-IUPAC
.	O	O
A	O	O
series	O	O
of	O	O
N	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkynyl	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
of	O	O
adenosine	O	O
(	O	O
Ado	O	O
)	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
for	O	O
their	O	O
affinity	O	O
at	O	O
human	O	O
A	O	O
(	O	O
1	O	O
)	O	O
,	O	O
A	O	O
(	O	O
2A	O	O
)	O	O
,	O	O
and	O	O
A	O	O
(	O	O
3	O	O
)	O	O
receptors	O	O
and	O	O
for	O	O
their	O	O
potency	O	O
at	O	O
A	O	O
(	O	O
2B	O	O
)	O	O
adenosine	O	O
receptor	O	O
subtypes	O	O
.	O	O
Amino	O	O
acid	O	O
analysis	O	O
subsequent	O	O
to	O	O
acid	O	O
hydrolysis	O	O
demonstrated	O	O
that	O	O
Met	O	O
had	O	O
been	O	O
selectively	O	O
alkylated	O	O
by	O	O
the	O	O
O'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
epoxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
tyrosine	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
.	O	O
administration	O	O
of	O	O
the	O	O
same	O	O
dose	O	O
.	O	O
On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
criteria	O	O
of	O	O
molecular	O	O
mass	O	O
,	O	O
RP	O	O
-	O	O
HPLC	O	O
elution	O	O
time	O	O
,	O	O
sequence	O	O
analysis	O	O
,	O	O
and	O	O
somatostatin	O	O
receptor	O	O
binding	O	O
affinity	O	O
,	O	O
our	O	O
synthetic	O	O
octreotide	O	O
is	O	O
identical	O	O
to	O	O
commercially	O	O
available	O	O
octreotide	O	O
.	O	O
A	O	O
series	O	O
of	O	O
(	B-IUPAC	B-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminoethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
indolones	I-IUPAC	I-IUPAC
and	O	O
related	O	O
compounds	O	O
was	O	O
synthesized	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
as	O	O
peripheral	O	O
prejunctional	O	O
dopaminergic	O	O
agonists	O	O
in	O	O
the	O	O
field	O	O
-	O	O
stimulated	O	O
isolated	O	O
perfused	O	O
rabbit	O	O
ear	O	O
artery	O	O
.	O	O
Analogue	O	O
3	O	O
was	O	O
a	O	O
good	O	O
substrate	O	O
for	O	O
human	O	O
folylpolyglutamate	O	O
synthetase	O	O
(	O	O
FPGS	O	O
)	O	O
derived	O	O
from	O	O
CCRF	O	O
-	O	O
CEM	O	O
cells	O	O
(	O	O
Km	O	O
8.5	O	O
microM	O	O
)	O	O
.	O	O
The	O	O
5,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dideaza	I-IUPAC	I-IUPAC
analogues	B-MODIFIER	B-MODIFIER
were	O	O
prepared	O	O
from	O	O
methyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aminobenzoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phthalimidopentanoate	I-IUPAC	I-IUPAC
and	O	O
2	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminoquinazoline	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbonitriles	I-IUPAC	I-IUPAC
.	O	O
In	O	O
this	O	O
cisplatin	O	O
-	O	O
sensitive	O	O
cell	O	O
line	O	O
the	O	O
complexes	O	O
containing	O	O
cyclohexane	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamine	I-IUPAC	I-IUPAC
(	O	O
chxn	O	O
)	O	O
displayed	O	O
a	O	O
high	O	O
activity	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
diammine	B-IUPAC	O
and	O	O
ethane	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamine	I-IUPAC	I-IUPAC
counterparts	O	B-MODIFIER
.	O	O
The	O	O
potency	O	O
of	O	O
13	O	O
against	O	O
P	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
ethyl	B-IUPAC	O
or	O	O
methyl	B-IUPAC	B-IUPAC
4	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
substituted	I-MODIFIER	I-MODIFIER
or	O	O
unsubstituted	B-MODIFIER	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidinecarboxylates	I-IUPAC	I-IUPAC
10-20	O	O
,	O	O
which	O	O
is	O	O
mainly	O	O
carried	O	O
out	O	O
by	O	O
reaction	O	O
of	O	O
ethyl	B-IUPAC	O
or	O	O
methyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methylene	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxoalkanoates	I-IUPAC	I-IUPAC
with	O	O
1,1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dimethylguanidine	I-IUPAC	I-IUPAC
,	O	O
is	O	O
described	O	O
.	O	O
Optimization	O	O
led	O	O
to	O	O
the	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
iodo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloro	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
(	O	O
53	O	O
)	O	O
,	O	O
which	O	O
is	O	O
the	O	O
most	O	O
potent	O	O
and	O	O
selective	O	O
glycine	O	O
/	O	O
NMDA	O	O
antagonist	O	O
to	O	O
date	O	O
(	O	O
IC50	O	O
vs	O	O
[	O	O
3H	O	O
]	O	O
glycine	O	O
binding	O	O
,	O	O
32	O	O
nM	O	O
;	O	O
IC50	O	O
's	O	O
for	O	O
other	O	O
excitatory	O	O
amino	O	O
acid	O	O
receptor	O	O
sites	O	O
,	O	O
greater	O	O
than	O	O
100	O	O
microM	O	O
)	O	O
.	O	O
Condensation	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
formylpteroic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
fAPA	O	O
)	O	O
with	O	O
dimethyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
DL	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyleneglutamate	I-IUPAC	I-IUPAC
by	O	O
the	O	O
mixed	O	O
carboxylic	O	O
-	O	O
carbonic	O	O
anhydride	O	O
method	O	O
yielded	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxypteroyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
DL	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyleneglutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
gamma	O	O
-	O	O
methyleneAMT	O	O
)	O	O
.	O	O
Comparison	O	O
of	O	O
both	O	O
the	O	O
sigma	O	O
receptor	O	O
affinities	O	O
and	O	O
nitrogen	O	O
atom	O	O
geometry	O	O
of	O	O
the	O	O
compounds	O	O
revealed	O	O
that	O	O
a	O	O
gauche	O	O
relation	O	O
of	O	O
the	O	O
nitrogen	O	O
atoms	O	O
of	O	O
cis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanediamines	I-IUPAC	I-IUPAC
is	O	O
not	O	O
imperative	O	O
for	O	O
high	O	O
affinity	O	O
as	O	O
we	O	O
had	O	O
previously	O	O
thought	O	O
.	O	O
Esterification	O	O
of	O	O
2a	O	O
with	O	O
isobutylene	O	O
afforded	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbobenzoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diaminopropionate	I-IUPAC	I-IUPAC
(	O	O
3a	O	O
)	O	O
,	O	O
which	O	O
was	O	O
then	O	O
blocked	O	O
at	O	O
the	O	O
2	O	O
position	O	O
with	O	O
the	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
(	O	O
Boc	O	O
)	O	O
group	B-MODIFIER	O
to	O	O
give	O	O
tert	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
carbobenzoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
propionate	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
.	O	O
The	O	O
primary	O	O
sulfonamides	O	O
were	O	O
reversible	O	O
noncompetitive	O	O
inhibitors	O	O
of	O	O
carbonic	O	O
anhydrase	O	O
,	O	O
with	O	O
no	O	O
effect	O	O
on	O	O
IOP	O	O
after	O	O
topical	O	O
administration	O	O
.	O	O
Hydrophobic	O	O
clustering	O	O
of	O	O
the	O	O
side	O	O
chains	O	O
of	O	O
Tyr	O	O
(	O	O
4	O	O
)	O	O
,	O	O
Phe	O	O
(	O	O
5	O	O
)	O	O
,	O	O
Ile	O	O
(	O	O
8	O	O
)	O	O
,	O	O
and	O	O
Trp	O	O
(	O	O
10	O	O
)	O	O
is	O	O
observed	O	O
.	O	O
High	O	O
affinity	O	O
was	O	O
found	O	O
in	O	O
some	O	O
cycloalkyl	B-MODIFIER	O
-	I-MODIFIER	O
annelated	I-MODIFIER	O
[	B-IUPAC	B-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
and	O	O
in	O	O
some	O	O
7,8,9,10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydropyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
c	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
in	O	O
which	O	O
the	O	O
degree	O	O
of	O	O
activity	O	O
was	O	O
strongly	O	O
dependent	O	O
on	O	O
the	O	O
N	O	O
-	O	O
substituent	O	O
in	O	O
the	O	O
9	O	O
-	O	O
position	O	O
.	O	O
The	O	O
"	O	O
pharmacophore	O	O
"	O	O
for	O	O
selective	O	O
dopamine	O	O
D	O	O
-	O	O
1	O	O
antagonist	O	O
activity	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
tertiary	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxyphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenethylamine	I-IUPAC	I-IUPAC
.	O	O
It	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
greater	O	O
conformational	O	O
flexibility	O	O
of	O	O
the	O	O
side	O	O
chain	O	O
allows	O	O
II	O	O
to	O	O
achieve	O	O
a	O	O
conformation	O	O
inaccessible	O	O
to	O	O
pirenzepine	O	O
,	O	O
which	O	O
allows	O	O
it	O	O
to	O	O
bind	O	O
preferentially	O	O
to	O	O
M2	O	O
receptors	O	O
.	O	O
Most	O	O
of	O	O
the	O	O
tested	O	O
compounds	O	O
19-31	O	O
proved	O	O
to	O	O
be	O	O
much	O	O
more	O	O
active	O	O
than	O	O
THA	O	O
in	O	O
reversing	O	O
the	O	O
neuromuscular	O	O
blockade	O	O
induced	O	O
by	O	O
d	O	O
-	O	O
tubocurarine	O	O
.	O	O
Compounds	O	O
were	O	O
evaluated	O	O
on	O	O
rat	O	O
cortical	O	O
tissue	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
the	O	O
binding	O	O
of	O	O
radioligands	O	O
selective	O	O
for	O	O
AMPA	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
AMPA	O	O
)	O	O
,	O	O
NMDA	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
CGS	O	O
19755	O	O
)	O	O
,	O	O
and	O	O
kainic	O	O
acid	O	O
(	O	O
[	O	B-IUPAC
3H	O	I-IUPAC
]	O	I-IUPAC
-	O	I-IUPAC
kainic	O	I-IUPAC
acid	O	I-IUPAC
)	O	O
receptors	O	O
and	O	O
for	O	O
their	O	O
ability	O	O
to	O	O
inhibit	O	O
depolarizations	O	O
induced	O	O
by	O	O
AMPA	O	O
(	O	O
40	O	O
microM	O	O
)	O	O
,	O	O
NMDA	O	O
(	O	O
40	O	O
microM	O	O
)	O	O
,	O	O
and	O	O
kainic	O	O
acid	O	O
(	O	O
10	O	O
microM	O	O
)	O	O
.	O	O
Pharmacological	O	O
evaluation	O	O
of	O	O
these	O	O
compounds	O	O
demonstrated	O	O
central	O	O
nervous	O	O
system	O	O
depressant	O	O
activity	O	O
,	O	O
potential	O	O
anticonvulsant	O	O
properties	O	O
,	O	O
and	O	O
a	O	O
low	O	O
order	O	O
of	O	O
acute	O	O
toxicity	O	O
.	O	O
As	O	O
shown	O	O
by	O	O
structure	O	O
-	O	O
activity	O	O
relationship	O	O
studies	O	O
in	O	O
8	B-IUPAC	O
-	I-IUPAC	O
(	I-IUPAC	O
substituted	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aryl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroisoquinolines	I-IUPAC	I-IUPAC
,	O	O
the	O	O
most	O	O
important	O	O
structural	O	O
requirement	O	O
for	O	O
a	O	O
marked	O	O
antidepressant	O	O
action	O	O
is	O	O
the	O	O
presence	O	O
of	O	O
an	O	O
ureido	B-IUPAC	O
,	O	O
(	B-IUPAC	B-IUPAC
alkoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
,	O	O
or	O	O
[	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
attached	O	O
to	O	O
the	O	O
isoquinoline	O	O
skeleton	O	O
in	O	O
position	O	O
8	O	O
.	O	O
Qualitative	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
within	O	O
this	O	O
series	O	O
were	O	O
explored	O	O
through	O	O
modifications	O	O
of	O	O
the	O	O
three	O	O
major	O	O
structural	O	O
units	O	O
of	O	O
dexoxadrol	O	O
,	O	O
the	O	O
piperidine	O	O
,	O	O
1,3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dioxolane	I-IUPAC	I-IUPAC
,	O	O
and	O	O
aromatic	O	O
rings	O	O
of	O	O
the	O	O
molecule	O	O
.	O	O
Acetate	O	O
salt	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amidinophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamidine	I-IUPAC	I-IUPAC
(	O	O
8a	O	O
)	O	O
was	O	O
obtained	O	O
from	O	O
4a	O	O
,	O	O
through	O	O
the	O	O
bis	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetoxyamidoxime	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
hydrogenation	O	O
in	O	O
a	O	O
mixture	O	O
of	O	O
ethanol	O	O
/	O	O
ethyl	O	B-IUPAC
acetate	O	I-IUPAC
.	O	O
aureus	O	O
ATCC	O	O
29213	O	O
is	O	O
0.008	O	O
microgram	O	O
/	O	O
mL	O	O
.	O	O
Recently	O	O
,	O	O
we	O	O
have	O	O
discovered	O	O
that	O	O
PATs	O	O
also	O	O
bind	O	O
with	O	O
high	O	O
affinity	O	O
to	O	O
the	O	O
[	O	O
(	O	O
3	O	O
)	O	O
H	O	O
]	O	O
mepyramine	O	O
-	O	O
labeled	O	O
H	O	O
(	O	O
1	O	O
)	O	O
receptor	O	O
in	O	O
rat	O	O
and	O	O
guinea	O	O
pig	O	O
brain	O	O
.	O	O
A	O	O
series	O	O
of	O	O
analogues	O	O
and	O	O
homologues	O	O
of	O	O
N1	B-IUPAC	O
,	I-IUPAC	O
N12	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diethylspermine	I-IUPAC	I-IUPAC
(	O	O
DESPM	O	O
)	O	O
was	O	O
synthesized	O	O
,	O	O
and	O	O
their	O	O
biological	O	O
properties	O	O
were	O	O
evaluated	O	O
.	O	O
A	O	O
number	O	O
of	O	O
compounds	O	O
(	O	O
1a	O	O
,	O	O
b	O	O
,	O	O
2a	O	O
-	O	O
c	O	O
,	O	O
f	O	O
,	O	O
3f	O	O
+	O	O
4d	O	O
)	O	O
showed	O	O
significant	O	O
cytotoxicity	O	O
to	O	O
cancer	O	O
cells	O	O
,	O	O
with	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidine	I-IUPAC	I-IUPAC
(	O	O
1b	O	O
)	O	O
being	O	O
the	O	O
most	O	O
potent	O	O
proliferation	O	O
inhibitor	O	O
(	O	O
EC	O	O
(	O	O
50	O	O
)	O	O
:	O	O
0.06-0.08	O	O
microM	O	O
)	O	O
to	O	O
all	O	O
types	O	O
of	O	O
cells	O	O
tested	O	O
.	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Oxa	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroretinoids	I-IUPAC	I-IUPAC
(	O	O
5	O	O
,	O	O
6	O	O
)	O	O
were	O	O
prepared	O	O
by	O	O
O	O	O
-	O	O
alkylation	O	O
of	O	O
phenoxides	O	O
by	O	O
methyl	B-IUPAC	B-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octatrienoate	I-IUPAC	I-IUPAC
.	O	O
Octreotide	O	O
,	O	O
an	O	O
analogue	O	O
of	O	O
the	O	O
hormone	O	O
somatostatin	O	O
,	O	O
has	O	O
applications	O	O
as	O	O
a	O	O
therapeutic	O	O
and	O	O
imaging	O	O
agent	O	O
for	O	O
somatostatin	O	O
-	O	O
positive	O	O
tumors	O	O
.	O	O
Single	O	O
-	O	O
point	O	O
replacement	O	O
of	O	O
each	O	O
amino	O	O
acid	O	O
by	O	O
alanine	O	O
led	O	O
to	O	O
the	O	O
identification	O	O
of	O	O
[	O	O
Ala8	O	O
]	O	O
-	O	O
,	O	O
[	O	O
Ala9	O	O
]	O	O
-	O	O
,	O	O
[	O	O
Ala15	O	O
]	O	O
-	O	O
(	O	O
Felix	O	O
et	O	O
al.	O	O
Peptides	O	O
1986	O	O
1986	O	O
,	O	O
481	O	O
)	O	O
,	O	O
[	O	O
Ala22	O	O
]	O	O
-	O	O
,	O	O
and	O	O
[	O	O
Ala28	O	O
,	O	O
Nle27	O	O
]	O	O
-	O	O
hGHRH	O	O
(	O	O
1-29	O	O
)	O	O
-	O	O
NH2	O	O
as	O	O
being	O	O
2-6	O	O
times	O	O
more	O	O
potent	O	O
than	O	O
hGHRH	O	O
(	O	O
1-40	O	O
)	O	O
-	O	O
OH	O	O
(	O	O
standard	O	O
)	O	O
in	O	O
vitro	O	O
.	O	O
In	O	O
the	O	O
3	O	O
-	O	O
day	O	O
immature	O	O
mouse	O	O
antiuterotrophic	O	O
assay	O	O
,	O	O
five	O	O
DTACs	O	O
with	O	O
either	O	O
a	O	O
methoxy	B-IUPAC	O
(	O	O
5a	O	O
)	O	O
,	O	O
benzyloxy	B-IUPAC	O
(	O	O
4d	O	O
,	O	O
5c	O	O
)	O	O
,	O	O
or	O	O
(	B-IUPAC	B-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
(	O	O
7a	O	O
,	O	O
7b	O	O
)	O	O
central	O	O
ring	O	O
side	O	O
chain	O	O
produced	O	O
significant	O	O
decreases	O	O
in	O	O
uterine	O	O
weight	O	O
at	O	O
doses	O	O
up	O	O
to	O	O
750	O	O
micrograms	O	O
.	O	O
The	O	O
results	O	O
of	O	O
radiosensitizing	O	O
activity	O	O
of	O	O
these	O	O
agents	O	O
against	O	O
hypoxic	O	O
Chinese	O	O
hamster	O	O
cells	O	O
(	O	O
V	O	O
-	O	O
79	O	O
)	O	O
indicated	O	O
that	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dinitroimidazoles	I-IUPAC	I-IUPAC
were	O	O
better	O	O
sensitizers	O	O
than	O	O
the	O	O
nitroimidazo	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
oxazoles	I-IUPAC	I-IUPAC
,	O	O
suggesting	O	O
the	O	O
necessity	O	O
of	O	O
the	O	O
2	B-IUPAC	O
-	I-IUPAC	O
nitro	I-IUPAC	O
function	B-MODIFIER	O
in	O	O
the	O	O
molecule	O	O
.	O	O
3,4	O	B-IUPAC
-	O	I-IUPAC
Dihydro	O	I-IUPAC
-	O	I-IUPAC
2	O	I-IUPAC
(	O	I-IUPAC
1H	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
quinolones	O	I-IUPAC
,	O	O
evolved	O	O
from	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,3,4	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydroquinolines	I-IUPAC	I-IUPAC
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
quinolones	I-IUPAC	I-IUPAC
,	O	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
in	O	O
vitro	O	O
for	O	O
antagonist	O	O
activity	O	O
at	O	O
the	O	O
glycine	O	O
site	O	O
on	O	O
the	O	O
NMDA	O	O
receptor	O	O
and	O	O
for	O	O
AMPA	O	O
[	O	B-IUPAC
(	B-IUPAC	I-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolepropionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
]	O	O
antagonist	O	O
activity	O	O
.	O	O
High	O	O
affinity	O	O
for	O	O
both	O	O
sigma	O	O
1	O	O
and	O	O
sigma	O	O
2	O	O
binding	O	O
sites	O	O
was	O	O
achieved	O	O
with	O	O
these	O	O
compounds	O	O
.	O	O
Structure	O	O
-	O	O
activity	O	O
relationships	O	O
showing	O	O
the	O	O
effect	O	O
of	O	O
a	O	O
substituent	O	O
(	O	O
Me	O	O
,	O	O
CF3	O	O
,	O	O
Cl	O	O
,	O	O
NO2	O	O
,	O	O
Ph	O	O
)	O	O
at	O	O
the	O	O
3	O	O
-	O	O
or	O	O
6	O	O
-	O	O
position	O	O
of	O	O
a	O	O
C	O	O
-	O	O
4	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
pyridyl	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
and	O	O
a	O	O
variety	O	O
of	O	O
ester	O	O
substituents	O	O
(	O	O
Me	O	O
,	O	O
Et	O	O
,	O	O
i	O	O
-	O	O
Pr	O	O
,	O	O
PhCH2CH2	O	O
-	O	O
)	O	O
upon	O	O
calcium	O	O
channel	O	O
modulation	O	O
are	O	O
described	O	O
.	O	O
When	O	O
tested	O	O
against	O	O
herpes	O	O
simplex	O	O
virus	O	O
type	O	O
1	O	O
,	O	O
only	O	O
9	O	O
was	O	O
active	O	O
with	O	O
an	O	O
IC50	O	O
=	O	O
8	O	O
microM	O	O
.	O	O
In	O	O
a	O	O
NOESY	O	O
experiment	O	O
,	O	O
cross	O	O
-	O	O
peaks	O	O
were	O	O
identified	O	O
between	O	O
both	O	O
the	O	O
aromatic	O	O
H9	O	O
proton	O	O
and	O	O
the	O	O
ethylidine	O	O
methyl	O	O
protons	O	O
of	O	O
tomaymycin	O	O
and	O	O
two	O	O
different	O	O
adenine	O	O
H2	O	O
protons	O	O
of	O	O
d	O	O
(	O	O
ATGCAT	O	O
)	O	O
2	O	O
.	O	O
These	O	O
data	O	O
confirm	O	O
that	O	O
the	O	O
distance	O	O
between	O	O
the	O	O
Dmt	O	O
-	O	O
Tic	O	O
pharmacophore	O	O
and	O	O
a	O	O
third	O	O
aromatic	O	O
nucleus	O	O
is	O	O
an	O	O
important	O	O
criterion	O	O
in	O	O
converting	O	O
Dmt	O	O
-	O	O
Tic	O	O
from	O	O
a	O	O
highly	O	O
potent	O	O
delta	O	O
-	O	O
antagonist	O	O
into	O	O
a	O	O
potent	O	O
delta	O	O
-	O	O
agonist	O	O
or	O	O
into	O	O
ligands	O	O
with	O	O
mixed	O	O
delta	O	O
-	O	O
and	O	O
mu	O	O
-	O	O
opioid	O	O
properties	O	O
.	O	O
Optimal	O	O
activity	O	O
was	O	O
attained	O	O
when	O	O
the	O	O
two	O	O
nipecotoyl	O	O
ring	O	O
N	O	O
atoms	O	O
were	O	O
connected	O	O
by	O	O
an	O	O
aralkyl	B-IUPAC	B-IUPAC
group	B-MODIFIER	B-MODIFIER
,	O	O
and	O	O
separated	O	O
by	O	O
approximately	O	O
7	O	O
A	O	O
.	O	O
Deprotection	O	O
of	O	O
ethyl	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyano	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
toluoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrr	I-IUPAC	I-IUPAC
ole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxylate	I-IUPAC	I-IUPAC
(	O	O
12	O	O
)	O	O
using	O	O
sodium	O	O
ethoxide	O	O
furnished	O	O
ethyl	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanopyrrole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
late	I-IUPAC	I-IUPAC
(	O	O
14	O	O
)	O	O
which	O	O
served	O	O
as	O	O
the	O	O
starting	O	O
material	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glycero	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
pyrrolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyridazin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
(	O	O
20	O	O
)	O	O
.	O	O
The	O	O
protected	O	O
peptide	O	O
was	O	O
cleaved	O	O
from	O	O
the	O	O
resin	O	O
by	O	O
aminolysis	O	O
with	O	O
threoninol	O	O
and	O	O
purified	O	O
by	O	O
semipreparative	O	O
RP	O	O
-	O	O
HPLC	O	O
.	O	O
Nicotinates	O	O
7b	O	O
,	O	O
d	O	O
-	O	O
g	O	O
were	O	O
converted	O	O
into	O	O
their	O	O
corresponding	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminopyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
12b	O	O
,	O	O
d	O	O
-	O	O
g	O	O
in	O	O
five	O	O
steps	O	O
,	O	O
via	O	O
reduction	O	O
,	O	O
protection	O	O
,	O	O
oxidation	O	O
,	O	O
condensation	O	O
with	O	O
guanidine	O	O
,	O	O
and	O	O
deprotection	O	O
.	O	O
When	O	O
acidolysis	O	O
was	O	O
preceded	O	O
by	O	O
catalytic	O	O
hydrogenation	O	O
,	O	O
the	O	O
final	O	O
product	O	O
was	O	O
the	O	O
corresponding	O	O
(	O	B-IUPAC
6R	O	I-IUPAC
,	O	I-IUPAC
6S	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
tetrahydro	O	I-IUPAC
derivative	O	B-MODIFIER
2	O	O
.	O	O
The	O	O
requisite	O	O
intermediate	O	O
gamma	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyanoglutamate	I-IUPAC	I-IUPAC
,	O	O
as	O	O
a	O	O
DL	O	O
-	O	O
threo	O	O
/	O	O
DL	O	O
-	O	O
erythro	O	O
mixture	O	O
,	O	O
was	O	O
prepared	O	O
from	O	O
methyl	B-IUPAC	B-IUPAC
N	I-IUPAC	I-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Boc	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
serinate	I-IUPAC	I-IUPAC
by	O	O
reaction	O	O
with	O	O
sodium	B-IUPAC	O
tert	I-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
cyanoacetate	I-IUPAC	I-IUPAC
followed	O	O
by	O	O
mild	O	O
trifluoroacetic	O	O
treatment	O	O
to	O	O
selectively	O	O
remove	O	O
the	O	O
Boc	O	O
group	O	O
.	O	O
This	O	O
manuscript	O	O
describes	O	O
our	O	O
synthetic	O	O
endeavors	O	O
around	O	O
4	O	O
,	O	O
5	O	O
,	O	O
and	O	O
7	O	O
mono	O	O
-	O	O
and	O	O
disubstitutions	O	O
of	O	O
1	O	O
and	O	O
discusses	O	O
related	O	O
HIV	O	O
-	O	O
1	O	O
inhibitory	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
.	O	O
3,5	B-IUPAC	O
-	I-IUPAC	O
Dimethylacetaminophen	I-IUPAC	O
was	O	O
slightly	O	O
more	O	O
nephrotoxic	O	O
but	O	O
showed	O	O
a	O	O
similar	O	O
hepatotoxicity	O	O
to	O	O
acetaminophen	O	O
.	O	O
The	O	O
in	O	O
vivo	O	O
potency	O	O
of	O	O
26	O	O
was	O	O
at	O	O
least	O	O
10	O	O
-	O	O
fold	O	O
less	O	O
than	O	O
that	O	O
of	O	O
monocyclic	O	O
cyclo	O	O
(	O	O
1-3	O	O
)	O	O
[	O	O
Ac	O	O
-	O	O
DAsp	O	O
(	O	O
1	O	O
)	O	O
,	O	O
DCpa	O	O
(	O	O
2	O	O
)	O	O
,	O	O
DLys	O	O
(	O	O
3	O	O
)	O	O
,	O	O
DNal	O	O
(	O	O
6	O	O
)	O	O
,	O	O
DAla	O	O
(	O	O
10	O	O
)	O	O
]	O	O
GnRH	O	O
(	O	O
5	O	O
)	O	O
;	O	O
this	O	O
suggested	O	O
the	O	O
existence	O	O
of	O	O
unfavorable	O	O
interactions	O	O
between	O	O
the	O	O
now	O	O
optimized	O	O
and	O	O
constrained	O	O
(	O	O
1-3	O	O
)	O	O
and	O	O
(	O	O
4-10	O	O
)	O	O
cyclic	O	O
moieties	O	O
that	O	O
must	O	O
interact	O	O
as	O	O
originally	O	O
hypothesized	O	O
.	O	O
They	O	O
combine	O	O
10	O	O
different	O	O
N	O	O
-	O	O
protecting	O	O
groups	O	O
(	O	O
R1	O	O
)	O	O
,	O	O
3	O	O
amino	O	O
acids	O	O
residues	O	O
in	O	O
P1	O	O
(	O	O
AA	O	O
)	O	O
,	O	O
and	O	O
44	O	O
distinct	O	O
substituents	O	O
on	O	O
the	O	O
alpha	O	O
-	O	O
keto	O	O
amide	O	O
nitrogen	O	O
(	O	O
R2	O	O
)	O	O
.	O	O
The	O	O
position	O	O
of	O	O
the	O	O
oxygen	O	O
atom	O	O
and	O	O
the	O	O
position	O	O
of	O	O
the	O	O
spiroconnection	O	O
with	O	O
the	O	O
4	O	O
-	O	O
position	O	O
of	O	O
the	O	O
piperidine	O	O
ring	O	O
were	O	O
varied	O	O
,	O	O
and	O	O
only	O	O
compounds	O	O
in	O	O
which	O	O
both	O	O
the	O	O
benzene	O	O
ring	O	O
and	O	O
the	O	O
heteroatom	O	O
are	O	O
attached	O	O
directly	O	O
to	O	O
the	O	O
piperidine	O	O
ring	O	O
retain	O	O
high	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
sigma	O	O
2	O	O
binding	O	O
sites	O	O
(	O	O
e.g.	O	O
,	O	O
3,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
spiro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzopyran	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidine	I-IUPAC	I-IUPAC
]	I-IUPAC	O
:	O	O
IC50	O	O
(	O	O
sigma	O	O
1	O	O
)	O	O
=	O	O
53	O	O
nM	O	O
,	O	O
IC50	O	O
(	O	O
sigma	O	O
2	O	O
)	O	O
=	O	O
0.9	O	O
nM	O	O
)	O	O
.	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Trimethylphenoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,4,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
octatrienoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
6b	O	O
)	O	O
was	O	O
the	O	O
most	O	O
active	O	O
of	O	O
the	O	O
7	O	O
-	O	O
oxa	O	O
-	O	O
7,8	O	O
-	O	O
dihydro	O	O
-	O	O
RAs	O	O
in	O	O
inhibiting	O	O
DMBA	O	O
-	O	O
initiated	O	O
and	O	O
TPA	O	O
-	O	O
promoted	O	O
mouse	O	O
-	O	O
skin	O	O
papillomas	O	O
.	O	O
With	O	O
the	O	O
exception	O	O
of	O	O
3e	O	O
and	O	O
3f	O	O
,	O	O
which	O	O
have	O	O
no	O	O
substituent	O	O
on	O	O
the	O	O
2beta	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazole	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ring	B-MODIFIER	B-MODIFIER
,	O	O
all	O	O
compounds	O	O
were	O	O
selective	O	O
for	O	O
the	O	O
DAT	O	O
relative	O	O
to	O	O
the	O	O
5	O	O
-	O	O
HTT	O	O
and	O	O
NET	O	O
.	O	O
The	O	O
previously	O	O
reported	O	O
diphenyl	B-IUPAC	B-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
prolylpyrrolidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphonate	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
was	O	O
used	O	O
as	O	O
a	O	O
lead	O	O
compound	O	O
for	O	O
the	O	O
development	O	O
of	O	O
potent	O	O
and	O	O
irreversible	O	O
inhibitors	O	O
of	O	O
dipeptidyl	B-IUPAC	O
peptidase	I-IUPAC	O
IV	I-IUPAC	O
(	O	O
DPP	O	O
IV	O	O
,	O	O
EC	O	O
3.4.14.5	O	O
)	O	O
.	O	O
Two	O	O
approaches	O	O
for	O	O
the	O	O
preparation	O	O
of	O	O
iodinated	O	O
versions	O	O
of	O	O
these	O	O
prostaglandins	O	O
were	O	O
evaluated	O	O
:	O	O
(	O	O
1	O	O
)	O	O
iodination	O	O
of	O	O
a	O	O
phenyl	O	O
azide	O	O
bearing	O	O
an	O	O
activating	O	O
hydroxyl	O	O
group	O	O
and	O	O
(	O	O
2	O	O
)	O	O
iodination	O	O
of	O	O
an	O	O
aniline	O	O
precursor	O	O
to	O	O
the	O	O
phenyl	O	O
azide	O	O
group	O	O
and	O	O
subsequent	O	O
conversion	O	O
of	O	O
the	O	O
aniline	O	O
to	O	O
the	O	O
phenyl	O	O
azide	O	O
.	O	O
When	O	O
administered	O	O
by	O	O
injection	O	O
twice	O	O
a	O	O
day	O	O
at	O	O
45	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
11	O	O
consecutive	O	O
days	O	O
,	O	O
both	O	O
compounds	O	O
showed	O	O
prolonged	O	O
survival	O	O
time	O	O
(	O	O
T	O	O
/	O	O
C	O	O
=	O	O
142-145%	O	O
)	O	O
,	O	O
thus	O	O
demonstrating	O	O
efficacy	O	O
against	O	O
ras	O	O
oncogene	O	O
-	O	O
containing	O	O
tumors	O	O
in	O	O
vivo	O	O
.	O	O
Both	O	O
alkyl	O	O
and	O	O
aryl	O	O
substituents	O	O
were	O	O
examined	O	O
.	O	O
Our	O	O
synthetic	O	O
route	O	O
provided	O	O
both	O	O
enantiomers	O	O
of	O	O
11a	O	O
and	O	O
11b	O	O
with	O	O
greater	O	O
than	O	O
97%	O	O
enantiomeric	O	O
purity	O	O
based	O	O
upon	O	O
evaluation	O	O
of	O	O
the	O	O
NMR	O	O
spectra	O	O
of	O	O
their	O	O
Mosher	O	O
's	O	O
acid	O	O
derivatives	O	O
.	O	O
Among	O	O
the	O	O
synthesized	O	O
compounds	O	O
,	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxochroman	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amide	I-IUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
showed	O	O
potent	O	O
ACAT	O	O
inhibitory	O	O
activity	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O
They	O	O
also	O	O
exhibited	O	O
the	O	O
promotional	O	O
effects	O	O
on	O	O
recovery	O	O
from	O	O
coma	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
po	O	O
.	O	O
At	O	O
cloned	O	O
metabotropic	O	O
Glu	O	O
receptors	O	O
mGluR1alpha	O	O
(	O	O
group	O	O
I	O	O
)	O	O
,	O	O
mGluR2	O	O
(	O	O
group	O	O
II	O	O
)	O	O
,	O	O
and	O	O
mGluR4a	O	O
(	O	O
group	O	O
III	O	O
)	O	O
,	O	O
neither	O	O
6	O	O
nor	O	O
7	O	O
showed	O	O
significant	O	O
agonist	O	O
or	O	O
antagonist	O	O
effects	O	O
.	O	O
The	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
of	O	O
7e	O	O
(	O	O
52%	O	O
)	O	O
also	O	O
supported	O	O
AE	O	O
activity	O	O
.	O	O
However	O	O
,	O	O
analysis	O	O
of	O	O
the	O	O
high	O	O
-	O	O
affinity	O	O
(	O	O
2R	O	O
,	O	O
3R	O	O
)	O	O
-	O	O
MePhe3	O	O
analog	O	O
revealed	O	O
a	O	O
strong	O	O
preference	O	O
for	O	O
a	O	O
single	O	O
side	O	O
chain	O	O
conformer	O	O
(	O	O
chi	O	O
1	O	O
approximately	O	O
60	O	O
degrees	O	O
)	O	O
.	O	O
Ester	O	O
cleavage	O	O
and	O	O
decarboxylation	O	O
at	O	O
C	O	O
-	O	O
10	O	O
were	O	O
accomplished	O	O
by	O	O
heating	O	O
with	O	O
sodium	O	O
cyanide	O	O
in	O	O
Me2SO	O	O
at	O	O
170-180	O	O
degrees	O	O
C	O	O
to	O	O
afford	O	O
the	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
8,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazapteroic	I-IUPAC	I-IUPAC
acids	I-IUPAC	I-IUPAC
.	O	O
Among	O	O
the	O	O
unsaturated	O	O
acyclonucleosides	O	O
tested	O	O
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propargyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloropurine	I-IUPAC	I-IUPAC
(	O	O
3	O	O
)	O	O
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propargyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopurine	I-IUPAC	I-IUPAC
(	O	O
15	O	O
)	O	O
,	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
propargyloxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
azathioprine	I-IUPAC	I-IUPAC
(	O	O
17	O	O
)	O	O
,	O	O
and	O	O
angustmycin	O	O
A	O	O
analogue	O	O
10	O	O
showed	O	O
inhibition	O	O
of	O	O
cancer	O	O
cell	O	O
growth	O	O
,	O	O
but	O	O
only	O	O
at	O	O
a	O	O
minimal	O	O
level	O	O
,	O	O
and	O	O
17	O	O
also	O	O
showed	O	O
14%	O	O
cancer	O	O
cell	O	O
death	O	O
in	O	O
vitro	O	O
.	O	O
Since	O	O
thrombin	O	O
inhibitors	O	O
appear	O	O
to	O	O
be	O	O
effective	O	O
in	O	O
the	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
thrombotic	O	O
and	O	O
embolic	O	O
disorders	O	O
,	O	O
considerable	O	O
attention	O	O
has	O	O
been	O	O
focused	O	O
on	O	O
the	O	O
structure	O	O
and	O	O
interactions	O	O
of	O	O
this	O	O
enzyme	O	O
.	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
Bromoallopurinol	I-IUPAC	I-IUPAC
ribonucleoside	B-MODIFIER	I-IUPAC
(	O	O
6a	O	O
)	O	O
was	O	O
found	O	O
to	O	O
be	O	O
more	O	O
active	O	O
than	O	O
allopurinol	O	O
ribonucleoside	O	O
against	O	O
Leishmania	O	O
tropica	O	O
within	O	O
human	O	O
macrophages	O	O
in	O	O
vitro	O	O
.	O	O
Analogues	O	O
incorporating	O	O
pyrrolidine	O	O
in	O	O
lieu	O	O
of	O	O
piperidine	O	O
were	O	O
also	O	O
prepared	O	O
.	O	O
This	O	O
was	O	O
particularly	O	O
evident	O	O
in	O	O
the	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylquinazolinone	I-IUPAC	I-IUPAC
series	B-MODIFIER	B-MODIFIER
(	O	O
IC50	O	O
values	O	O
0.13-0.27	O	O
microM	O	O
)	O	O
,	O	O
which	O	O
are	O	O
among	O	O
the	O	O
most	O	O
potent	O	O
PARP	O	O
inhibitors	O	O
reported	O	O
to	O	O
date	O	O
.	O	O
Three	O	O
of	O	O
these	O	O
compounds	O	O
-	O	O
8azaadenosine	B-IUPAC	O
(	O	O
4	O	O
)	O	O
,	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
ribonucleoside	I-IUPAC	B-MODIFIER
(	O	O
5	O	O
)	O	O
,	O	O
and	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
purine	I-IUPAC	I-IUPAC
ribonucleoside	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
-	O	O
showed	O	O
borderline	O	O
activity	O	O
in	O	O
the	O	O
leukemia	O	O
L1210	O	O
system	O	O
.	O	O
The	O	O
replacement	O	O
of	O	O
piperazine	O	O
and	O	O
furan	O	O
units	O	O
of	O	O
prazosin	O	O
(	O	O
1	O	O
)	O	O
by	O	O
1	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexanediamine	I-IUPAC	I-IUPAC
and	O	O
phenyl	B-IUPAC	B-IUPAC
moieties	B-MODIFIER	B-MODIFIER
,	O	O
respectively	O	O
,	O	O
affording	O	O
3-20	O	O
,	O	O
markedly	O	O
affected	O	O
both	O	O
affinity	O	O
and	O	O
selectivity	O	O
for	O	O
alpha1	O	O
-	O	O
adrenoreceptor	O	O
subtypes	O	O
in	O	O
functional	O	O
experiments	O	O
.	O	O
Most	O	O
of	O	O
the	O	O
analogs	O	O
displaced	O	O
[	O	O
3H	O	O
]	O	O
1	O	O
from	O	O
its	O	O
binding	O	O
sites	O	O
,	O	O
with	O	O
compounds	O	O
14	O	O
(	O	O
IC50	O	O
0.42	O	O
microM	O	O
)	O	O
and	O	O
15	O	O
(	O	O
IC50	O	O
0.88	O	O
microM	O	O
)	O	O
having	O	O
equivalent	O	O
potencies	O	O
to	O	O
1	O	O
(	O	O
IC50	O	O
0.59	O	O
microM	O	O
)	O	O
,	O	O
in	O	O
rat	O	O
brain	O	O
,	O	O
and	O	O
no	O	O
appreciable	O	O
activity	O	O
at	O	O
the	O	O
[	O	O
3H	O	O
]	O	O
TCP	O	O
or	O	O
[	O	O
3H	O	O
]	O	O
glycine	O	O
-	O	O
labeled	O	O
sites	O	O
.	O	O
N10	B-IUPAC	O
-	I-IUPAC	O
Propargylfolic	I-IUPAC	O
acid	I-IUPAC	O
(	O	O
2	O	O
)	O	O
,	O	O
which	O	O
is	O	O
the	O	O
closest	O	O
pteridine	O	O
analogue	O	O
of	O	O
the	O	O
thymidylate	O	O
synthase	O	O
inhibitor	O	O
N10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propargyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazafolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
PDDF	O	O
)	O	O
,	O	O
was	O	O
synthesized	O	O
starting	O	O
from	O	O
diethyl	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propargylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
(	O	O
5	O	O
)	O	O
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxopropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
phthalimide	I-IUPAC	I-IUPAC
(	O	O
8	O	O
)	O	O
.	O	O
Both	O	O
(	B-PARTIUPAC	O
R	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
daunosaminyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,12	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azanaphthacene	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dione	I-IUPAC	I-IUPAC
were	O	O
inactive	O	O
ip	O	O
in	O	O
mice	O	O
carrying	O	O
the	O	O
P388	O	O
tumor	O	O
.	O	O
These	O	O
compounds	O	O
exhibited	O	O
significantly	O	O
potent	O	O
activity	O	O
upon	O	O
oral	O	O
administration	O	O
with	O	O
ED50	O	O
values	O	O
of	O	O
0.068-0.17	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O
From	O	O
series	O	O
I	O	O
,	O	O
a	O	O
mixed	O	O
RAR	O	O
beta	O	O
-	O	O
gamma	O	O
agonist	O	O
with	O	O
potent	O	O
cellular	O	O
differentiating	O	O
activity	O	O
was	O	O
selected	O	O
for	O	O
development	O	O
as	O	O
a	O	O
topical	O	O
antiacne	O	O
agent	O	O
,	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
adamantyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxyphenyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
5	O	O
,	O	O
CD	O	O
271	O	O
)	O	O
[	O	O
Ki	O	O
(	O	O
RAR	O	O
alpha	O	O
)	O	O
=	O	O
1100	O	O
nM	O	O
,	O	O
Ki	O	O
-	O	O
(	O	O
RAR	O	O
beta	O	O
)	O	O
=	O	O
34	O	O
nM	O	O
,	O	O
Ki	O	O
(	O	O
RAR	O	O
gamma	O	O
)	O	O
=	O	O
130	O	O
nM	O	O
,	O	O
AC50	O	O
(	O	O
F9	O	O
)	O	O
=	O	O
37	O	O
nM	O	O
]	O	O
.	O	O
This	O	O
[	B-IUPAC	B-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazine	I-IUPAC	I-IUPAC
core	B-MODIFIER	O
structure	I-MODIFIER	O
has	O	O
now	O	O
been	O	O
improved	O	O
by	O	O
incorporating	O	O
various	O	O
piperazine	O	O
derivatives	O	O
.	O	O
The	O	O
general	O	O
requirement	O	O
of	O	O
acidity	O	O
for	O	O
high	O	O
affinity	O	O
binding	O	O
at	O	O
the	O	O
glycine	O	O
/	O	O
NMDA	O	O
site	O	O
is	O	O
supported	O	O
with	O	O
the	O	O
good	O	O
activity	O	O
of	O	O
the	O	O
other	O	O
3	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
nitro	I-PARTIUPAC	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
(	O	O
13-21	O	O
)	O	O
,	O	O
all	O	O
of	O	O
which	O	O
are	O	O
deprotonated	O	O
at	O	O
physiological	O	O
pH	O	O
.	O	O
All	O	O
three	O	O
compounds	O	O
fully	O	O
antagonized	O	O
the	O	O
effects	O	O
of	O	O
carbachol	O	O
at	O	O
the	O	O
M1	O	O
receptor	O	O
,	O	O
while	O	O
only	O	O
4d	O	O
completely	O	O
antagonized	O	O
carbachol	O	O
at	O	O
the	O	O
M2	O	O
receptor	O	O
.	O	O
Amination	O	O
of	O	O
9a	O	O
-	O	O
e	O	O
with	O	O
aqueous	O	O
chloramine	O	O
solution	O	O
afforded	O	O
the	O	O
corresponding	O	O
purine	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfenamides	I-IUPAC	I-IUPAC
(	O	O
10	O	O
-	O	O
a	O	O
-	O	O
e	O	O
)	O	O
,	O	O
which	O	O
on	O	O
controlled	O	O
oxidation	O	O
with	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloroperoxbenzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
MCPBA	O	O
)	O	O
gave	O	O
the	O	O
respective	O	O
(	B-IUPAC	B-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alkylpurine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
sulfinamides	I-IUPAC	I-IUPAC
(	O	O
11a	O	O
-	O	O
e	O	O
)	O	O
.	O	O
The	O	O
nisoxetine	O	O
derivatives	O	O
8	O	B-IUPAC
(	O	I-IUPAC
rac	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
dimethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthale	I-IUPAC	I-IUPAC
nesulfonamide	I-IUPAC	I-IUPAC
)	O	O
and	O	O
9	O	B-IUPAC
(	O	I-IUPAC
rac	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
nitro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoxadiazole	I-IUPAC	I-IUPAC
)	O	O
and	O	O
especially	O	O
the	O	O
guanidine	O	B-IUPAC
derivative	O	B-MODIFIER
4	O	B-IUPAC
(	O	I-IUPAC
1	B-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butadienyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
benzyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
guanidinium	I-IUPAC	I-IUPAC
sulfate	I-IUPAC	I-IUPAC
)	O	I-IUPAC
which	O	I-IUPAC
are	O	O
characterized	O	O
by	O	O
intermediate	O	O
affinity	O	O
for	O	O
the	O	O
NET	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
370-850	O	O
nM	O	O
)	O	O
caused	O	O
significant	O	O
and	O	O
nisoxetine	O	O
-	O	O
sensitive	O	O
cell	O	O
fluorescence	O	O
.	O	O
Of	O	O
the	O	O
compounds	O	O
examined	O	O
,	O	O
the	O	O
greatest	O	O
degree	O	O
of	O	O
activity	O	O
in	O	O
vitro	O	O
was	O	O
found	O	O
with	O	O
the	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
mercaptopyrazolo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
.	O	O
(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
A	O	O
series	O	O
of	O	O
analogues	O	O
of	O	O
the	O	O
conformationally	O	O
restricted	O	O
delta	O	O
opioid	O	O
receptor	O	O
selective	O	O
tetrapeptide	O	O
Tyr	O	O
-	O	O
c	O	O
[	O	O
D	O	O
-	O	O
Cys	O	O
-	O	O
Phe	O	O
-	O	O
D	O	O
-	O	O
Pen	O	O
]	O	O
OH	O	O
(	O	O
JOM	O	O
13	O	O
)	O	O
was	O	O
prepared	O	O
in	O	O
which	O	O
the	O	O
conformationally	O	O
labile	O	O
Tyr	O	O
residue	O	O
was	O	O
replaced	O	O
with	O	O
several	O	O
less	O	O
flexible	O	O
tyrosine	O	O
analogues	O	O
.	O	O
Sugar	O	O
derivatives	O	O
1	O	O
and	O	O
6	O	O
were	O	O
also	O	O
condensed	O	O
with	O	O
benzoylacetone	O	O
to	O	O
give	O	O
14	O	O
and	O	O
18	O	O
,	O	O
with	O	O
acetoacetanilide	O	O
to	O	O
give	O	O
16	O	O
and	O	O
19	O	O
,	O	O
with	O	O
malononitrile	O	O
to	O	O
give	O	O
17	O	O
and	O	O
20	O	O
,	O	O
and	O	O
with	O	O
alpha	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
gamma	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyrolactonylidene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
triphenylphosphorane	I-IUPAC	I-IUPAC
to	O	O
give	O	O
21	O	O
and	O	O
22	O	O
,	O	O
respectively	O	O
.	O	O
After	O	O
the	O	O
syn	O	O
diastereomers	O	O
were	O	O
found	O	O
to	O	O
have	O	O
the	O	O
highest	O	O
activity	O	O
in	O	O
these	O	O
preliminary	O	O
assays	O	O
,	O	O
the	O	O
N	O	B-IUPAC
-	O	I-IUPAC
alkylated	O	I-IUPAC
analogues	O	B-MODIFIER
syn	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphtho	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bc	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
(	O	O
4e	O	O
)	O	O
and	O	O
syn	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dipropyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2a	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3,4,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphtho	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bc	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
furan	I-IUPAC	I-IUPAC
(	O	O
4f	O	O
)	O	O
were	O	O
prepared	O	O
and	O	O
assayed	O	O
for	O	O
their	O	O
affinities	O	O
at	O	O
[	O	O
3H	O	O
]	O	O
ketanserin	O	O
-	O	O
labeled	O	O
5	O	O
-	O	O
HT2A	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
-	O	O
8	O	O
-	O	O
OH	O	O
-	O	O
DPAT	O	O
-	O	O
labeled	O	O
5	O	O
-	O	O
HT1A	O	O
sites	O	O
.	O	O
The	O	O
synthesis	O	O
and	O	O
biological	O	O
evaluation	O	O
of	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
diamino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
(	O	O
5	O	O
-	O	O
DACTHF	O	O
,	O	O
543U76	O	O
)	O	O
,	O	O
an	O	O
acyclic	O	O
analogue	O	O
of	O	O
5,6,7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydrofolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
THFA	O	O
)	O	O
,	O	O
are	O	O
described	O	O
.	O	O
Analogue	O	O
4a	O	O
and	O	O
its	O	O
enantiomer	O	O
have	O	O
been	O	O
tritiated	O	O
at	O	O
C	O	O
-	O	O
1	O	O
and	O	O
both	O	O
were	O	O
found	O	O
to	O	O
be	O	O
activated	O	O
to	O	O
a	O	O
nucleotide	O	O
sugar	O	O
,	O	O
which	O	O
was	O	O
followed	O	O
by	O	O
incorporation	O	O
into	O	O
the	O	O
macromolecular	O	O
fraction	O	O
of	O	O
SW613	O	O
human	O	O
mammary	O	O
tumor	O	O
cells	O	O
in	O	O
vitro	O	O
.	O	O
The	O	O
synthesis	O	O
of	O	O
a	O	O
range	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyridinones	I-IUPAC	I-IUPAC
with	O	O
potential	O	O
for	O	O
the	O	O
chelation	O	O
of	O	O
iron	O	O
(	O	O
III	O	O
)	O	O
is	O	O
described	O	O
.	O	O
The	O	O
benzopyrans	O	O
have	O	O
thus	O	O
emerged	O	O
as	O	O
a	O	O
new	O	O
class	O	O
of	O	O
potent	O	O
antiestrogens	O	O
.	O	O
The	O	O
1	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
showed	O	O
broadly	O	O
similar	O	O
activity	O	O
to	O	O
the	O	O
analogous	B-MODIFIER	O
pyrido	B-IUPAC	B-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
8H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
,	O	O
whereas	O	O
the	O	O
1	B-IUPAC	B-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
naphthyridin	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
at	O	O
least	O	O
10	O	O
(	O	O
3	O	O
)	O	O
-	O	O
fold	O	O
less	O	O
potent	O	O
.	O	O
At	O	O
A1	O	O
,	O	O
A2A	O	O
,	O	O
and	O	O
A3	O	O
receptors	O	O
however	O	O
the	O	O
optimum	O	O
occurs	O	O
with	O	O
four	O	O
methylene	O	O
groups	O	O
.	O	O
The	O	O
compounds	O	O
within	O	O
this	O	O
series	O	O
were	O	O
prepared	O	O
as	O	O
analogues	O	O
of	O	O
the	O	O
previously	O	O
described	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperidyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
indoles	I-IUPAC	I-IUPAC
by	O	O
interchange	O	O
of	O	O
the	O	O
C	O	O
-	O	O
3	O	O
carbon	O	O
atom	O	O
and	O	O
the	O	O
nitrogen	O	O
atom	O	O
in	O	O
the	O	O
indole	O	O
nucleus	O	O
.	O	O
Receptor	O	O
-	O	O
binding	O	O
studies	O	O
with	O	O
specific	O	O
radiolabeled	O	O
ligands	O	O
indicate	O	O
that	O	O
the	O	O
specificity	O	O
conferred	O	O
by	O	O
the	O	O
site	O	O
of	O	O
fluorine	O	O
substituents	O	O
results	O	O
from	O	O
a	O	O
change	O	O
in	O	O
the	O	O
affinity	O	O
of	O	O
these	O	O
analogues	O	O
for	O	O
the	O	O
alpha	O	O
-	O	O
and	O	O
beta	O	O
-	O	O
adrenergic	O	O
receptors	O	O
.	O	O
;	O	O
Cheatham	O	O
,	O	O
S	O	O
.	O	O
A	O	O
series	O	O
of	O	O
new	O	O
S	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
adenosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
homocysteine	I-IUPAC	I-IUPAC
(	O	O
AdoHcy	O	O
)	O	O
analogues	B-MODIFIER	O
with	O	O
modifications	O	O
to	O	O
amino	O	O
acid	O	O
and	O	O
nucleoside	O	O
moieties	O	O
was	O	O
prepared	O	O
via	O	O
condensation	O	O
of	O	O
appropriate	O	O
nucleoside	O	O
precursors	O	O
and	O	O
suitably	O	O
protected	O	O
L	O	O
-	O	O
homocystine	O	O
derivatives	O	O
.	O	O
Within	O	O
this	O	O
series	O	O
,	O	O
naphthalene	O	O
was	O	O
found	O	O
to	O	O
be	O	O
superior	O	O
to	O	O
other	O	O
groups	O	O
for	O	O
eliciting	O	O
antihyperglycemic	O	O
activity	O	O
,	O	O
including	O	O
the	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
alkoxyphenyl	I-IUPAC	I-IUPAC
group	B-MODIFIER	B-MODIFIER
found	O	O
in	O	O
ciglitazone	O	O
,	O	O
a	O	O
prototypical	O	O
agent	O	O
for	O	O
this	O	O
activity	O	O
.	O	O
Phosphate	O	O
prodrugs	O	O
were	O	O
prepared	O	O
by	O	O
classical	O	O
phosphorylation	O	O
using	O	O
phosphorus	O	O
oxychloride	O	O
and	O	O
alternatively	O	O
by	O	O
using	O	O
a	O	O
phosphoramidite	O	O
method	O	O
.	O	O
In	O	O
an	O	O
effort	O	O
to	O	O
develop	O	O
selective	O	O
inhibitors	O	O
of	O	O
vesicular	O	O
acetylcholine	O	O
storage	O	O
,	O	O
we	O	O
have	O	O
synthesized	O	O
a	O	O
series	O	O
of	O	O
semirigid	O	O
vesamicol	O	O
receptor	O	O
ligands	O	O
based	O	O
on	O	O
the	O	O
structure	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpiperidino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclohexanol	I-IUPAC	I-IUPAC
(	O	O
vesamicol	O	O
,	O	O
AH5183	O	O
,	O	O
1	O	O
)	O	O
.	O	O
These	O	O
compounds	O	O
were	O	O
tested	O	O
in	O	O
the	O	O
rat	O	O
passive	O	O
cutaneous	O	O
anaphylaxis	O	O
(	O	O
PCA	O	O
)	O	O
assay	O	O
.	O	O
Nuclear	O	O
Overhauser	O	O
(	O	O
NOE	O	O
)	O	O
studies	O	O
indicated	O	O
there	O	O
is	O	O
a	O	O
significant	O	O
rotamer	O	O
fraction	O	O
in	O	O
solution	O	O
where	O	O
the	O	O
pyridyl	O	O
nitrogen	O	O
is	O	O
oriented	O	O
above	O	O
the	O	O
1,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropyridine	I-IUPAC	I-IUPAC
ring	B-MODIFIER	B-MODIFIER
,	O	O
irrespective	O	O
of	O	O
whether	O	O
a	O	O
substituent	O	O
is	O	O
located	O	O
at	O	O
the	O	O
3	O	O
-	O	O
or	O	O
6	O	O
-	O	O
position	O	O
.	O	O
[	O	O
3	O	B-IUPAC
-	O	I-IUPAC
(	O	I-IUPAC
1,4	O	I-IUPAC
-	O	I-IUPAC
Cyclohexadienyl	O	I-IUPAC
)	O	I-IUPAC
-	O	I-IUPAC
L	O	I-IUPAC
-	O	I-IUPAC
alanine	O	I-IUPAC
,	O	I-IUPAC
8	O	I-IUPAC
-	O	I-IUPAC
lysine	O	I-IUPAC
]	O	I-IUPAC
vasopressin	O	I-IUPAC
,	O	O
otherwise	O	O
known	O	O
as	O	O
[	B-IUPAC	B-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenylalanine	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
lysine	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
vasopressin	I-IUPAC	I-IUPAC
or	O	O
[	O	B-IUPAC
DiHPhe3	O	I-IUPAC
]	O	I-IUPAC
lysine	O	I-IUPAC
-	O	I-IUPAC
vasopressin	O	I-IUPAC
,	O	O
has	O	O
been	O	O
synthesized	O	O
in	O	O
an	O	O
attempt	O	O
to	O	O
utilize	O	O
2,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydrophenylalanine	I-IUPAC	I-IUPAC
(	O	O
DiHPhe	O	O
)	O	O
to	O	O
evaluate	O	O
the	O	O
contribution	O	O
of	O	O
aromaticity	O	O
in	O	O
position	O	O
3	O	O
to	O	O
biological	O	O
activity	O	O
.	O	O
The	O	O
selectivity	O	O
index	O	O
(	O	O
SI	O	O
)	O	O
of	O	O
each	O	O
compound	O	O
was	O	O
obtained	O	O
by	O	O
dividing	O	O
its	O	O
50%	O	O
inhibitory	O	O
concentration	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
)	O	O
against	O	O
Pc	O	O
,	O	O
Tg	O	O
,	O	O
or	O	O
Ma	O	O
DHFR	O	O
by	O	O
its	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
against	O	O
rat	O	O
DHFR	O	O
.	O	O
Binding	O	O
potencies	O	O
of	O	O
these	O	O
compounds	O	O
to	O	O
receptor	O	O
sites	O	O
labeled	O	O
with	O	O
[	O	O
3H	O	O
]	O	O
dextromethorphan	O	O
(	O	O
[	O	O
3H	O	O
]	O	O
1	O	O
)	O	O
,	O	O
in	O	O
rat	O	O
brain	O	O
and	O	O
guinea	O	O
pig	O	O
brain	O	O
subcellular	O	O
fractions	O	O
,	O	O
and	O	O
[	O	B-IUPAC
3H	O	I-IUPAC
]	O	I-IUPAC
thienylcyclohexylpiperidine	O	I-IUPAC
(	O	O
TCP	O	O
)	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
glycine	O	O
in	O	O
rat	O	O
brain	O	O
,	O	O
were	O	O
determined	O	O
.	O	O
In	O	O
order	O	O
to	O	O
study	O	O
the	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
L	B-PARTIUPAC	O
-	I-PARTIUPAC	O
(	I-PARTIUPAC	O
2S	I-PARTIUPAC	O
,	I-PARTIUPAC	O
4S	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
L	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxolanyl	I-IUPAC	I-IUPAC
nucleoside	I-IUPAC	I-IUPAC
as	O	O
potential	O	O
anti	O	O
-	O	O
HIV	O	O
agents	O	O
,	O	O
various	O	O
enantiomerically	O	O
pure	O	O
L	B-PARTIUPAC	O
-	I-PARTIUPAC	O
(	I-PARTIUPAC	O
2S	I-PARTIUPAC	O
,	I-PARTIUPAC	O
4S	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
and	O	O
(	B-IUPAC	B-IUPAC
2S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
4R	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxolanylpyrimidine	I-IUPAC	I-IUPAC
and	O	O
-	B-PARTIUPAC	O
purine	I-PARTIUPAC	O
nucleosides	I-PARTIUPAC	O
have	O	O
been	O	O
synthesized	O	O
and	O	O
evaluated	O	O
against	O	O
HIV	O	O
-	O	O
1	O	O
in	O	O
human	O	O
peripheral	O	O
blood	O	O
mononuclear	O	O
(	O	O
PBM	O	O
)	O	O
cells	O	O
.	O	O
Med.	O	O
Chem.	O	O
1992	O	O
,	O	O
35	O	O
,	O	O
4334-4343	O	O
)	O	O
we	O	O
conformationally	O	O
restricted	O	O
the	O	O
sigma	O	O
-	O	O
receptor	O	O
ligand	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrrolidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dichlorophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylethylamine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
by	O	O
incorporating	O	O
it	O	O
into	O	O
a	O	O
series	O	O
of	O	O
homologous	O	O
piperazines	O	O
3-9	O	O
and	O	O
homopiperazines	O	O
10	O	O
and	O	O
11	O	O
,	O	O
diazabicyclononanes	O	O
and	O	O
decanes	O	O
,	O	O
bridgehead	O	O
bicyclooctanes	O	O
and	O	O
nonanes	O	O
as	O	O
well	O	O
as	O	O
other	O	O
miscellaneous	O	O
compounds	O	O
.	O	O
Therefore	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetamidophenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
prolylpyrrolidine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phosphonate	I-IUPAC	I-IUPAC
(	O	O
11e	O	O
)	O	O
is	O	O
considered	O	O
as	O	O
a	O	O
major	O	O
improvement	O	O
and	O	O
will	O	O
be	O	O
a	O	O
highly	O	O
valuable	O	O
DPP	O	O
IV	O	O
inhibitor	O	O
for	O	O
further	O	O
studies	O	O
on	O	O
the	O	O
biological	O	O
function	O	O
of	O	O
the	O	O
enzyme	O	O
and	O	O
the	O	O
therapeutic	O	O
value	O	O
of	O	O
its	O	O
inhibition	O	O
.	O	O
Selectivity	O	O
for	O	O
the	O	O
NMDA	O	O
receptor	O	O
ion	O	O
channel	O	O
sites	O	O
over	O	O
sigma	O	O
receptors	O	O
appears	O	O
to	O	O
be	O	O
dependent	O	O
upon	O	O
the	O	O
structure	O	O
of	O	O
the	O	O
additional	O	O
substituents	O	O
on	O	O
the	O	O
guanidine	O	O
nitrogen	O	O
atoms	O	O
bearing	O	O
the	O	O
aryl	O	O
groups	O	O
.	O	O
Condensation	O	O
of	O	O
cyanothioacetamide	O	O
(	O	O
4	O	O
)	O	O
with	O	O
ethyl	B-IUPAC	B-IUPAC
alpha	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxymethylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetoacetate	I-IUPAC	I-IUPAC
(	O	O
5b	O	O
)	O	O
,	O	O
ethyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxymethylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxobutanoate	I-IUPAC	I-IUPAC
(	O	O
5c	O	O
)	O	O
,	O	O
ethyl	B-IUPAC	B-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
ethoxymethylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
phenylpropanoate	I-IUPAC	I-IUPAC
(	O	O
5d	O	O
)	O	O
afforded	O	O
exclusively	O	O
the	O	O
corresponding	O	O
6	O	B-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
pyridines	O	B-IUPAC
(	O	O
6b	O	O
-	O	O
d	O	O
)	O	O
.	O	O
However	O	O
,	O	O
the	O	O
bicyclic	O	O
hydantoins	O	O
were	O	O
much	O	O
less	O	O
potent	O	O
binders	O	O
to	O	O
the	O	O
neuronal	O	O
voltage	O	O
-	O	O
dependent	O	O
sodium	O	O
channel	O	O
than	O	O
their	O	O
monocyclic	O	O
counterparts	O	O
.	O	O
Treatment	O	O
of	O	O
the	O	O
5'	B-IUPAC	O
-	I-IUPAC	O
carboxaldehyde	I-IUPAC	O
derived	O	O
by	O	O
Moffatt	O	O
oxidation	O	O
of	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isopropylideneadenosine	I-IUPAC	I-IUPAC
(	O	O
1	O	O
)	O	O
with	O	O
the	O	O
"	O	O
(	B-IUPAC	O
bromofluoromethylene	I-IUPAC	O
)	I-IUPAC	O
triphenylphosphorane	I-IUPAC	O
"	O	O
reagent	O	O
and	O	O
deprotection	O	O
gave	O	O
9	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
bromo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
fluoro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
beta	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ribo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hex	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
enofuranosyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
adenine	I-IUPAC	I-IUPAC
(	O	O
4	O	O
)	O	O
.	O	O
Most	O	O
potent	O	O
among	O	O
the	O	O
bicyclic	O	O
derivatives	O	O
was	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
n	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dimethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
meth	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
imidazo	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
triazole	I-IUPAC	I-IUPAC
(	O	O
93	O	O
,	O	O
IC50	O	O
7.8	O	O
nM	O	O
)	O	O
.	O	O
The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
demonstrate	O	O
that	O	O
B	O	O
-	O	O
ring	O	O
analogues	O	O
of	O	O
3	O	O
inhibit	O	O
DHFR	O	O
activity	O	O
and	O	O
tumor	O	O
cell	O	O
colony	O	O
formation	O	O
as	O	O
well	O	O
as	O	O
,	O	O
or	O	O
better	O	O
than	O	O
,	O	O
the	O	O
parent	O	O
compound	O	O
.	O	O
Five	O	O
new	O	O
analogues	O	O
(	O	O
1c	O	O
-	O	O
g	O	O
)	O	O
of	O	O
the	O	O
antifolate	O	O
N10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
propargyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazafolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
1a	O	O
)	O	O
are	O	O
described	O	O
in	O	O
which	O	O
the	O	O
benzoyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
was	O	O
replaced	O	O
by	O	O
benzoic	O	O
acid	O	O
(	O	O
desglutamyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
N10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
propargyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazafolic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
)	O	O
,	O	O
benzoyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
aspartate	I-IUPAC	I-IUPAC
,	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenylbutyrate	I-IUPAC	I-IUPAC
,	O	O
benzoylglycine	O	O
,	O	O
and	O	O
benzoyl	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanine	I-IUPAC	I-IUPAC
.	O	O
Glycosylation	O	O
of	O	O
4	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
with	O	O
3,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
di	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
p	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
toluoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
D	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
erythro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentofuranosyl	I-IUPAC	I-IUPAC
chloride	I-IUPAC	I-IUPAC
via	O	O
mercuric	O	O
cyanide	O	O
method	O	O
provided	O	O
an	O	O
anomeric	O	O
mixture	O	O
of	O	O
the	O	O
blocked	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methylimidazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
deoxynucleoside	I-IUPAC	I-IUPAC
14	O	O
along	O	O
with	O	O
an	O	O
anomeric	O	O
mixture	O	O
of	O	O
the	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxamide	I-IUPAC	I-IUPAC
isomer	B-MODIFIER	B-MODIFIER
15	O	O
.	O	O
We	O	O
also	O	O
noted	O	O
that	O	O
further	O	O
deletions	O	O
(	O	O
residues	O	O
8-14	O	O
)	O	O
produced	O	O
antagonists	O	O
such	O	O
as	O	O
astressin	O	O
\C2	O	O
\BF	O	O
cyclo	O	O
(	O	O
30-33	O	O
)	O	O
[	O	O
DPhe12	O	O
,	O	O
Nle21	O	O
,	O	O
38	O	O
,	O	O
Glu30	O	O
,	O	O
Lys33	O	O
]	O	O
hCRF	O	O
(	O	O
12-41	O	O
)	O	O
\C2	O	O
\BF	O	O
(	O	O
1	O	O
)	O	O
.	O	O
;	O	O
Wins	O	O
,	O	O
P	O	O
.	O	O
In	O	O
the	O	O
indole	O	O
series	O	O
,	O	O
certain	O	O
alkylsulfonyl	O	O
amides	O	O
possessing	O	O
a	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
cyanobenzyl	I-IUPAC	I-IUPAC
substituent	B-MODIFIER	B-MODIFIER
at	O	O
the	O	O
N	O	O
-	O	O
1	O	O
position	O	O
(	O	O
60	O	O
,	O	O
61	O	O
)	O	O
were	O	O
produced	O	O
that	O	O
had	O	O
KB	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
10	O	O
(	O	O
-	O	O
9	O	O
)	O	O
M	O	O
on	O	O
guinea	O	O
pig	O	O
trachea	O	O
.	O	O
Debenzoylation	O	O
of	O	O
these	O	O
nucleosides	O	O
(	O	O
5a	O	O
-	O	O
c	O	O
)	O	O
gave	O	O
the	O	O
corresponding	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
bromo	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
3	B-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
cyano	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
and	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
methylthio	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
allopurinol	I-IUPAC	I-IUPAC
nucleosides	B-MODIFIER	B-MODIFIER
(	O	O
6a	O	O
-	O	O
c	O	O
)	O	O
.	O	O
Compound	O	O
21	O	O
(	O	O
L	O	O
-	O	O
698,544	O	O
)	O	O
is	O	O
active	O	O
(	O	O
ED50	O	O
=	O	O
13.2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
the	O	O
DBA	O	O
/	O	O
2	O	O
mouse	O	O
anticonvulsant	O	O
model	O	O
and	O	O
is	O	O
the	O	O
most	O	O
potent	O	O
combined	O	O
glycine	O	O
/	O	O
NMDA	O	O
-	O	O
AMPA	O	O
antagonist	O	O
yet	O	O
reported	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
and	O	O
may	O	O
prove	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
pharmacological	O	O
tool	O	O
.	O	O
These	O	O
results	O	O
show	O	O
that	O	O
when	O	O
the	O	O
structure	O	O
of	O	O
the	O	O
target	O	O
protein	O	O
is	O	O
unknown	O	O
,	O	O
the	O	O
stereochemical	O	O
diversity	O	O
-	O	O
oriented	O	O
approach	O	O
can	O	O
be	O	O
a	O	O
powerful	O	O
strategy	O	O
in	O	O
medicinal	O	O
chemical	O	O
studies	O	O
.	O	O
The	O	O
biological	O	O
activity	O	O
of	O	O
these	O	O
heteroarotinoids	O	O
was	O	O
assayed	O	O
by	O	O
either	O	O
the	O	O
suppression	O	O
of	O	O
the	O	O
12	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetradecanoylphorbol	I-IUPAC	I-IUPAC
13	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
acetate	I-IUPAC	I-IUPAC
(	O	O
TPA	O	O
)	O	O
induced	O	O
synthesis	O	O
of	O	O
ornithine	O	O
decarboxylase	O	O
(	O	O
ODC	O	O
)	O	O
in	O	O
mouse	O	O
skin	O	O
or	O	O
the	O	O
induction	O	O
of	O	O
differentiation	O	O
of	O	O
human	O	O
(	O	O
HL	O	O
-	O	O
60	O	O
)	O	O
promyelocytic	O	O
cells	O	O
.	O	O
Whereas	O	O
most	O	O
analogues	O	O
derived	O	O
from	O	O
substituted	O	O
purine	O	O
and	O	O
pyrimidine	O	O
bases	O	O
and	O	O
bearing	O	O
various	O	O
hydroxy	B-MODIFIER	O
-	I-MODIFIER	O
or	O	O
amino	B-MODIFIER	O
-	I-MODIFIER	O
substituted	I-MODIFIER	O
alkyl	B-IUPAC	O
chains	B-MODIFIER	O
did	O	O
not	O	O
show	O	O
evidence	O	O
of	O	O
antiviral	O	O
activity	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
2	O	O
mM	O	O
,	O	O
(	O	O
S	O	O
)	O	O
-	O	O
DHPA	O	O
inhibited	O	O
both	O	O
vaccinia	O	O
and	O	O
vesicular	O	O
stomatitis	O	O
virus	O	O
replication	O	O
at	O	O
0.05-0.1	O	O
mM	O	O
.	O	O
Interestingly	O	O
,	O	O
the	O	O
finding	O	O
that	O	O
polyamines	O	O
11	O	O
,	O	O
16	O	O
,	O	O
and	O	O
20	O	O
,	O	O
bearing	O	O
a	O	O
1,6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hexanediamine	I-IUPAC	I-IUPAC
moiety	B-MODIFIER	B-MODIFIER
,	O	O
retained	O	O
high	O	O
affinity	O	O
for	O	O
alpha1	O	O
-	O	O
adrenoreceptor	O	O
subtypes	O	O
suggests	O	O
that	O	O
the	O	O
substituent	O	O
did	O	O
not	O	O
give	O	O
rise	O	O
to	O	O
negative	O	O
interactions	O	O
with	O	O
the	O	O
receptor	O	O
.	O	O
None	O	O
of	O	O
the	O	O
synthesized	O	O
nucleosides	O	O
was	O	O
toxic	O	O
up	O	O
to	O	O
100	O	O
microM	O	O
in	O	O
PBM	O	O
cells	O	O
.	O	O
Thus	O	O
,	O	O
the	O	O
binding	O	O
data	O	O
show	O	O
that	O	O
this	O	O
conformation	O	O
is	O	O
recognized	O	O
by	O	O
the	O	O
DAT	O	O
-	O	O
associated	O	O
binding	O	O
site	O	O
and	O	O
also	O	O
suggest	O	O
that	O	O
this	O	O
conformation	O	O
of	O	O
paroxetine	O	O
is	O	O
recognized	O	O
by	O	O
the	O	O
5	O	O
-	O	O
HTT	O	O
-	O	O
associated	O	O
binding	O	O
site	O	O
.	O	O
The	O	O
remaining	O	O
trans	O	O
-	O	O
4,5	O	O
-	O	O
di	O	B-MODIFIER
-	O	I-MODIFIER
Me	O	I-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
,	O	O
cis	O	B-PARTIUPAC
-	O	I-PARTIUPAC
and	O	O
trans	O	O
-	O	O
4,7	O	O
-	O	O
di	O	B-MODIFIER
-	O	I-MODIFIER
Me	O	I-MODIFIER
-	O	I-MODIFIER
substituted	O	I-MODIFIER
,	O	O
and	O	O
all	O	O
4,5	O	B-PARTIUPAC
-	O	I-PARTIUPAC
,	O	O
5,6	O	O
-	O	O
,	O	O
6,7	O	B-PARTIUPAC
-	O	I-PARTIUPAC
,	O	O
and	O	O
7,8	O	O
-	O	O
fused	O	O
disubstituted	O	O
analogues	O	O
of	O	O
1	O	O
possessed	O	O
no	O	O
noticeable	O	O
desired	O	O
activity	O	O
.	O	O
Compound	O	O
37	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrimidinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperazinyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
butyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
hexahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
etheno	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
cyclobut	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzisothiazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2H	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
one	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxide	I-IUPAC	I-IUPAC
,	O	O
buspirone	O	O
,	O	O
and	O	O
ipsapirone	O	O
showed	O	O
similarities	O	O
in	O	O
their	O	O
neurochemical	O	O
and	O	O
behavioral	O	O
profiles	O	O
.	O	O
In	O	O
murine	O	O
biodistribution	O	O
studies	O	O
,	O	O
[	O	O
131I	O	O
]	O	O
MIH	O	O
-	O	O
NGA	O	O
exhibited	O	O
rapid	O	O
accumulation	O	O
in	O	O
the	O	O
liver	O	O
followed	O	O
by	O	O
radioactivity	O	O
elimination	O	O
from	O	O
the	O	O
liver	O	O
at	O	O
a	O	O
rate	O	O
that	O	O
was	O	O
identical	O	O
to	O	O
and	O	O
faster	O	O
than	O	O
those	O	O
of	O	O
131I	O	O
-	O	O
labeled	O	O
NGA	O	O
via	O	O
direct	O	O
iodination	O	O
(	O	O
[	O	O
131I	O	O
]	O	O
NGA	O	O
)	O	O
and	O	O
[	O	O
131I	O	O
]	O	O
ATE	O	O
-	O	O
labeled	O	O
NGA	O	O
,	O	O
respectively	O	O
.	O	O
This	O	O
implies	O	O
interesting	O	O
differences	O	O
in	O	O
N	O	O
-	O	O
substituent	O	O
sensitivity	O	O
for	O	O
the	O	O
different	O	O
classes	O	O
of	O	O
compounds	O	O
with	O	O
respect	O	O
to	O	O
the	O	O
direction	O	O
of	O	O
their	O	O
respective	O	O
N	O	O
-	O	O
substituents	O	O
at	O	O
the	O	O
drug	O	O
-	O	O
receptor	O	O
interaction	O	O
.	O	O
v	O	O
.	O	O
We	O	O
have	O	O
previously	O	O
shown	O	O
that	O	O
the	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
AMPA	O	O
)	O	O
receptor	O	O
agonist	O	O
,	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
isoxazolyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
propionic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
(	O	O
ACPA	O	O
,	O	O
2	O	O
)	O	O
,	O	O
binds	O	O
to	O	O
AMPA	O	O
receptors	O	O
in	O	O
a	O	O
manner	O	O
different	O	O
from	O	O
that	O	O
of	O	O
AMPA	O	O
(	O	O
1	O	O
)	O	O
itself	O	O
and	O	O
that	O	O
2	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
1	O	O
,	O	O
also	O	O
binds	O	O
to	O	O
kainic	O	O
acid	O	O
receptor	O	O
sites	O	O
.	O	O
The	O	O
remaining	O	O
compounds	O	O
generally	O	O
had	O	O
IC50	O	O
values	O	O
in	O	O
the	O	O
0.1-1.0	O	O
microM	O	O
range	O	O
.	O	O
They	O	O
displayed	O	O
only	O	O
low	O	O
to	O	O
moderate	O	O
affinity	O	O
for	O	O
these	O	O
sites	O	O
(	O	O
pA	O	O
(	O	O
2	O	O
)	O	O
&	O	O
lt	O	O
;	O	O
6	O	O
)	O	O
.	O	O
Inclusion	O	O
of	O	O
thymidine	O	O
did	O	O
not	O	O
establish	O	O
TS	O	O
as	O	O
the	O	O
site	O	O
of	O	O
cytotoxic	O	O
action	O	O
for	O	O
either	O	O
4	O	O
or	O	O
PDDF	O	O
in	O	O
the	O	O
cell	O	O
lines	O	O
used	O	O
.	O	O
A	O	O
few	O	O
indoles	O	O
belonging	O	O
to	O	O
the	O	O
previously	O	O
investigated	O	O
benzylamides	O	O
1	O	O
and	O	O
phenylhydrazides	O	O
2	O	O
were	O	O
synthesized	O	O
and	O	O
tested	O	O
to	O	O
enrich	O	O
the	O	O
SARs	O	O
in	O	O
these	O	O
two	O	O
series	O	O
.	O	O
Recently	O	O
,	O	O
we	O	O
reported	O	O
the	O	O
first	O	O
human	O	O
study	O	O
of	O	O
[	O	O
99mTc	O	O
]	O	O
TRODAT	O	O
-	O	O
1	O	O
,	O	O
technetium	O	O
,	O	O
2	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
3	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
chlorophenyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
methyl	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
8	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
azabicyclo	I-PARTIUPAC	I-IUPAC
[	O	I-IUPAC
3.2.1	O	I-IUPAC
]	O	I-IUPAC
oct	B-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
yl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
methyl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
mercaptoethyl	I-PARTIUPAC	I-IUPAC
)	I-PARTIUPAC	I-IUPAC
amino	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
ethyl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
amino	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
ethanethiolato	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	O
3	I-PARTIUPAC	O
-	I-PARTIUPAC	O
)	I-PARTIUPAC	O
-	I-PARTIUPAC	O
o	I-PARTIUPAC	O
xo	I-PARTIUPAC	B-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
[	I-PARTIUPAC	I-PARTIUPAC
1R	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
(	I-PARTIUPAC	I-PARTIUPAC
exo	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
exo	I-PARTIUPAC	I-PARTIUPAC
)	I-PARTIUPAC	I-PARTIUPAC
]	I-PARTIUPAC	I-PARTIUPAC
-	I-PARTIUPAC	I-PARTIUPAC
,	O	O
as	O	O
an	O	O
imaging	O	O
agent	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
dopamine	O	O
transporters	O	O
.	O	O
Reaction	O	O
of	O	O
3	O	O
-	O	O
-	O	O
5	O	O
and	O	O
7	O	O
with	O	O
bis	B-IUPAC	B-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
chloroethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
amine	I-IUPAC	I-IUPAC
led	O	O
to	O	O
the	O	O
corresponding	O	O
pyrazole	O	O
nitrogen	O	O
mustards	O	O
10	O	O
-	O	O
-	O	O
13	O	O
.	O	O
The	O	O
cancer	O	O
chemopreventive	O	O
activity	O	O
of	O	O
(	O	O
all	O	O
-	O	O
E	O	O
)	O	O
-	O	O
1	O	O
was	O	O
comparable	O	O
to	O	O
that	O	O
of	O	O
(	B-IUPAC	B-IUPAC
all	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
E	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
retinoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
,	O	O
and	O	O
the	O	O
toxicity	O	O
was	O	O
comparable	O	O
to	O	O
or	O	O
slightly	O	O
better	O	O
than	O	O
that	O	O
of	O	O
the	O	O
natural	O	O
vitamin	O	O
.	O	O
The	O	O
potency	O	O
in	O	O
blocking	O	O
A1	O	O
-	O	O
adenosine	O	O
receptors	O	O
(	O	O
inhibition	O	O
of	O	O
binding	O	O
of	O	O
N6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
cyclohexyladenosine	I-IUPAC	I-IUPAC
to	O	O
brain	O	O
membranes	O	O
)	O	O
and	O	O
A2	O	O
-	O	O
adenosine	O	O
receptors	O	O
(	O	O
inhibition	O	O
of	O	O
2	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
chloroadenosine	I-IUPAC	I-IUPAC
-	O	O
elicited	O	O
accumulations	O	O
of	O	O
cyclic	O	O
AMP	O	O
in	O	O
brain	O	O
slices	O	O
)	O	O
was	O	O
markedly	O	O
affected	O	O
by	O	O
structural	O	O
changes	O	O
distal	O	O
to	O	O
the	O	O
primary	O	O
pharmacophore	O	O
(	O	O
8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dialkylxanthine	I-IUPAC	I-IUPAC
)	O	O
.	O	O
Condensation	O	O
of	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
bromomethyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrazinecarbonitrile	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxide	I-IUPAC	I-IUPAC
(	O	O
V	O	O
)	O	O
with	O	O
the	O	O
appropriately	O	O
substituted	O	O
amine	O	O
afforded	O	O
a	O	O
series	O	O
of	O	O
3	B-PARTIUPAC	B-IUPAC
-	I-PARTIUPAC	I-IUPAC
amino	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
6	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
[	I-PARTIUPAC	I-IUPAC
(	I-PARTIUPAC	I-IUPAC
aryl	I-PARTIUPAC	I-IUPAC
and	O	O
aralkyl	B-PARTIUPAC	B-IUPAC
)	I-PARTIUPAC	I-IUPAC
amino	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
methyl	I-PARTIUPAC	I-IUPAC
]	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
2	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
pyrazinecarbonitrile	I-PARTIUPAC	I-IUPAC
4	I-PARTIUPAC	I-IUPAC
-	I-PARTIUPAC	I-IUPAC
oxides	I-PARTIUPAC	I-IUPAC
VI	O	O
.	O	O
Most	O	O
of	O	O
the	O	O
compounds	O	O
showed	O	O
antihistaminic	O	O
activity	O	O
and	O	O
some	O	O
of	O	O
the	O	O
1	B-MODIFIER	B-IUPAC
-	I-MODIFIER	I-IUPAC
[	I-MODIFIER	I-IUPAC
2	I-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
(	I-MODIFIER	I-IUPAC
substituted	I-MODIFIER	I-IUPAC
-	I-MODIFIER	I-IUPAC
oxy	I-MODIFIER	I-IUPAC
)	I-MODIFIER	I-IUPAC
ethyl	I-MODIFIER	I-IUPAC
]	I-MODIFIER	I-IUPAC
derivatives	B-MODIFIER	B-MODIFIER
exhibited	O	O
potent	O	O
activity	O	O
.	O	O
The	O	O
stereochemical	O	O
and	O	O
steric	O	O
demands	O	O
for	O	O
sigma	O	O
receptor	O	O
affinity	O	O
are	O	O
much	O	O
less	O	O
stringent	O	O
.	O	O
One	O	O
of	O	O
the	O	O
nonquaternary	O	O
compounds	O	O
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
oxadiazole	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiohydroximic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
diethylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
S	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
,	O	O
is	O	O
a	O	O
powerful	O	O
reversible	O	O
inhibitor	O	O
of	O	O
AChE	O	O
(	O	O
I50	O	O
=	O	O
7.5	O	O
microM	O	O
)	O	O
.	O	O
With	O	O
the	O	O
exception	O	O
of	O	O
the	O	O
3,4,5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
triphenylpyrazole	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
13g	O	O
,	O	O
compounds	O	O
presenting	O	O
the	O	O
(	B-IUPAC	B-IUPAC
m	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethylphenoxy	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
acetic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
side	B-MODIFIER	O
chain	I-MODIFIER	O
discovered	O	O
with	O	O
3	O	O
demonstrated	O	O
enhanced	O	O
potency	O	O
compared	O	O
to	O	O
the	O	O
analogously	O	O
substituted	O	O
alkanoic	O	O
acid	O	O
derivative	O	O
.	O	O
We	O	O
find	O	O
that	O	O
for	O	O
the	O	O
fluorine	O	O
-	O	O
substituted	O	O
derivatives	O	O
studied	O	O
,	O	O
the	O	O
position	O	O
of	O	O
the	O	O
fluorine	O	O
on	O	O
the	O	O
quinolone	O	O
nucleus	O	O
or	O	O
the	O	O
number	O	O
of	O	O
fluorine	O	O
atoms	O	O
does	O	O
not	O	O
seem	O	O
to	O	O
be	O	O
important	O	O
for	O	O
good	O	O
Gram	O	O
positive	O	O
activity	O	O
.	O	O
r	O	O
.	O	O
Inhibition	O	O
of	O	O
the	O	O
binding	O	O
of	O	O
[	B-IUPAC	B-IUPAC
3H	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
phorbol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
12,13	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dibutyrate	I-IUPAC	I-IUPAC
to	O	O
PK	O	O
-	O	O
C	O	O
alpha	O	O
showed	O	O
that	O	O
only	O	O
the	O	O
threo	O	O
-	O	O
isomer	O	O
,	O	O
5	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
O	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetradecanoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
threo	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hexono	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
lactone	I-IUPAC	I-IUPAC
(	O	O
2	O	O
)	O	O
was	O	O
a	O	O
good	O	O
PK	O	O
-	O	O
C	O	O
ligand	O	O
(	O	O
Ki	O	O
=	O	O
1	O	O
microM	O	O
)	O	O
.	O	O
Relative	O	O
to	O	O
ethyl	B-IUPAC	B-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
6	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
N	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methylanilino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pteridine	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carbamate	I-IUPAC	I-IUPAC
(	O	O
11	O	O
)	O	O
and	O	O
the	O	O
corresponding	O	O
6	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
phenyl	I-IUPAC	I-IUPAC
compound	B-MODIFIER	B-MODIFIER
(	O	O
12	O	O
)	O	O
,	O	O
no	O	O
antitumor	O	O
activity	O	O
was	O	O
observed	O	O
with	O	O
7,8	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dihydropteridines	I-IUPAC	I-IUPAC
,	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
deaza	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7,8	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dihydropteridines	I-IUPAC	I-IUPAC
,	O	O
and	O	O
the	O	O
corresponding	O	O
heteroaromatic	O	O
compounds	O	O
.	O	O
Under	O	O
the	O	O
same	O	O
conditions	O	O
,	O	O
nitroxyl	B-IUPAC	O
generation	O	O
from	O	O
6	O	O
was	O	O
minimal	O	O
,	O	O
a	O	O
result	O	O
compatible	O	O
with	O	O
a	O	O
previous	O	O
observation	O	O
that	O	O
nitroxyl	O	O
generation	O	O
from	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
hydroxysaccharin	I-IUPAC	I-IUPAC
(	O	O
7	O	O
)	O	O
,	O	O
the	O	O
product	O	O
of	O	O
the	O	O
hydrolysis	O	O
of	O	O
the	O	O
carbethoxy	B-IUPAC	O
group	B-MODIFIER	O
of	O	O
6	O	O
,	O	O
was	O	O
minimal	O	O
at	O	O
physiological	O	O
pH	O	O
.	O	O
In	O	O
general	O	O
,	O	O
the	O	O
chloro	O	O
and	O	O
bromo	O	B-IUPAC
analogs	O	B-MODIFIER
were	O	O
more	O	O
effective	O	O
than	O	O
the	O	O
unsubstituted	O	O
naphthylalanines	O	O
as	O	O
growth	O	O
inhibitors	O	O
of	O	O
the	O	O
three	O	O
microorganisms	O	O
studied	O	O
.	O	O
This	O	O
report	O	O
focuses	O	O
on	O	O
the	O	O
synthesis	O	O
and	O	O
structure	O	O
-	O	O
activity	O	O
relationships	O	O
of	O	O
these	O	O
compounds	O	O
.	O	O
This	O	O
route	O	O
to	O	O
9b	O	O
intersects	O	O
reported	O	O
synthetic	O	O
approaches	O	O
leading	O	O
to	O	O
10	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deazaaminopterin	I-IUPAC	I-IUPAC
(	O	O
10	O	O
-	O	O
EDAM	O	O
,	O	O
edatrexate	O	O
)	O	O
,	O	O
an	O	O
agent	O	O
now	O	O
in	O	O
advanced	O	O
clinical	O	O
trials	O	O
.	O	O
In	O	O
series	O	O
I	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
phenol	B-PARTIUPAC	O
group	B-MODIFIER	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
nature	O	O
of	O	O
tertioalkyl	B-PARTIUPAC	O
group	B-MODIFIER	O
,	O	O
imparted	O	O
at	O	O
least	O	O
partial	O	O
RAR	O	O
gamma	O	O
selectivity	O	O
,	O	O
whereas	O	O
in	O	O
series	O	O
II	O	O
,	O	O
the	O	O
presence	O	O
of	O	O
both	O	O
adamantyl	B-PARTIUPAC	O
and	O	O
phenol	B-PARTIUPAC	O
groups	B-MODIFIER	O
is	O	O
needed	O	O
to	O	O
confer	O	O
RAR	O	O
gamma	O	O
selectivity	O	O
.	O	O
Hydrogenation	O	O
of	O	O
8a	O	O
and	O	O
8b	O	O
at	O	O
their	O	O
9,10	O	O
-	O	O
double	O	O
bond	O	O
afforded	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
5,10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dideazapteroic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
9a	O	O
)	O	O
and	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deoxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
10	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
deazapteroic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
(	O	O
9b	O	O
)	O	O
.	O	O
Replacement	O	O
of	O	O
a	O	O
hydroxyl	B-IUPAC	O
group	B-MODIFIER	O
for	O	O
a	O	O
fluorine	O	O
atom	O	O
in	O	O
the	O	O
4	O	O
position	O	O
of	O	O
muscarine	O	O
produces	O	O
1	O	O
order	O	O
of	O	O
magnitude	O	O
increase	O	O
in	O	O
affinity	O	O
for	O	O
cardiac	O	O
M2	O	O
muscarinic	O	O
receptors	O	O
controlling	O	O
rate	O	O
,	O	O
while	O	O
the	O	O
affinity	O	O
at	O	O
cardiac	O	O
M2	O	O
muscarinic	O	O
receptors	O	O
controlling	O	O
force	O	O
is	O	O
unchanged	O	O
,	O	O
opening	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
further	O	O
classification	O	O
of	O	O
cardiac	O	O
muscarinic	O	O
receptors	O	O
.	O	O
Variation	O	O
of	O	O
the	O	O
bridge	O	O
linking	O	O
the	O	O
heterocyclic	O	O
ring	O	O
and	O	O
p	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
aminobenzoyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
glutamate	I-IUPAC	I-IUPAC
portions	B-MODIFIER	B-MODIFIER
of	O	O
our	O	O
previously	O	O
described	O	O
classical	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
diaminofuro	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
d	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
pyrimidines	I-IUPAC	I-IUPAC
1	O	O
and	O	O
2	O	O
are	O	O
reported	O	O
as	O	O
inhibitors	O	O
of	O	O
dihydrofolate	O	O
reductase	O	O
(	O	O
DHFR	O	O
)	O	O
and	O	O
thymidylate	O	O
synthase	O	O
(	O	O
TS	O	O
)	O	O
and	O	O
as	O	O
antitumor	O	O
agents	O	O
.	O	O
[	O	O
D	O	O
-	O	O
Trp	O	O
(	O	O
Boc	O	O
)	O	O
4	O	O
,	O	O
Lys	O	O
(	O	O
Boc	O	O
)	O	O
5	O	O
,	O	O
Thr	O	O
(	O	O
tBu	O	O
)	O	O
6	O	O
]	O	O
octreotide	O	O
was	O	O
utilized	O	O
for	O	O
the	O	O
solution	O	O
-	O	O
phase	O	O
synthesis	O	O
of	O	O
CPTA	O	O
-	O	O
D	O	O
-	O	O
Phe1	O	O
-	O	O
octreotide	O	O
,	O	O
where	O	O
CPTA	O	O
is	O	O
4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,4,8,11	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetraazacyclotetradec	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
benzoic	I-IUPAC	I-IUPAC
acid	I-IUPAC	I-IUPAC
.	O	O
Among	O	O
all	O	O
the	O	O
synthesized	O	O
compounds	O	O
,	O	O
only	O	O
12	O	O
compounds	O	O
,	O	O
namely	O	O
3a	O	O
,	O	O
3c	O	O
,	O	O
3d	O	O
,	O	O
3f	O	O
,	O	O
4c	O	O
,	O	O
4d	O	O
,	O	O
4f	O	O
,	O	O
5a	O	O
,	O	O
6f	O	O
,	O	O
6h	O	O
,	O	O
6i	O	O
,	O	O
and	O	O
7h	O	O
,	O	O
have	O	O
exhibited	O	O
either	O	O
&	O	O
gt	O	O
;	O	O
90%	O	O
micro	O	O
-	O	O
or	O	O
macrofilaricidal	O	O
activity	O	O
or	O	O
sterlization	O	O
of	O	O
female	O	O
worms	O	O
.	O	O
1	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
Chloro	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
biphenyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
yl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
a1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
piperdinyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
ethanone	I-IUPAC	I-IUPAC
hydrochloride	I-IUPAC	I-IUPAC
(	O	O
18	O	O
,	O	O
RMI	O	O
12436A	O	O
)	O	O
was	O	O
found	O	O
to	O	O
lower	O	O
serum	O	O
cholesterol	O	O
levles	O	O
in	O	O
rats	O	O
with	O	O
concurrent	O	O
accumulation	O	O
of	O	O
(	B-IUPAC	O
3beta	I-IUPAC	O
)	I-IUPAC	O
-	I-IUPAC	O
cholesta	I-IUPAC	O
-	I-IUPAC	O
5,7	I-IUPAC	O
-	I-IUPAC	O
dien	I-IUPAC	O
-	I-IUPAC	O
3	I-IUPAC	O
-	I-IUPAC	O
ol	I-IUPAC	O
,	O	O
suggesting	O	O
inhibition	O	O
of	O	O
7	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dehydrocholesterol	I-IUPAC	I-IUPAC
delta7	O	O
-	O	O
reductase	O	O
.	O	O
[	O	O
DiHPhe3	O	O
]	O	O
lysine	O	O
-	O	O
vasopressin	O	O
exhibited	O	O
125	O	O
-	O	O
-	O	O
130	O	O
units	O	O
/	O	O
mg	O	O
of	O	O
antidiuretic	O	O
,	O	O
129	O	O
-	O	O
-	O	O
132	O	O
units	O	O
/	O	O
mg	O	O
of	O	O
rat	O	O
pressor	O	O
,	O	O
and	O	O
6	O	O
units	O	O
/	O	O
mg	O	O
of	O	O
rat	O	O
uterus	O	O
contracting	O	O
activity	O	O
.	O	O
In	O	O
some	O	O
cases	O	O
,	O	O
C	O	O
-	O	O
alkylation	O	O
also	O	O
occurred	O	O
.	O	O
Thus	O	O
,	O	O
(	B-IUPAC	B-IUPAC
1S	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
3R	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
6S	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
Z	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
9	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
biphenylylmethylene	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
azatricyclo	I-IUPAC	I-IUPAC
[	I-IUPAC	O
4.3.1	I-IUPAC	O
.	I-IUPAC	O
Conformational	O	O
analysis	O	O
of	O	O
the	O	O
stereoisomers	O	O
,	O	O
assuming	O	O
rotation	O	O
of	O	O
the	O	O
aryl	O	O
substituent	O	O
and	O	O
ester	O	O
groups	O	O
,	O	O
shows	O	O
small	O	O
energy	O	O
differences	O	O
(	O	O
about	O	O
4	O	O
kcal	O	O
.	O	O
Deprotection	O	O
afforded	O	O
6	O	O
,	O	O
which	O	O
was	O	O
condensed	O	O
with	O	O
expoxides	O	O
or	O	O
alkyl	O	O
halides	O	O
to	O	O
furnish	O	O
the	O	O
title	O	O
compounds	O	O
.	O	O
These	O	O
results	O	O
are	O	O
in	O	O
agreement	O	O
with	O	O
other	O	O
studies	O	O
suggesting	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
lipophilic	O	O
pocket	O	O
in	O	O
the	O	O
AR	O	O
binding	O	O
site	O	O
that	O	O
is	O	O
filled	O	O
by	O	O
moderately	O	O
sized	O	O
cycloalkyl	O	O
rings	O	O
at	O	O
the	O	O
N	O	O
(	O	O
6	O	O
)	O	O
position	O	O
of	O	O
both	O	O
adenine	O	O
and	O	O
adenosine	O	O
derivatives	O	O
.	O	O
The	O	O
free	O	O
ligands	O	O
,	O	O
their	O	O
Zn	O	O
(	O	O
II	O	O
)	O	O
complexes	O	O
,	O	O
and	O	O
the	O	O
ferric	O	O
complex	O	O
of	O	O
3,4,3	O	O
-	O	O
LIHOPO	O	O
were	O	O
administered	O	O
to	O	O
mice	O	O
[	O	O
30	O	O
mumol	O	O
/	O	O
kg	O	O
intraperitoneally	O	O
1	O	O
h	O	O
after	O	O
Pu	O	O
(	O	O
IV	O	O
)	O	O
-	O	O
238	O	O
citrate	O	O
,	O	O
kill	O	O
at	O	O
24	O	O
h	O	O
]	O	O
.	O	O
Finally	O	O
,	O	O
two	O	O
tripeptides	O	O
containing	O	O
O'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
epoxyalkyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tryosines	I-IUPAC	I-IUPAC
were	O	O
synthesized	O	O
[	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
tert	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butoxycarbonyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
alanyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
epoxypropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tyrosi	I-IUPAC	I-IUPAC
ne	I-IUPAC	I-IUPAC
ethyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
and	O	O
N	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
trifluoroacetyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
valyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
O'	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
2,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
epoxypropyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tyrosyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
L	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
valine	I-IUPAC	I-IUPAC
methyl	I-IUPAC	I-IUPAC
ester	I-IUPAC	I-IUPAC
]	O	O
as	O	O
potential	O	O
elastase	O	O
inhibitors	O	O
and	O	O
were	O	O
found	O	O
to	O	O
reversibly	O	O
and	O	O
competitively	O	O
inhibit	O	O
porcine	O	O
pancreatic	O	O
elastase	O	O
.	O	O
avium	O	O
DHFR	O	O
was	O	O
the	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
butynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
dibenz	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
b	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
f	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
azepinyl	I-IUPAC	I-IUPAC
derivative	B-MODIFIER	B-MODIFIER
20	O	O
(	O	O
IC	O	O
(	O	O
50	O	O
)	O	O
=	O	O
2.9	O	O
nM	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
most	O	O
selective	O	O
was	O	O
the	O	O
2'	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
5	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
carboxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pentynyl	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
analogue	B-MODIFIER	B-MODIFIER
21	O	O
,	O	O
with	O	O
SI	O	O
values	O	O
of	O	O
&	O	O
gt	O	O
;	O	O
100	O	O
against	O	O
both	O	O
P	O	O
.	O	O
Isoquinoline	O	O
and	O	O
some	O	O
pyridopyrimidine	O	O
derivatives	O	O
were	O	O
completely	O	O
inactive	O	O
;	O	O
therefore	O	O
,	O	O
1	B-IUPAC	O
-	I-IUPAC	O
aza	I-IUPAC	O
has	O	O
an	O	O
important	O	O
role	O	O
.	O	O
CV	O	O
-	O	O
11974	O	O
at	O	O
0.1-1	O	O
mg	O	O
/	O	O
kg	O	O
iv	O	O
reduced	O	O
blood	O	O
pressure	O	O
dose	O	O
-	O	O
dependently	O	O
in	O	O
spontaneously	O	O
hypertensive	O	O
rats	O	O
.	O	O
falciparum	O	O
with	O	O
two	O	O
exhibiting	O	O
values	O	O
of	O	O
14	O	O
nM	O	O
.	O	O
Thf2	O	O
-	O	O
FU	O	O
was	O	O
easily	O	O
hydrolyzed	O	O
to	O	O
Thf	O	O
-	O	O
FU	O	O
.	O	O
Binding	O	O
in	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
-	O	O
transfected	O	O
cells	O	O
was	O	O
completely	O	O
displaced	O	O
by	O	O
SRIF	O	O
-	O	O
28	O	O
or	O	O
the	O	O
sst	O	O
(	O	O
4	O	O
)	O	O
-	O	O
selective	O	O
L	O	O
-	O	O
803,087	O	O
.	O	O
According	O	O
to	O	O
their	O	O
selectivity	O	O
for	O	O
the	O	O
B	O	O
-	O	O
cell	O	O
(	O	O
endocrine	O	O
tissue	O	O
)	O	O
vs	O	O
the	O	O
vascular	O	O
(	O	O
smooth	O	O
muscle	O	O
tissue	O	O
)	O	O
ionic	O	O
channel	O	O
,	O	O
selected	O	O
3	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
(	I-IUPAC	I-IUPAC
alkylamino	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
pyrido	I-IUPAC	I-IUPAC
[	I-IUPAC	I-IUPAC
4,3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
e	I-IUPAC	I-IUPAC
]	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
,	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
thiadiazine	I-IUPAC	I-IUPAC
1,1	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
dioxides	I-IUPAC	I-IUPAC
may	O	O
serve	O	O
as	O	O
pharmacological	O	O
tools	O	O
in	O	O
studying	O	O
the	O	O
K	O	O
(	O	O
ATP	O	O
)	O	O
channels	O	O
(	O	O
"	O	O
pancreatic	O	O
-	O	O
like	O	O
"	O	O
K	O	O
(	O	O
ATP	O	O
)	O	O
channels	O	O
)	O	O
in	O	O
other	O	O
tissues	O	O
.	O	O
Whereas	O	O
(	B-IUPAC	B-IUPAC
RS	I-IUPAC	I-IUPAC
)	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
amino	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
hydroxy	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
4,5,6,7	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
tetrahydro	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
benzisoxazole	I-IUPAC	I-IUPAC
(	O	O
8	O	O
,	O	O
exo	O	O
-	O	O
THPO	O	O
)	O	O
was	O	O
synthesized	O	O
via	O	O
aluminum	O	O
amalgam	O	O
reduction	O	O
of	O	O
oxime	O	O
22a	O	O
or	O	O
22b	O	O
,	O	O
compounds	O	O
9	O	O
,	O	O
11-13	O	O
,	O	O
and	O	O
15-17	O	O
were	O	O
obtained	O	O
via	O	O
reductive	O	O
aminations	O	O
.	O	O
The	O	O
ligands	O	O
disclosed	O	O
herein	O	O
provide	O	O
additional	O	O
pharmacological	O	O
tools	O	O
of	O	O
use	O	O
in	O	O
attempting	O	O
to	O	O
correlate	O	O
structure	O	O
and	O	O
transporter	O	O
selectivity	O	O
with	O	O
in	O	O
vivo	O	O
studies	O	O
of	O	O
behavioral	O	O
outcomes	O	O
.	O	O
[	O	B-IUPAC
1	O	I-IUPAC
-	O	I-IUPAC
Beta	O	I-IUPAC
-	O	I-IUPAC
mercapto	O	I-IUPAC
-	O	I-IUPAC
beta	O	I-IUPAC
,	O	I-IUPAC
beta	O	I-IUPAC
-	O	I-IUPAC
pentamethylenepropionic	O	I-IUPAC
acid	O	I-IUPAC
]	O	I-IUPAC
oxytocin	O	I-IUPAC
was	O	O
prepared	O	O
from	O	O
beta	O	O
-	O	O
Mpa	O	O
(	O	O
beta	O	O
-	O	O
(	O	O
CH2	O	O
)	O	O
5	O	O
)	O	O
(	O	O
Bzl	O	O
)	O	O
-	O	O
Tyr	O	O
(	O	O
Bzl	O	O
)	O	O
-	O	O
Ile	O	O
-	O	O
Gln	O	O
-	O	O
Asn	O	O
-	O	O
Cys	O	O
(	O	O
Bzl	O	O
)	O	O
-	O	O
Pro	O	O
-	O	O
Leu	O	O
-	O	O
Gly	O	O
-	O	O
NH2	O	O
by	O	O
removal	O	O
of	O	O
the	O	O
Bzl	O	O
-	O	O
protecting	O	O
groups	O	O
with	O	O
Na	O	O
-	O	O
NH3	O	O
followed	O	O
by	O	O
cyclization	O	O
of	O	O
the	O	O
resulting	O	O
disulfhydryl	O	O
compound	O	O
with	O	O
K3Fe	O	O
(	O	O
CN	O	O
)	O	O
6	O	O
.	O	O
Orally	O	O
administered	O	O
3,4,3	O	O
-	O	O
LI	O	O
-	O	O
(	O	O
diCAM	O	O
-	O	O
diHOPO	O	O
)	O	O
promoted	O	O
significantly	O	O
more	O	O
Pu	O	O
excretion	O	O
than	O	O
an	O	O
equimolar	O	O
amount	O	O
of	O	O
CaNa3DTPA	O	O
.	O	O
The	O	O
resulting	O	O
2	B-MODIFIER	B-MODIFIER
-	I-MODIFIER	I-MODIFIER
unsubstituted	I-MODIFIER	I-MODIFIER
3H	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
were	O	O
then	O	O
alkylated	O	O
,	O	O
yielding	O	O
2,4	B-IUPAC	B-IUPAC
-	I-IUPAC	I-IUPAC
dialkyl	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3H	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
1,2,4	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
triazol	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
3	I-IUPAC	I-IUPAC
-	I-IUPAC	I-IUPAC
ones	I-IUPAC	I-IUPAC
.	O	O

